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A Transgenic Mouse with PMP-22 Directed G F P Expression - A Model for 
Schwann Cell Behaviour 
Angela M. Wright 
University of Durham, Department of Biological Sciences, 
South Road, Durham, DH1 3LE, U.K. 
In the peripheral nervous system the myelin sheath is produced by the spiral wrappings of 
the Schwann cell (SC) membrane around the axon. This provides insulation and increases 
the velocity of impulse propagation. The structure of myelin is maintained by a group of 
myelin proteins. Peripheral myelin protein-22 (PMP-22) is a 22 KDa glycoprotein, 
originally identified following nerve crush injury, that is found within SCs and is 
identical to the growth arrest specific protein GAS-3. The PMP-22 gene is regulated by 
two alternative promoters immediately upstream of two alternative non-coding exons. In 
order to study temporal and spatial expression of the PMP-22 gene and regulation of SC 
ensheathment and myelination, a transgenic mouse expressing the green fluorescent 
protein (GFP) driven by the myelin specific PMP-22 promoter was produced. 
To achieve this the PI promoter isolated from genomic D N A was initially incorporated 
into a plasmid containing the EGFP gene. In vitro transfection studies demonstrated 
appropriate expression of EGFP fluorescence. Microinjection of the transgene into pre-
implantation fertilised embryos gave rise to three transgenic lines as confirmed by 
Southern blot and PCR. One founder expressed the transgene in a tissue specific manner. 
Mosaicism of expression both within an individual and between individuals was noted. In 
vitro manipulations showed that the expression patterns observed were independent of 
axonal contact and myelination but could be influenced by the extracellular matrix. 
These GFP expressing transgenic mice potentially provide a means to determine the 
dynamics of SC-axon interactions during myelination and the behaviour of transplanted 
SCs into myelin deficient regions and the SCs response to injury. 
Preliminary reports of this work are found in abstract form: British Neurosci. Assoc. 
Abstr., Vo l 15, pi04, 1999. 
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Chapter 1: Introduction 
1.1 Glial Cells 
The majority of nerve cells in the central and peripheral nervous system are surrounded 
by glia, the ratio of neurons to glia being in the order of 1 to 1 and they constitute half of 
the volume of the brain. Glial cells can be divided into different cell types by 
morphology, function and the cell surface antibody repertoire that they display. They 
perform a variety of functions including neuronal guidance during growth and 
development, maintaining the delicately balanced fluid environment of the neurons 
including the blood brain barrier, and a potential role in the immune response of the 
central nervous system has been suggested. One of the most important functions of any 
glial cell is the generation of the myelin sheath that insulates the axon allowing 
propagation of the action potential. Below is a brief description of a number of different 
glial types, their classification and potential roles in the nervous system. 
1.1.1 Astrocytes - a versatile cell type 
Astrocytes are one of the most common glial cell types found in the central nervous 
system (CNS) and their potential functions are varied. They can be readily identified 
with an antibody against the intermediate filament glial fibrillary acidic protein (GFAP) 
(Bignami et al., 1972; Dahl and Bignami, 1985). Two distinct subpopulations of 
astrocytes have been identified in vitro, designated type I and type I I astrocytes, which 
can be identified by their distinct morphologies, the cell surface markers they express 
and their growth kinetics (Raff et al., 1983a; ffrench-Constant and Raff, 1986). 
The variation between the two cell types reflects different developmental origins of 
each. Type I astrocytes that appear from birth are unable to differentiate into type I I 
astrocytes that are present from the second post-natal week (Raff et al., 1983a). However 
the type I I astrocytes were found to share a common precursor with oligodendrocytes, 
the oligodendrocyte precursor cell (Raff et al., 1983b; Raff et al., 1989). 
A common role for cells of this lineage was suggested by the observation that type I I 
astrocytes in vitro contribute to the node of Ranvier, extending processes that encircle 
the exposed axonal plasma membrane the region between adjacent myelin internodes 
formed by the oligodendrocytes (ffrench -Constant and Raff, 1986; Waxman, 1986). 
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Astrocytic processes are also found to ensheath brain blood capillaries and can induce 
tight junction formation in endothelial cells, maintaining the blood brain barrier (Tao-
Cheng et al., 1987). Secretion of growth factors and cytokines that are modulators of the 
immune system and the expression of class I I antigens of the major histocompatibility 
complex also suggest a role in the defense of the nervous system for this glial cell type 
(Duchen a/., 1992). 
1.1.2 Radial Glia- neuronal guidance 
During the development of the brain migrating neurons were first seen travelling along 
the fibres of glial cells. Glial guidance mechanisms have since been shown to provide a 
means of positioning maturing neurons at their correct location within developing 
structures (Rakic, 1971; 1972). Once neuronal migration is complete the majority of 
radial glial cell's differentiate into astrocytes (Levitt and Rakic, 1980). Transitional 
forms, as the cell's progress from bipolar radial cells to stellate astrocytes can be 
identified with monoclonal antibodies. The exceptions are the Bergmann glial cells in 
the cerebellum and Muller cells of the retina that maintain their radial structure in the 
adult brain (Suarez et al., 1995). 
The process of neuronal migration along glial fibres has been extensively studied in the 
cerebellar system where granule cells migrate along Bergmann glial fibres (Hatten e£ al., 
1984; Edmondson and Hatten, 1987). The soma of the bipolar neuron becomes closely 
apposed to the glial cell arm and a specialised junction is observed between them 
(Gregory et al., 1988), a leading process is extended in the direction of movement. 
Neuronal filopodia and lamellipodia are seen to extend in many directions, but the 
driving force for migration is the neuron-glia apposition at the neuronal soma (Hatten et 
al., 1984; Edmondson and Hatten, 1987; Gasser and Hatten, 1990). 
The pattern of migration is remarkably similar in other regions of the brain and 
heterotypic cultures of cerebellar and hippocampal neurons and glia have demonstrated 
the commonality of the mechanism (Gasser and Hatten, 1990). It has been proposed that 
the interaction between the neurons and glia is mediated by the neural ligand astrotactin 
(Hatten 1990). 
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1.1.3 Microglia - immune responsive glial cells 
Microglia were first described by del Rio Hortega (1932) in silver stained preparations 
for the light microscope. They have a characteristic morphology, with long branched and 
crenellated process and are found throughout the CNS. Monocytes generated from bone 
marrow circulate in the blood and are delivered to their target tissue where they 
differentiate further. During embryonic development monocytes can be seen to enter the 
retina and brain, where they differentiate into microglia (Austyn and Gordon, 1981; 
Hume et al., 1983; Perry et al., 1985). 
Naturally occuring cell death during development is thought to attract circulating 
microglia to the site, indicating a possible role in tissue modeling. Additionally they 
have been shown to secrete factors that can stimulate angiogenesis and gliogenesis, 
processes that occur both pre- and post-natally (Perry and Gordon, 1988). 
Cell surface antigens found on adult microglial cells include that of the complement type 
3 (CR3) receptor (Perry et al., 1985). Other components of the immune system have 
been identified. For example class I I antigens of the major histocompatibilty complex 
are important in the activation of T helper lymphocytes. In certain pathological 
conditions microglia have been shown to express class I I antigens on their surface, as 
have astrocytes (Fontana et al., 1984; Lampson, 1987). The two cell types also share the 
ability to secrete a number of products common to macrophages (Fontana et al., 1982). 
In response to injury of the brain circulating monocytes are recruited to the site of 
trauma, however the proportion that are resident microglia is difficult to determine 
(Lindsey etal, 1986). 
1.1.4 Myelin forming cells 
One of the most important roles of glial cells in both regions of the nervous system is the 
production and maintenance of the myelin sheath. In the central nervous system this is 
achieved by the oligodendrocyte that can extend many processes, forming multiple 
internodes on different axonal processes. The Schwann cell of the peripheral nervous 
system forms a one-to-one relationship with an axon, forming only a single internode. 
More detailed discussion of these two cell types is found elsewhere (see section 1.2 and 
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1.3 and B l . l ) . Myelin is formed by the spiral wrapping of the oligodendrocyte or 
Schwann cell plasma membrane around the axon. The cytoplasm is then extruded, and 
the structure of compact myelin is maintained by a specific set of myelin proteins 
(section 1.1.5). 
The myelin sheath is not continuous along the length of the axon, between each myelin 
internode is found a node of Ranvier. The overlapping membranes that build up the 
myelin sheath at the internode constitute a region of high resistance, restricting current 
flow through this area. Despite the support of the node in the central nervous system by 
astrocytic processes, lower resistance at the node of Ranvier means the action potential 
can flow through the neuronal membrane at this point. In this way the current is passed 
in a saltatory manner along the nerve fibre (Tasaki, 1939; Huxley and Stampfli, 1949). 
The impulse jumps from one node to the next, greatly increasing the rate of nerve 
conductance velocity. 
The structure of the node of Ranvier and its role in mediating the axonal signal is 
complemented by the expression pattern of the axonal Na + channels that generate the 
action potential. Studies have shown an intrinsic difference in the membrane properties 
of the axon beneath the myelin internode and at the node of Ranvier. A high density of 
Na + channels is seen at the node both by cytochemical investigations and 
immunolabelling. It has also been confirmed by radiolabeled toxin and 
electrophysiology studies (Waxman and Ritchie, 1985). This distribution ensures that 
the channels are in the correct position relative to the resistance of the myelin sheath and 
that they are concentrated in such numbers as to enable propagation of the signal. Other 
potential advantages arise from this organisation. Fewer ions will enter and leave the 
axon as they are restricted to the node, in turn this limits the metabolic expenditure 
required to return the membrane potential to its resting state. 
1.1.4.1 Formation of the node of Ranvier 
The clustering of Na + channels that is crucial for successful conduction of the action 
potential can be seen to occur before the formation of the node of Ranvier. The 
mechanisms and interactions between neurons and glia that regulate this phenomenon 
are still disputed. 
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A number of reports describe the clustering of Na channels without direct contact 
between neurons and glia. Kaplan et al. (1997) for example show that the culture of 
optic nerve glia beneath retinal ganglion cells can induce clustering along the retinal 
neurons, and that this capacity is restricted to oligodendrocytes. In contrast in the sciatic 
nerve Schwann cell contact with axons and myelination have been shown to be required 
for the aggregation of channels (Joe and Angelides, 1992; Dugandzija-Novakovic et al., 
1995; Vabnick et al., 1996;). Rasband et al. (1999) have shown that in vivo in the CNS 
oligodendrocytes immunoreactive for early myelin proteins are present before Na + 
channel clustering begins. In the shiverer mouse, in which the primary phenotype affects 
Schwann cell behaviour, fewer and abnormal Na+ clustering is seen (Rasband et al., 
1999). 
1.1.4.2 Structure of a Myelinated Axon 
A schematic representation of myelin is shown in figure 1.1.4.2a, the central axon is 
surrounded by many wrappings of the myelin membrane. Electron micrographic images 
of peripheral myelin show the Schwann cell body and the inner leaflet in apposition to 
the axon (Figure 1.1.4.2b). At higher magnification each membrane layer can be clearly 
seen (1.1.4.2c). Below are descriptions of a number of structures associated with 
different regions of the myelin sheath. 
Schmidt-Lanterman Incisures: Regions of uncompacted myelin found in the compact 
myelin of the peripheral nervous system. They contain significant amounts of cytoplasm 
(Ghabriel and Allt, 1981). The incisure spirals radially producing a continuous channel 
from the inner or adaxonal cytoplasm to the outer or abaxonal cytoplasm (Friede and 
Samorajski, 1969). 
Paranodal Loops: Sections of uncompacted myelin adjacent to the nodes of Ranvier. 
These contain a helical rim of cytoplasm that connects the adaxonal and abaxonal 
domains. A number of desmosome like structures and tight junctions are found in the 
paranodal region and the lateral margins of the Schmidt-Lanterman incisures (Schnapp 
and Mugnaini, 1975; Shinowara et al., 1980; Ghabriel and Allt, 1981). K + channels are 
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Figure 1.1.4.2 Representations of Myelin. 
a. Schematic representation of the myelin sheath in both the peripheral and central 
nervous systems. A denotes the node of Ranvier, B is the paranodal region as the 
interaode ends and C shows a region of compact myelin, ai. transverse section, aii. 
Cross sectional view. From Nichols et al. 1992 b. 34,000x electron micrograph of 
peripheral myelin. The Schwann cell body (D) is evident with multiple layers of 
membrane encircling the axon (E). c. 340,000x magnification electron micrograph of the 
myelin sheath. Individual lamellae of compact myelin can be seen. 
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found in this region of the Schwann cell plasma membrane, and are likely to be involved 
in K + buffering at the node. 
Structural Artifacts: electron dense structures representing the apposition of the 
intracellular and extracellular membranes of the myelin membrane as it wraps around 
the axon are termed the major dense line and the intraperiod line respectively. These 
structures are maintained by specific sets of proteins. 
1.1.5 Myelin Proteins 
The majority of the dry weight of myelin is composed of many different classes of lipid 
(Inouye and Kirschner, 1988). Whilst some species are enriched in the myelin 
membrane over other plasma membranes none are specific to the myelin sheath. This is 
in contrast to the myelin proteins that are unique to myelin and integral to the formation 
of a functional sheath. 
Connexin 32: Connexins are membrane spanning proteins that assemble to form gap 
junctions that facilitate the movement of ions and small molecules from cell to cell. 
Connexin 32 (Cx32) is found in both the central and peripheral nervous systems, in 
addition it can be localised to the liver and epithelial cells ( Bennett et ah, 1991). 
In the CNS, Cx32 is found in the cell bodies and processes of oligodendrocytes, but not 
in compact myelin. In the peripheral nervous system it displays similar temporal 
expression patterns to other PNS myelin proteins, and nerve crush results in its loss and 
recovery following axonal regeneration (Scherer et ah, 1995). Peripheral expression of 
Cx32 is restricted to the paranodal region and Schmidt-Lanterman incisures of compact 
myelin (Bergoffen et al., 1993; Scherer et al., 1995). These junctions are thought to form 
a radial pathway across the myelin membrane that is significantly shorter than the 
circumferential pathway through the Schwann cell cytoplasm (Scherer et al., 1995). 
In non-myelin forming Schwann cells Cx32 immunostaining is punctate and 
discontinuous, and is found in significantly less abundance than in the myelinating 
phenotype (Scherer et al., 1995). 
7 
Chapter 1: Introduction 
Myelin Associated Glycoprotein: Myelin associated glycoprotein (MAG) is found co-
localised with Cx32 both in the PNS at the Schmidt-Lanterman incisures and the 
paranode, and the CNS in oligodendrocytes. In addition it is found along the adaxonal 
surface of myelinating Schwann cells in apposition to the axon, where it may mediate 
Schwann cell axon interactions. MAG is absent from regions of compact myelin. The 
presence of immunoglobulin like domains on the extracellular surface of the protein 
(Salzer et al., 1987) and the L2/HNK epitope on the carbohydrate component (Krusee/ 
al. 1984) suggest cell adhesion as the role for MAG. However it has not been found to 
form homophilic interactions and is thought unlikely to maintain the structure of the 
paranode and Schmidt-Lanterman incisures. This is more likely to be achieved by E-
cadherin, a cell adhesion molecule that can interact homotypically and serve to hold the 
layers of uncompacted myelin together (Fannon et al., 1995). 
E-cadherin: E-cadherin is an adhesive glycoprotein that is restricted in its expression to 
the non-compacted regions of peripheral myelin. It is excluded from compact myelin 
and so has no role in the adhesion or compaction of the sheath. Uniquely to the cadherin 
family it mediates adhesion between membranes of the same cell. It is found at the 
Schmidt-lanterman incisures and paranodal loops where it forms junctions across the 
membranes, maintaining the structure of the non-compacted myelin (Fannon et al., 
1995). 
Protein Zero: Protein zero (Po) is a 28-30kDa protein exclusive to peripheral myelin 
where it constitutes approximately 50% of the total myelin protein (Greenfield et al., 
1973; Lemke and Axel, 1985; Lai et al., 1987). Po is an integral membrane protein with 
a single membrane spanning domain. The extracellular domain has a primary sequence 
characteristic of the immunoglobulin family (Lai et al., 1987; Lemke et al., 1988), it also 
carries the L2/HNK epitope common to cells involved in adhesion (Bollensen and 
Schachner, 1987). 
Po molecules form tetramers in the plane of the plasma membrane (Shapiro et al., 1996). 
This functional unit interacts with tetramers of the opposing myelin membrane holding 
the compact myelin together (Filbin et al., 1990; D'Urso et al., 1990). The importance of 
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this level of structural support for the myelin sheath is seen in the shiverer mouse. This 
mouse mutant lacks the family of myelin basic proteins. They show severe loss of 
myelin in the central nervous system, yet the absence of MBP in the peripheral myelin 
does not affect myelin formation. It has been proposed that in the PNS compactbn is 
maintained by another myelin protein that is absent from the CNS, namely P0. 
A recent report has also identified interactions between Po and another myelin protein, 
peripheral myelin protein 22 (PMP-22). Immunoprecipitation with antibodies to either 
protein brings down both myelin proteins. When cells transfected with one of the 
proteins were cultured with cells expressing the other, the proteins were recruited to and 
co-localised at apposing membrane surfaces (D'Urso et al., 1999). 
The intracellular domain of the Po molecule may also be of functional importance. It is 
highly charged and may stabilise interactions between phospholipid head groups of the 
myelin membrane at the major dense line (Lemke, 1988; Ding and Brunden, 1994). 
The P 0 null mutant mouse (Giese et al., 1992) is characterised by a severe but 
incomplete loss of peripheral myelin. However the correct association of Schwann cells 
and axons in the null mouse suggests that Po is not necessary for the initial interactions 
of myelin formation but that its main role is to maintain the structure of compact myelin. 
Myelin Basic Proteins: This family of proteins range in size from 14 to 23kDa. The 
diversity is produced by alternative splicing of a single gene (Barbarese et al, 1977; 
Greenfield et al., 1982). It was later shown that in fact the MBP gene lies within a larger 
gene region designated golli-MBP (Campagnoni et al., 1993). 
MBP are positively charged soluble proteins that are associated with the major dense 
line and are involved in maintaining the structure of compact myelin in both the central 
and peripheral nervous system. The different isoforms are expressed both spatially and 
temporally throughout development (Staugaitis et al., 1990; Allinquante/ al., 1991). 
In the shiverer mouse mutant all MBP isoforms are absent. The mice display a central 
nervous system deficit only, myelin is abnormal and the major dense line is absent. In 
the peripheral nervous system redundancy of function among the myelin proteins 
maintains myelin structure. For a more detailed discussion about the myelin basic 
protein family see section B1.3. 
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Peripheral Myelin Protein 22: Peripheral myelin protein 22 (PMP22) is an 18kDa 
protein that is glycosylated to a final molecular mass of 22kDa and is expressed 
predominantly in the peripheral nervous system. The carbohydrate entity contains the 
adhesion molecule L2/HNK-1 epitope. The expression of PMP-22 mirrors that of other 
myelin proteins during development and degeneration and subsequent regeneration. It is 
also expressed in a range of non-neural tissues where its function is unknown. Two 
alternate promoters mediate the widespread expression of PMP-22, one of which is 
specific to myelination. The role of PMP-22 in myelination is unknown although it 
shares properties typical of adhesion molecules. It is expressed concomitantly to Po and 
has been to shown to interact with this major structural protein of peripheral myelin. A 
mechanism is proposed where by the correct stoichiometry between the two proteins is 
necessary to maintain compact myelin. When this is disrupted through mutation of one 
of the components abnormal myelin may be formed (Pareek et ai., 1997; Notterpek et 
ai, 1999). 
1.2 The Developmental Origins of the Schwann cell. 
The subject of the following study focuses on myelination in the peripheral nervous 
system where this is accomplished by Schwann cells. The development, differentiation, 
and regulation of these cells are discussed below. 
Following gastrulation the embryo comprises three distinct layers, Ihe endoderm, 
mesoderm and ectoderm. Interaction between them initiates organogenesis and induces 
the ectodemal tissue to form the neural plate, neural folds rise and enclose to form the 
neural tube which will eventually give rise to the brain and spinal cord. The dorsal most 
portion of the neural tube becomes the neural crest cells. These cells differentiate into 
diverse cell types including Schwann cells (Le Douarin and Smith, 1988; Le Douarine? 
al, 1991). 
Crest cells destined to become Schwann cell precursors migrate through the anterior 
section of the somites that form along either side of the neural tube. This same pathway 
is taken by the first peripheral nerves as they emerge from the ventrolateral part of the 
10 
Chapter 1: Introduction 
neural tube. In this way the Schwann cells and the neurons with which they must form 
an intimate relationship are present with the same spatial and temporal pattern enabling 
the initial interactions to occur (Rickman et al. 1985; Loring and Erickson, 1987). 
Neural crest cells, destined to become Schwann cells that have not yet associated with 
neurons have been difficult to identify, although it has been shown that a protein more 
usually associated with mature Schwann cells can be used as a cell marker. A basal level 
of expression of the myelin protein, protein zero (Po) is found on both precursor 
Schwann cells (Lee et al., 1997) and a subpopulation of neural crest cells that are 
thought to have recently entered the Schwann cell lineage (Bhattacharyya et al., 1991; 
Lee et ah, 1997). Subsequent differentiation of Schwann cells into the myelinating or 
non-myelinating form are accompanied by either an up-regulation or down-regulation of 
this basal level (Lee et al., 1997). 
Schwann cell precursors are defined by their interaction with embryonic neurons. By 
embryonic day 13 to 14, (El3/14) in the rat, nerves begin to extend into the hindlimb 
(Reynolds et al., 1991). Around this time El4/15 (El2 and El3 in the mouse) precursors 
are a distinct cell type. In vitro, Schwann cell precursors are flattened and have extensive 
cell-cell contacts. In comparison, immature Schwann cells are bi- or tri-polar in 
appearance. Additionally, precursors lack the expression of the cytoplasmic dimeric 
calcium binding protein SI00 that is characteristic of mature Schwann cells (lessens 
al., 1994). The expression of S-100 in the nervous system is restricted to glial cells, 
astrocytes of the CNS and Schwann cells of the PNS (Brockes et al., 1979). 
The two populations of cells show distinct differences in their survival ability. When 
isolated from rat nerves at E14 the precursor cells undergo apoptosis within 20 hours. 
Cells isolated from neonatal rat nerves under the same conditions in contrast survive. 
(Jessen et al., 1994; Dong et al., 1995; Gavrilovic et al., 1995; Mirsky and Jessen, 
1996). The switch from precursor to immature Schwann cell types has been shown to 
occur between El5 and El7. The cells identified at E17 possess all the characteristics 
used to describe Schwann cells, survival, SI00 expression and morphology (Jessen and 
Mirsky, 1997). 
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1.2.1 Survival factors from Schwann cells and Neurons 
The death of isolated precursor Schwann cells indicated the absence of some factor 
necessary for their survival. An obvious difference between the two was the absence of 
neurons in vitro. It was shown that the death of Schwann cell precursors could be 
rescued by the presence of dorsal root ganglion (DRG) neurons. Media conditioned by 
DRG neurons was also sufficient to promote survival (Jessen et al., 1994). 
The axonally derived survival signal has been identified as P-neuregulin (also known as 
NDF and heregulin). The neuregulins are generated from a single gene and are present in 
both soluble and membrane bound forms (Pinkas-Kramarski et al., 1994) that bind to 
members of the ErbB family of tyrosine kinases. They have been found to be involved in 
the growth and differentiation of several different cell types including epithelial, glial 
and muscle cells (Meyer and Birchmeier, 1995). 
(3-neuregulin is seen to support the survival of Schwann cell precursors, and their in vitro 
differentiation to immature Schwann cells with a time frame similar to that observed in 
vivo (Jessen et al., 1994; Dong et al., 1995). Additionally it is mitogenic for the 
immature Schwann cells, as their proliferation in response to axonal signals attempts to 
match the numbers of the two (Lemke, 1996; Jessen and Mirsky., 1999). These effects 
are lost when the cultures are incubated with a hybrid protein that incorporates the 
extracellular domain of the high affinity neuregulin receptor ErbB4 (Dong et al., 1995). 
Neural crest and Schwann cell precursors have been shown to express neuregulin 
receptors (Jin et al., 1993; Dong et al., 1995) and antibody blocking experiments have 
further corroborated the role of this molecule. The stimulation of immature Schwann cell 
proliferation brought on by incubation with axonal membranes was seen to be reduced 
10 fold when either neuronal membranes were pre-incubated with anti-neuregulin or 
Schwann cells pre-incubated with anti-ErbB2 antibodies (Morrissey et al., 1995). 
Transgenic mice in which the neuregulin gene has been inactivated demonstrate the 
importance of this axonal signal. While heterozygous animals are healthy and survive, 
homozygous mutant embryos die during early embryogenesis. They show disruption of 
the development of the heart, with irregular heartbeat and malformations of the heart 
muscle. Schwann cell precursors fail to develop normally, as do the cranial ganglia 
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(Meyer and Birchmeier, 1995). The loss of this axonal signal has grave implications 
upon the survival of the Schwann cells and other critical areas of development. 
A reciprocal dependence of axons on Schwann cell signals is inferred by the production 
of transgenic mice in which the neuregulin receptor ErbB3 is knocked out. Homozygous 
ErbB3~A mice lack Schwann cells and their precursors, in addition the majority of 
sensory and motoneurons are lost. At E12 the numbers of sensory neurons present are 
normal, but by El4 they are reduced by 80%, motoneurons are lost at El8 (Riethmacher 
et ah, 1997). The death of these neuronal populations is thought to be due to the loss of a 
survival factor that would normally have been secreted by the absent Schwann cells. 
Possible candidate molecules include the glial cell line derived neurotrophic factor 
(GDNF). This is found in both precursor and immature Schwann cells and is a potent 
mitogen for motoneurons both in vivo and in vitro, mice lacking GDNF lose around 20% 
of their motoneurons by birth (Henderson, 1996; Moore et al., 1996). GDNF however 
cannot account for all effects seen in the ErbB3-/- mouse as at the time of sensory 
neuron death in this mouse only a few of the sensory DRG neurons express the GDNF 
receptor. Since mice lacking Schwann cells suffer more extensively than those in which 
single growth factors have been deleted it is likely that a range of growth factors are 
involved in the regulation of axons (Molliver et al., 1997). 
1.2.2 Transcription Factor Regulation 
A number of transcription factors have been implicated in the development of Schwann 
cells. The suppressed cAMP inducible POU domain protein (SCIP, also known as Oct-
6) is expressed in Schwann cell precursors from El6, upregulated by axonal contact and 
is then downregulated as myelination proceeds (Scherer et al., 1994; Zwart, 1996). 
Heterozygous mice in which this gene was disrupted with the lacZ gene show 0-
galactosidase activity in regions of SCIP expression, corroborating the expression 
pattern described previously. However the homozygous deletion proved more severe 
with the majority of pups dying soon after birth (Jaegle et al., 1996). Those that did 
survive showed small and occasional tremors, suggesting deficiencies within the nervous 
system. Immunohistochemistry identified normal nerves in these animals at El8, yet at 
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postnatal day 8 (P8) their nerves possessed less myelin than wild type, although 
Schwann cells had formed the usual 1:1 relationship with the axons (Bermingham et al., 
1996; Jaegler et al. 1996). By PI4, although levels were still reduced they had begun to 
rise, and at adulthood homozygous animals presented with normal myelination of the 
peripheral nerves (Jaegler et al., 1996). This was interpreted to describe a role for SCIP 
in the regulation of genes involved in the transition from promyelinating to myelinating 
Schwann cells, but not in the terminal differentiation of the cells. Its loss causes a delay 
in the transitional step. I f this can be overcome, as in the small number of homozygous 
animals that survive beyond birth, then normal myelination can follow. 
This delayed effect on myelination seen in the SCIP knockout mouse contrasts with a 
mouse system in which ASCIP was expressed under the regulation of the Po promoter. 
This is a dominant negative protein with respect to SCIP and was intended to inactivate 
endogenous SCIP in cells that had been induced to myelinate (Blanchard et al., 1996). 
Unexpectedly it was seen that myelination was not blocked but induced prematurely and 
excessively (Weinstein et al., 1995). This experiment was designed to occur in cells that 
had been stimulated to myelinate, inactivating the SCIP at a time when it is being 
downregulated. This may explain the conflicting results. The discrepancy may be due to 
differential roles for SCIP in early and late Schwann cell development (Weinstein et al., 
1995; Mirsky and Jessen, 1996). 
Krox 20 is a zinc finger protein that is activated in Schwann cells before the onset of 
myelination and continues to be expressed throughout adult life (Topilko et al., 1994). 
Its involvement in myelination is demonstrated by the inhibition of development of 
mature myelin in its absence. Schwann cells associate with individual axons and turn 1.5 
times around the fibre. Early markers of myelin are present, such as SI00 and myelin 
associated glycoprotein (MAG). The myelin proteins, myelin basic protein (MBP) and 
Po, associated with mature myelin are reduced. Homozygous null alleles produced by 
insertion of the lacZ gene within the mouse Krox 20 gene show evidence of peripheral 
nervous system deficit with tremors that begin at 10-15 days after birth (Schneider-
Maunoury et al., 1993). Sciatic nerves from homozygous PI5 animals revealed a total 
lack of myelin, whilst heterozygotes displayed a normal myelinated phenotype. The 
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formation of an association between Schwann cell and neuron and the absence of myelin 
debris suggests that Krox 20 is affecting the Schwann cell before compaction occurs but 
is not necessary for the initial interaction of the two cell types (Topilko et al, 1994). 
The involvement of these two transcription factors at the same stage of development, 
from the pro-myelinating Schwann cell to the myelinating phenotype lead to an 
investigation into the interaction of the two. In P12 Krox 20 -/" mice SCIP levels are 
elevated, they have not declined as in the wild type mouse. This is accompanied by an 
increase in Schwann cell proliferation and apoptosis typical of SCIP+ve cells (Zorick et 
al., 1999). It has also been shown that Krox 20 is able to cause the transactivation of Po 
expression, a myelin protein the upregulation of which usually accompanies the decline 
in SCIP levels. This suggests that the two interact to allow the smooth transition between 
states of differentiation. 
1.2.3 Autocrine Survival Mechanisms 
Complex interactions between Schwann cells and neurons during development have 
been described that are crucial for the survival of both. 
In the adult animal, however, the dependence of Schwann cell viability on axonal input 
is reduced. Mature Schwann cells possess an autocrine support loop and no longer 
depend upon axons for their survival. The importance of this distinction between the 
mature and precursor Schwann cells types is seen clearly following mature nerve injury 
when axons are seen to degenerate without significant loss in Schwann cell numbers 
(Trachtenberg and Thompson, 1996). I f a loss of axonal signal were to result in the death 
of the surrounding Schwann cells axonal regeneration would be severely impaired as 
Schwann cells have been shown to provide a permissive substrate over which 
regenerating axons can grow (Hall, 1986; Fawcett and Keynes, 1990; Nadim et al., 
1990). 
The autocrine loop is active from El8 and is seen in postnatal nerves, however it is 
absent in the Schwann cell precursors that require axonal signals for survival. Meier et 
al. (1999) investigated a range of different growth factors for their ability to support the 
survival of Schwann cells plated at very low density. At such low density autocrine 
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growth factors secreted by Schwann cells would be present in concentrations that are too 
low to be effective. Conditioned media from confluent cultures of Schwann cells, 
isolated from 7day old rat nerve, was sufficient to rescue the low density cells, 
preventing apoptosis. The effect of the conditioned media was replicated by the addition 
of platelet derived growth factor BB (PDGF-BB), insulin like growth factor (IGF-1 and 
IGF-2) and neurotrophin 3 (NT-3) specifically. Blocking antibodies against each of 
these growth factors inhibited their ability to prevent cell death. These three elements act 
synergistically to mimic the effect of the conditioned media. 
This series of experiments was carried out over a period of two days in culture, long 
term cell survival was seen to be poor. When the experiments were repeated in cultures 
in which the Schwann cells were plated on laminin, a component of the Schwann cell 
basal lamina, survival times were increased. It is therefore likely that further signals are 
involved. 
1.2.4 Summary 
The development of the Schwann cell is controlled at many levels by axonal signals and 
the cell's own intrinsic mechanisms. Axonal input is important in the support of 
precursor Schwann cells and in stimulating the proliferation of immature Schwann cells. 
Coordinated regulation by transcription factors facilitates the progression then from 
promyelinating immature Schwann cells to the myelin forming phenotype. Throughout 
this the immature Schwann cells have developed an internal autocrine regulatory system 
that affords them independence from axonal signals for their survival. 
1.3 Formation of the Myelin Sheath 
As the immature Schwann cells become associated with axons, the properties of the 
neuron they segregate with determines their subsequent phenotype - namely myelin 
forming or non-myelin forming Schwann cells. The neuronal nature of this signal was 
demonstrated by a series of experiments by Aguayo et al. (1976) in which a graft from 
the sympathetic nerve that contains non-myelin forming Schwann cells, was introduced 
into a site of myelinated nerve. Following degeneration of the donor axonal fibres the 
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remaining Schwann cells were able to myelinate the host fibres, indicating that the 
ability to myelinate is intrinsic to all Schwann cells and that axonal phenotype 
determines the fate of the Schwann cell. The identity of the neuronal signal remains 
unknown. 
1.3.1 Elaboration of Myelin 
That the myelin sheath was a product of the extension of the Schwann cell plasmalemma 
was first realised by Geren in 1954. The study of electron micrographs of peripheral 
nerve identified Schwann cell elongation and spiraling around the axon, and as the spiral 
elongated the membranes within it extruded their cytoplasm and became compacted 
(Geren, 1954). 
Once Schwann cell proliferation has ceased and the Schwann cell has identified with a 
single axon, it elongates along the axon defining the edges of the futire internode. This 
is a positive association as competition between Schwann cells for access to the axon 
can result in less strongly attached Schwann cells falling off the neuron. Regular spacing 
of Schwann cell nuclei can be seen before the onset of myelination, and Schwann cell 
length does not increase as myelination proceeds. 
During the initial stages of the myelin formation the Schwann cell nucleus is seen to 
circumnavigate the axon, this phenomenon slows as the sheath matures. Electron 
micrograph studies have shown that it is the inner lip of the myelin membrane that is 
traversing around the axon, with newly formed layers tucking under the previously 
deposited lamina (Raine, 1984; Webster and Favilla, 1984). The nuclear movement seen 
in the early stages occurs before a fully formed basal lamina is present and motion of the 
inner folds drags the sheath and Schwann cell nucleus with it. Once the basal lamina 
matures it anchors the external aspect of the myelin and nuclear movement ceases 
(Bunge et al., 1989). The course of myelin formation can occur in either direction and 
independent Schwann cells associated with the same axon have been seen to spiral in 
opposing directions. 
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1.3.2 Basal Lamina 
Associated with the myelin sheath are a number of layers of extra cellular material. As 
the myelin membrane ensheaths the axon, so it is ensheathed at the abaxonal surface by 
a basal lamina secreted by the Schwann cell. This in turn is surrounded by a collagen 
matrix (Peters et al., 1976). The correct secretion of a basal lamina is essential for 
myelin formation. The Schwann cell basal lamina is composed of collagen types I , I I I , 
IV and V, laminin, entactin and heparin sulfate proteoglycan, HSPG (Bunge, 1986). The 
basal lamina is acquired by all Schwann cells early in development, as migration ceases 
and Schwann cells begin to segregate with individual axons (Webster, 1975). 
It has been shown that axonal contact is necessary for the formation of the basal lamina 
(Bunge et al., 1982). Schwann cells express laminin at all times in development, and 
when cultured in the absence of neuronal contact it is distributed in a punctate pattern. 
With the introduction of neurons, laminin expression becomes confluent throughout the 
basal lamina (Cornbrookes et al., 1983). Another limiting component appears to be 
collagen type IV, in the absence of neurons the secretion of this protein is greatly 
reduced (Carey et al., 1983). 
In vitro tissue culture techniques have allowed analysis of the molecules involved in the 
promotion of basal lamina formation. In addition to neuronal contact, ascorbic acid and 
an unknown component of serum are essential for correct basal lamina production. 
Schwann cells cultured in a defined media in the absence of these factors are unable to 
produce a basal lamina and myelin. I f this media is exchanged for a myelin permissive 
media that contains serum and ascorbic acid, a basal lamina is secreted and the Schwann 
cells will myelinate (Eldridge et al., 1987). 
Two lines of evidence demonstrate that the ascorbic acid affects myelination indirectly 
through the production of the basal lamina. In the central nervous system 
oligodendrocytes produce myelin in the absence of a basal lamina (Peters et al., 1976), 
and cultures of oligodendrocytes do not need ascorbic acid to produce myelin, therefore 
this is not a requirement for myelin formation. Moreover ascorbic acid and serum can be 
replaced by the addition of exogenous basal lamina, but not other extra cellular matrices 
(Eldridge et al., 1989). This indicates that a functional basal lamina is required before 
myelination can proceed. 
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Ascorbic acid is required for the hydroxylation of proline and lysine residues in type IV 
collagen (Wang et ah, 1989). This is necessary for the triple helical association of 
collagen chains and leads to increased secretion of triple helical type IV collagen 
(Eldridge et al., 1987; Wang et al., 1989). This is then assembled into a regular network 
that provides a mechanical stability to the matrix (Timpl et al., 1981). 
When normal secretion of the basal lamina is prevented, successive abnormalities of 
myelination are observed. Schwann cells associated with "guy roping" axons have no 
contact with the tissue culture dish substratum and are unable to form a basal lamina or 
myelin, however i f they are forced to the surface of the dish, myelination can be 
promoted (Bunge et al., 1989). A second surface is required by the Schwann cell, 
possibly to increase local concentrations of individual components. This polarisation 
leads to the reorganisation and morphological changes that accompany myelination, 
establishing plasmalemma domains. For example laminin receptors are expressed on the 
abaxonal surface of the Schwann cell, while those responsible for axonal contact will be 
localised to the adaxonal surface (Bunge et al., 1986). 
1.3.3 Non-myelinating Schwann cells 
The molecular nature of the changes that accompany myelination have been extensively 
studied. This has elucidated the differences between the two Schwann cell phenotypes 
and determined important molecular changes that occur following injury. 
Non-myelin forming cells may enclose a number of axons within a furrow of cytoplasm, 
ensheathing them within their membrane, yet the membranes do not show the same 
compact nature as myelin. The two Schwann cell types express distinct sets of surface 
membrane antigens and proteins, whilst they possess many of the same lipids. 
Adult non-myelin forming Schwann cells have been shown to express the GFAP 
intermediate filament protein, the cell surface proteins A5E3 and 217c(Ran-2), and the 
cell adhesion molecules N-CAM and Ll/Ng-CAM (Yen and Fields, 1981; Jessen et al., 
1984; Jessen and Mirsky, 1984; Mirsky and Jessen, 1984; Mirsky et al., 1986; Martini 
and Schachner, 1986; Daniloff et al., 1986). Each of these is not present or is found at 
much lower levels in myelin forming Schwann cells. During development the number of 
immature Schwann cells expressing A5E3 and 217c(Ran-l) increases from 75% of cells 
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at El5 to nearly all cells at birth. GFAP, first detectable at El8 is expressed in 50% of 
Schwann cells at birth. As myelination proceeds as indicated by the levels of myelin 
proteins present, these markers are lost in the majority of cells, and retained only in non-
myelin forming Schwann cells, indicating the similarity between embryonic Schwann 
cells with the adult non-myelinating phenotype (Jessen et al., 1990). 
The loss of axonal contact has little effect on the expression patterns of non-myelin 
forming Schwann cells (Jessen et al., 1990). Neural cell adhesion molecule, N-CAM is 
expressed on all neonatal Schwann cells and concurrent with myelination its expression 
is decreased in the myelin forming Schwann cells. However, within 24 hours of loss of 
axonal contact these cells re-express N-CAM (Jessen et al., 1997), as well as other 
markers of non-myelin forming Schwann cells A5E3, 217c(ran-l) and GFAP. 
1.3.4 Myelin Forming Schwann cells - the Expression of Myelin Proteins 
Once myelination has begun, as the expression of proteins associated with neonatal and 
non-myelin forming Schwann cells decline, a concomitant upregulation of a number of 
myelin proteins occurs in a temporal and spatial pattern. Immunohistochemical and in 
situ studies have been used to describe the appearance of structurally important myelin 
proteins. 
During development, as immature Schwann cells associate with myelin promoting axons 
a basal lamina is formed and the Schwann cells begin to myelinate at birth, reaching a 
peak at postnatal day P7-14. The major myelin proteins peripheral myelin protein 22 
(PMP-22) and protein zero (P 0) are detectable at birth. A rapid increase in expression 
reaches half maximal levels at P3 and a maximum by P7, levels then decline slightly to 
stable adult levels. The expression of the remaining structural proteins of the myelin 
basic protein, MBP family occurs with a slight delay, first detectable at P3 with a 
maximum expression at PI4. There is no significant decline in adulthood (Kuhn et al., 
1993; Notterpek et al., 1999). The myelin associated glycoprotein (MAG) is readily 
detected at PI and is near maximal by P4, this is in line with its proposed role in the 
initiation of early axon Schwann cell interactions (review Martini and Schachner, 1997; 
Yin etai, 1998). 
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The expression of myelin proteins is dependent upon axonal signals (Lemke and Chao, 
1988). The withdrawal of axons from tissue culture or following nerve crush or 
transection results in the downregulation of myelin proteins, expression is recovered 
once axonal regeneration has taken place. Within three days of nerve injury there is a 
rapid decline in the levels of PMP-22, P 0 and MBP in the distal nerve segment. The time 
course of the reinduction of the three proteins is tightly correlated to axonal regeneration 
(Kuhn et al., 1993). Bolin and Shooter (1993) have shown that at least one component of 
the axonal signals involved in this process is soluble. In neuronal co-cultures in which 
axons and Schwann cells are unable to make direct contact induction of a myelin 
associated transcription factor, SCIP and myelin protein Po is seen, indicating the 
diffusible nature of the signal. 
Despite the close correlation in the expression of PMP-22 and P0, distinct differences 
exist in their regulation. In non-myelin forming Schwann cells stimulated with forskolin 
(an activator of cAMP), low levels of Po and PMP-22 expression are seen. cAMP has 
been implicated in mediating the signals between axons and Schwann cells (Lemke and 
Chao, 1988; Morgan et al., 1991). Whilst Po was inserted into the plasma membrane, 
PMP-22 expression was restricted to the Golgi compartment. The introduction of 
neurons was able to promote the translocation of PMP-22 to the plasma membrane in the 
presence of a basal lamina (Pareek et al., 1997). 
1.3.5 The Effects of Demyelination 
In the peripheral nervous system successful regeneration of function following nerve 
injury is possible. The basal lamina deposited by the Schwann cells remains after axonal 
loss and degradation of the myelin sheath. This environment is permissive for the 
regeneration of both PNS and CNS axons. 
Axonal crush is followed by a defined sequence of histopathological reactions termed 
Wallerian degeneration. This is charactersied by a loss of axons and myelin breakdown; 
changes in the permeability of blood vessels; Schwann cell proliferation; invasion of the 
trauma site by phagocytes; and the phagocytosis of myelin debris by Schwann cells and 
macrophages (for review Sunderland, 1978). The loss of axonal signals causes the 
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downregulation of the myelin proteins and the return of expression of proteins 
characteristic of non-myelin forming Schwann cells (section 1.3.4). The existing myelin 
sheath is broken into myelin fragments and ovoids. The sum of the data available 
suggests that the Schwann cell itself initiates the degradation process and that the 
appearance of macrophages following this then takes over the majority of this process. 
Myelin degradation is then quickly and efficiently completed (Goodrum and Bouldin, 
1996). 
Within hours of the nerve crush injury the de novo lipid synthesis is reduced by 50% in 
the Schwann cell and by 3 days post crush has all but ceased entirely. In contrast to the 
immediate reaction of lipid synthesis, lipid degradation does not begin until a week after 
the initial trauma, but subsequently proceeds rapidly. This timing corresponds to the 
appearance of macrophages at the injury site. The lipids are broken down into droplets 
that are then localised to the macrophages. 
Myelination is accompanied by a massive increase in the production of plasmalemma, a 
major part of which is accounted for by lipids. Radiolabeled studies have shown that the 
cholesterol components of an existing myelin sheath that are labelled before breakdown 
begins are subsequently present in newly synthesised myelin sheaths following 
regeneration (Rawlins et al., 1970; 1972). This recycling of the cholesterol is consistent 
with the observation that the overall total amount of cholesterol does not change during 
degeneration (Goodrum, 1991). Further investigation has revealed that while all 
phospholipids are degraded, approximately half of all fatty acids are also reincorporated 
into new myelin membranes (Goodrum et al., 1995). For review see Goodrum and 
Bouldin, 1996. 
Following myelin breakdown some of the Schwann cells proliferate, as is the case 
during the developmental proliferation of Schwann cells, this is mediated by axonal 
contact and membrane interaction between the two is necessary for the stimulatory 
effect of neurons. I f the axons and Schwann cells are separated by a permeable 
membrane, the stimulation to divide is lost (Salzer and Bunge, 1980; Salzer et al., 
1980a, 1980b). As axonal regeneration occurs through the site of injury connections are 
made with the appropriate target and myelination and upregulation of myelin proteins 
begins again. The resulting myelin sheath tends to have slightly shorter internodes but 
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normal cytochemical properties, and the axonal signal is propagated at near normal 
conduction velocities (Cragg and Thomas, 1964; Rasminsky, 1978; Weiner et al., 1980). 
1.3.5.1 Trophic Factors 
The signals that circulate during different stages of differentiation of the Schwann cell 
and axon relationship are also subject to change following nerve injury. For example the 
nerve growth factor (NGF), that promotes the survival of peripheral sensory and 
sympathetic neurons (Levi-Montalcini, 1987) and cholinergic neurons of the forebrain 
(Williams et al., 1986) are increased following nerve injury at the distal site. Levels 
decline once regeneration is complete (Heumann et al., 1987). Since Schwann cells 
posses high levels of a receptor for NGF following loss of axonal contact during injury, 
it may be that in binding the trophic factor they are providing a localised source on their 
surface, over which regenerating neurons migrate (Johnson et al., 1988). As myelination 
resumes, NGF expression falls, as does the level of the receptor on the Schwann cell 
surface. 
Ciliary neurotrophic factor (CNTF) is upregulated by Schwann cells following axonal 
contact (Dobrea et al., 1992; Friedman et al., 1992) as is brain derived neurotrophic 
factor (BDNF, Sendtner et al., 1992). These molecules support different neuronal 
populations than NGF (Reynolds and Woolf 1993). 
1.4 Peripheral Myelin Protein 22 
During the late 1980's the mechanisms of nerve degeneration resulting from injury to 
the peripheral nervous system had become well recognised, yet much of the molecular 
basis of this process was unknown. The expression of the myelin proteins MBP and P0 
had been shown to be regulated during the loss of axonal contact and an attempt was 
made to describe other gene products that were regulated during regeneration. Peripheral 
myelin protein-22 (PMP-22) was identified independently by two groups from rat sciatic 
nerve cDNA libraries as being differentially regulated following nerve crush. 
Welcher et al. (1991) isolated SRI 3. This described a 1.8kb mRNA transcript that was 
rapidly repressed to less than 5% of normal values in the distal nerve segment 3-14 days 
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after nerve crush injury. By 40 days post crush, levels had recovered and were 
approaching those of control nerves. When the distal segment was prevented from 
regenerating transcript expression remained low. Spreyer et al (1991) identified a 
transcript designated CD25 with a similar expression pattern during degeneration and 
regeneration of nerve crush. The connection between expression and neuronal contact 
was confirmed in a series of experiments where nerve sections that had been prevented 
from regenerating were reconnected. Within one week nerves were seen to migrate into 
the distal stump, this was followed a week later by the expression of the CD25 
transcript. 
Both groups described a 1.8kb transcript that encoded for a 160 amino acid protein with 
a predicted molecular mass of 18kDa. The addition of a carbohydrate moiety at a 
consensus N-linked glycosylation site at Asn41 results in a final protein of 22kDa. 
Hydrophobicity plots and secondary structure predicts four putative transmembrane 
spanning domains. The N-terminus contains a putative signal peptide with a predicted 
cleavage site between Ser26 and Gly27, however cleavage is not seen. In addition 
phosphorylation sites are found at Ser57 and Thrl 18. 
Despite the very high homology of rat SR13/CD25 with the murine Gas-3 growth arrest 
specific protein it was thought to be a potential myelin protein since the described 
regulation of expression following nerve crush reflected that of other myelin proteins 
(Lemke and Chao, 1988; Trapp et al., 1988). Levels of SR13/CD25 increase 
developmentally rising from birth to a peak by postnatal day 21 (Snipes et al., 1992). 
RNA antisense probes and myelin specific antibodies localised the expression to SI00 
immunoreactive Schwann cells of peripheral nerves (Spreyer et al., 1991; Welcher et al., 
1991; Snipes et al., 1992). Given these characteristics, the protein was renamed 
peripheral myelin protein 22 (Snipes et al., 1992). 
The coding sequence and 3' untranslated region of SRI 3 and CD25 have been shown to 
be identical, however discrepancies occur in the sequence of the 5' untranslated region. 
The regulatory region of SRI 3 is identical to that of the GAS-3 gene, yet distinct from 
that of CD25. Investigation of the PMP-22 gene elucidated the gene structure. PMP-22 
is coded for by four exons, designated exons 2-5. Exon 2 codes for the first 
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transmembrane spanning domain. Exon 3 carries the extracellular loop that includes the 
N-linked glycosylation site. The second transmembrane spanning domain and half of the 
third is encoded for by exon 4. Exon 5 codes the remainder of the third membrane 
spanning domain, the fourth transmembrane domain, and the 3' untranslated region. 
Before these coding regions lies two non-translated exons la and lb that are responsible 
for the CD25 and SRI 3 transcripts respectively. Each of these in turn is regulated by the 
alternative promoters PI and P2 (Suter et al., 1994). 
The alternative transcripts were shown to have disparate expression patterns. During 
development the exon la containing (CD25) transcript can be seen to rise from birth to 
peak at PI4, initially the transcript amounts to only 30% of the total PMP-22 mRNA 
present, it rises to 80% of the total in the postnatal period corresponding to myelination. 
Following nerve injury its expression becomes undetectable 3 days post-crush. By the 
second week levels begin to recover, and at 21 days after the injury it is the major PMP-
22 transcript. 
In comparison, the exon lb containing transcript levels rise from birth to peak at 
postnatal day 4 and then decreases until postnatal day 21. Nerve injury results in a rapid 
downregulation in the first 3-7days and control levels have returned by four weeks. This 
does not parallel the formation of myelin and the expression patterns of other myelin 
proteins (Bosse et al., 1994; Suter et al., 1994). 
The gene structure presents a gene whose expression is controlled by two alternate 
promoters. PI and exon la containing transcripts are involved in the formation and 
maintenance of peripheral myelin. The P2 promoter and exon lb transcripts are more 
strongly expressed in non-neural sites and may have a separate function to that 
implicated in myelination. 
1.4.1 Non-neural Expression of PMP-22 
Manfioletti et al. (1990) reported the presence of the growth arrest specific Gas-3 in 
NIH3T3 fibroblasts. Further investigation found detectable levels in other tissues such as 
the lung and colon. Northern blot studies and the use of RT-PCR have identified a 
number of non-neural sites of expression for both transcripts of PMP-22. 
In the adult mouse, weak extra-neural expression of PMP-22 is seen in the lung, liver 
colon, skeletal muscle, testes. In the brain PMP-22 mRNA but not protein is found 
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(Spreyer et al., 1991; Welcher et al., 1991; Snipes et al., 1992). The central nervous 
system expression has been shown to be restricted to the motor neurons of the spinal 
cord, ventral horn and the cranial nerve motor nuclei (Parmantier et al., 1995, 1997). 
Bosse et al. (1994) used RT-PCR to further distinguish between the nature of the PMP-
22 transcripts. The exon la containing transcript was found to be near or below detection 
levels in all tissues except the peripheral nerve, whilst exon lb transcripts were 
expressed in the lung, skeletal muscle and the colon. In contrast a later report has found 
expression of both transcripts in the heart, lung, skeletal muscle, testis, stomach and 
tongue (Van der Weetering et ah, 1999). 
This diverse expression of PMP-22 and the existence of alternative promoters and non-
translated exons suggest a dual function for the PMP-22 protein. 
1.4.2 The PMP-22 Gene Family 
A number of hydrophobic proteins have been described that share structural similarities, 
transmembrane spanning domains and glycosylation sites with PMP-22. Recently a 
group of these have been shown to belong to the same gene family. 
This subgroup of membrane spanning proteins consists of PMP-22, the epithelial 
membrane proteins EMP-1, EMP-2 and EMP-3, and a more distant member the lens 
epithelial membrane protein MP20 (Church and Wang, 1993; Taylor et al., 1995; 
Marvin et al. 1995; Taylor and Suter, 1996; Bolin et al., 1997). Each protein shares 
amino acid sequence homology with PMP-22, with the highest degree corresponding to 
the four transmembrane spanning domains, particularly that of the second 
transmembrane region. The first hydrophilic loop contains one or more sites for N -
linked glycosylation sites, and in EMP-1 one of these is conserved with that of PMP-22 
(Marvin et al., 1995). 
The gene encoding each has been shown to be independent from, but related to that of 
PMP-22 (Jetten and Suter, 2000). 
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The epithelial membrane proteins EMP-1, EMP-2 and EMP-3 all show extensive 
expression in non-neural tissues, many sites of which are shared by PMP-22. However 
the regulation of these proteins in the nervous system is distinct from that of PMP-22. 
A study into the expression of EMP-1 during nerve injury has shown that initially EMP-
1 levels are lower than those of PMP-22 in sciatic nerve. Following trauma the levels are 
inversely correlated, EMP-1 levels rise whilst PMP-22 levels are reduced (Taylor et al., 
1995) . This contrasting expression pattern is also seen following forskolin stimulation of 
Schwann cell cultures and serum starvation induced growth arrest. As PMP-22 levels 
increase those of EMP-1 decrease (Taylor et al., 1995; Ben-Porath and Benvenisty, 
1996) . In support of this increase in expression during proliferative conditions in vitro 
the greatest expression of EMP-1 in vivo is seen in the proliferation and differentiation 
zones of the outer gastric gland and the mature epithelia of the gastric pit. 
Bolin et al. (1997) studied the expression of EMP-3/HNMP-1 during the development of 
peripheral nerves. During embryogeneis at El2, the spinal cord nerve fibres display 
EMP-3 expression, and by El 6 it is seen in the cell bodies of motoneurons. In the adult 
sciatic nerve EMP-3 is barely detectable but localised to the axon. After nerve crush, 
EMP-3 is rapidly induced distal to the injury. One week post crush, the EMP-3 
expression is no longer axonal, but is localised to regions of Schwann cell proliferation. 
Three weeks post crush, and the axon associated expression has returned. Expression 
continues after functional recovery of the injury, but with a time scale that suggests an 
active role in myelination. 
The membrane protein MP20 is a major component of the eyes lens and shares a lesser 
degree of sequence similarity with PMP-22 (25-29%), despite this, the major regions of 
conservation across the family are maintained (Taylor and Suter, 1996). It co-localises 
with connexin 46 at the junctional plaques of the lens. Expression is high in 
differentiating and mature lens cells, but it is absent from the proliferating cells 
(Tenbroek et al., 1992; Kumar et al., 1993). 
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Despite other non-neural sites of expression, mutations in the PMP-22 gene affect only 
the peripheral nervous system. It has been suggested that in these non-neural tissues, 
other members of the PMP-22 family could substitute for PMP-22 therefore the 
phenotype is not extended to these sites. It has been shown, however, that although they 
show expression in a similar range of cell types, the regulation of alternative family 
members during proliferation and growth arrest is discrete and often conflicting to that 
ofPMP-22. 
1.5 Growth Arrest 
The wide expression pattern of PMP-22 in non-neural tissues and its homology with the 
mouse growth arrest protein Gas-3 suggest it may be involved in cell cycle regulation. 
Supporting evidence is found in human and mouse disease caused by mutation of PMP-
22, Carcot-Marie-Tooth disease and the mouse models trembler and trembler-J. These 
neuropathies are accompanied by abnormal Schwann cell proliferation. 
Further investigations into the possible effects of PMP-22 on the cell cycle have 
indicated some involvement, although an exact role is still unknown. 
A characteristic of the immature Schwann cell phenotype is that both proliferation and 
programmed cell death are found in their population. Cell death is most evident during 
the first two postnatal weeks and levels decline in the adult (Grinspan et al., 1996; 
Syroid et al., 1996; Trachtenberg and Thompson, 1996). It is thought this period of 
apoptosis matches the number of Schwann cells to axons and in this way the correct 
balance for myelination and functional neuronal activity is achieved (Nakao et al., 
1997). 
In the disease state associated with Charcot Marie Tooth disease, abnormal Schwann cell 
proliferation has been associated with a subsequent decrease in Schwann cell number. In 
addition, an increase in the number of cells undergoing programmed cell death is 
observed. It is thought that this is a result of the axonal loss seen during progression of 
the disease (Erdem et al. 1998). 
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1.5.1 Growth Arrest Specific Protein-3 
Biochemical and genetic changes are involved throughout the cell cycle that are 
modulated by both positive and negative signals (Craig and Sager, 1985). A number of 
genes have been identified that are concerned specifically with the Grf3i state 
(Pepperkok et al., 1988; Schneider et al., 1988), the growth arrest specific geneGAS-3 is 
one of six genes expressed at this time in NIH3T3 fibroblasts (Schneider et al., 1988). 
It has been shown that the Gas-3 gene sequence is identical to that of PMP-22 and 
includes the 5' untranslated region of the P2 exon lb containing transcript (Manfioletti et 
al., 1990; Bosse et al., 1994). 
1.5.2 Expression of PMP-22 in Growth Arrest 
Suter et al. (1994) found that following growth arrest of rat embryonic fibroblasts, the 
increase in expression of PMP-22/Gas-3 was less dramatic than that observed in 
NIH3T3 fibroblasts. Studies showed that both the transcripts of PMP-22 were induced to 
similar levels, and the ratio between the two did not alter during growth arrest. This was 
corroborated by Zoidl et al. (1995) in rat Schwann cells. They were able to show by RT-
PCR that following serum deprivation the levels of both PMP-22 transcripts increased. 
Serum induced re-entry into the cell cycle caused a further initial increase in both, that 
was more pronounced in the lb transcript than the la. This then decreased to 
undetectable levels within 6 hours. 
In contrast Bosse et al. (1994) found that the PMP-22 exon lb containing transcript was 
exclusively upregulated in arrested rat meningeal fibroblasts, however no growth arrest-
specific expression of either transcript was found in rat Schwann cells. 
The over and under expression of PMP-22/Gas-3 in Schwann cells through retroviral 
mediated transfection gave further insight into possible mechanisms of action of PMP-
22 in cell cycle control. The introduction of excess amounts of sense cDNA coding for 
PMP-22 caused the number of cells in the S phase of the cell cycle (undergoing DNA 
synthesis as described by BrdU staining) to decrease. The expression of an antisense 
construct, however, resulted in enhanced levels of BrdU incorporation. A delay of eight 
hours in the entry of resting Schwann cells into the S phase of the cell cycle was caused 
by the overexpression of PMP-22 (Zoidl et al., 1995). This suggests that the site of 
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action of PMP-22 lies in the transition between G0G1 and the S phase, a process known 
to be under strict regulatory control (Pardee, 1989; Muller et al., 1993). 
1.5.3 Apoptosis and PMP-22/Gas 3 Expression 
In NIH3T3 cells an overexpression of the wild type PMP-22 was seen to give rise to a 
distinct phenotype. More than 50% of cells became loosely attached to the substratum, 
they showed condensed nuclei and blebbing of the plasma membrane was observed 
(Fabretti et al., 1995). This morphological appearance is characteristic of cells 
undergoing apoptosis (Kerr et al., 1971; WyllieeJ al., 1980; Evan et al., 1992). However 
no evidence for increased apoptotic activity was suggested by study of nuclear 
fragmentation using the TUNEL technique (Gravieli et al., 1992). 
Using the morphological criteria for programmed cell death described above, mutations 
in the PMP-22 gene were evaluated for the ability to induce apoptosis. Al l the mutations 
studied, including that responsible for the Tr-J mouse showed a normal phenotype. 
Zoidl et al. (1997) also investigated the role of PMP-22 in NIH3T3 fibroblasts. 
Overexpression of the wild type protein was found to reduce the number of viable cells 
in culture by an average of 61.9% (+/- 23.8%). Overexpression of the cDNA for the 
trembler mutant form of the protein however caused only a 31.8% (+/-14.2%) reduction 
in viable cells in comparison to controls. Cells were seen to be arrested at Gi with 
reduced numbers in the S and G2 phases, although all transfected cells were able to 
progress through the cell cycle. This indicates again that PMP-22 is involved in the 
progression of the cell through the transition between Gi and S phase and that this is 
disrupted in the mutant mice. 
In response to the observations of Fabbretti et al. (1995), the role of programmed cell 
death in the reduction of viable cells was investigated. In previous studies the 
overexpression of PMP-22 in Schwann cells did not give rise to any evidence of 
apoptotic activity (Zoidl et al., 1995). 
Assessment of apoptosis via nuclear staining and the TUNEL assay for DNA 
fragmentation indicated an increase in cell death by 4% with the overexpression of wild 
type PMP-22. The mutated protein, with the point mutation characteristic of the trembler 
mouse, caused no detectable apoptosis. 
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The degree of apoptosis that occurred in the two studies greatly differed, Fabbretti et al 
(1995) reported over 50% of cells showed evidence of cell death, whilst Zoidl et al. 
(1997) described apoptosis in only 4% of cells. The discrepancy may be due to the levels 
of overexpression of the protein or the method of detection. 
It has been demonstrated that withdrawal from the cell cycle after growth factor 
deprivation increases the cellular sensitivity towards apoptosis (Raff, 1992; Hoffman 
and Liebermann, 1994). I f PMP-22 expression is maintaining and regulating the growth 
arrest phase of the cell cycle it follows that a consequence of this may be increased 
apoptosis. 
The lack of evidence for an apoptotic role for PMP-22 in Schwann cells may reflect an 
increased tolerance of the cell to PMP-22, necessary because of the strong upregulation 
of its expression during myelination. Alternatively it may represent observations that 
different cell types vary in their activation of the cell death program (Collins and Lopez 
Rivas, 1993; McConkey and Orrenius, 1994). 
1.6 Disorders of the Peripheral Nervous System 
The hereditary motor and sensory neuropathies (HMSN) comprise of a group of diverse 
disorders that affect the nervous system. The causative genetic defects in a number of 
the peripheral neuropathies have been determined with the aid of studies into mouse 
mutant models. 
1.6.1 Charcot Marie Tooth Disease 
First described in 1886 by Jean Marin Charcot and Pierre Marie (Charcot and Marie 
1886) and Howard Henry Tooth (Tooth, 1886) the disease bears their names, Charcot 
Marie Tooth disease (CMT). From the age of onset at 12.2 years (+/- 7.3 years, Lupski 
et ah, 1991a), patients show progressive distal muscle weakness and atrophy that often 
begins in the feet and progress to the hands and arms. There is impairment of sensation 
and diminished tendon reflexes (Dyke et al., 1993). A significant reduction in the nerve 
conduction velocity (NCV) is also found (Nicholson, 1991) and is thought to be due to 
the progressive loss of axons (Lupski et al., 1991b). Nerve biopsies from CMT patients 
present with "onion bulbs" a sign of repeated demyelination followed by remyelination, 
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followed by remyelination, in addition large calibre axons are enclosed by abnormally 
thin sheaths (Suter and Snipes, 1995). 
The clinical features of the disease can be diverse, and it can be categorised further. The 
most common form is Charcot Marie Tooth disease type 1 (CMT-1). The disease is 
characterised by a reduced NCV and repeated demyelination/remyelination cycles. 
Patients with CMT type 2 however have near normal NCV and the main pathological 
feature is the loss of large myelinated axons (Dyke et al., 1993). A more severe form of 
the disease, known as Dejerine-Sottas disease (DSS) is also observed. Patients show 
marked hypermyelination of the peripheral nervous system and onion bulb formation 
(Suter and Snipes, 1995). 
The genetic defect of CMT-1 in the majority of patients has been mapped to 
chromosome 17 (Ionascescu et al., 1993), although a minority of the defects arise on 
chromosome 1 (Bird et al., 1982). On this basis the disease was further subdivided as 
CMT type 1A and CMT type IB respectively, the clinical symptoms of the two are 
indistinguishable (Dyke et al., 1993). 
An X-linked form of the disease CMT-X occurs in 10% of patients (Skre, 1974). 
Childhood onset, progressive distal weakness and sensory loss are more severe than in 
CMT-1. The reduction in NCV however is less than that of most CMT-1 patients (Suter 
and Snipes 1995). 
1.6.2 Hereditary Neuropathy with Liability to Pressure Palsies 
First described by Davies in 1954 hereditary neuropathy with liability to pressure palsies 
(HNPP) presents symptoms in adolescence. Patients show acute or recurrent transient 
muscle palsies that can be precipitated by trauma or pressure to peripheral nerves 
(Amato et al., 1996; Windebank, 1993). The pathological characteristics are multiple 
focal thickenings of myelin that form sausage shaped enlargements along the axon fibre, 
known as tomacula. Some individuals show a reduction of the NCV and evidence for 
demyelination and remyelination more commonly associated with CMT but no onion 
bulb formation (Windebank, 1993). 
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1.6.3 Genetics of Disease 
In 70-80% of CMT-1A sufferers, the mutation in CMT-1A is caused by a duplication of 
1.5 megabases of chromosome 17 (Lupski et al., 1991a; Raeymaekers et al., 1991; Wise 
et ah, 1993). The duplicated region is flanked by repeated sequences 17-19kb in length. 
De novo duplications arise from the misalignment of these repeats during meiosis 
(Pentao et al., 1992; Chance et al., 1994), and are overwhelmingly of paternal origin 
(Palau et al., 1993). The reciprocal deletion of this region is seen in patients with HNPP 
(Chance et al., 1993). 
1.6.4 Spontaneous Mouse Mutant Models of Disease 
A number of different spontaneously occurring mouse mutants have been described that 
present with affected nervous systems. Two stand out as displaying parallel phenotypes 
to the human peripheral neuropathy diseases. The trembler (7>) mouse and its allelic 
mutant trembler J (7V7) both show behaviour deficits as a result of abnormal myelin 
formation in the peripheral nerves. 
1.6.4.1 The Trembler Mouse 
The Tr mutation shows an autosomal dominant pattern of expression. The affected mice 
show tremor and transient seizures with no abnormality of the central nervous system. 
The morphology of the peripheral nervous system shows hypomyelination at an early 
stage. Evidence of demyelination can be seen, and the progressive nature of the 
phenotype is evident by the presence of onion bulb formation in older animals. Onion 
bulbs consist of a central thinly myelinated axon surrounded by supernumerary Schwann 
cell processes that have increased amounts of interstitial tissue (Suter and Snipes 1995). 
Despite the abnormalities, mice homozygous for the mutation are long lived (Henry and 
Sidman, 1988). 
Many Schwann cells can be seen to be in a pro-myelin state, having formed a 1:1 
relationship with the axon more typical of neonatal myelin formation. The initial axon 
Schwann cell interactions are maintained, whilst later stages of myelination are affected 
by the loss of PMP-22. 
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A great reduction in the number of myelinated fibres is seen, and those that are 
myelinated have sheaths that are thin relative to the calibre of the axon. The myelin is 
poorly compacted, particularly at the node of Ranvier, and the nodes may be wider than 
normal. The Schwann cells also contain cytoplasmic debris (for review see Suter and 
Snipes 1995). The hypomyelination is reflected in the expression of myelin proteins. 
The levels of mRNA for compact myelin proteins such as Po and MBP are greatly 
reduced (Jacque et al., 1983; Bascles et al., 1992; Garbay and Bonnet, 1992), while 
MAG levels are unchanged (Inuzuka et al., 1985). 
In the wild type mouse Schwann cells cease proliferation after the first few postnatal 
weeks, in the Tr mouse, increased Schwann cell numbers are seen as proliferation 
continues throughout life (Perkins et al., 1981a). A similar pattern of Schwann cell 
proliferation has been described in CMT and HNPP patients (Behse et al., 1972; Perkins 
et al., 1981a; Henry et al., 1983). 
It has been suggested that the abnormal proliferation of Schwann cells in Tr mice may 
be due to stimulatory signals released during the repeated cycles of myelin breakdown 
(Salzer and Bunge, 1980; De Vries et al., 1982; Koenig et al., 1991). Tissue culture 
studies show that the abnormal proliferation rates of Tr Schwann cells are lost in vitro 
(White et al., 1986; Do Thi et al., 1993). 
1.6.4.2 Trembler J 
The semi-dominant mutation in the trembler J mouse arose spontaneously and 
independently from the trembler mouse (Henry et al., 1983). It has been proposed to be 
allelic to trembler through linkage studies and the similarity of phenotype (Henry and 
Sidman, 1983). 
Heterozygotes for the TrJ mutation can be identified behaviourally by postnatal day 20. 
P20 to P25, they have a mild tremor with no obvious seizures, and a gait abnormality 
affecting the hind limbs progresses only slightly with age (Henry et al., 1983; Robertson 
et al., 1997). The severity of disease in heterozygous TrJ animals is less than that of Tr 
heterozygotes, yet it is more severe in the homozygotes. Homozygous TrJ mice are 
obvious by P5-P8, they are smaller animals and display severely dystonic, ineffective 
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movement and have difficulty in righting themselves. They do not survive beyond PI 7-
P18 (Henry et al., 1983). 
The morphology of peripheral myelin in Tr mice is affected. At P14 some of the large 
diameter axons have no visible myelin, although by P16 most posses a thin layer. By 1 
year of age nearly all axons have some myelin sheath, no evidence is seen of myelin 
breakdown and onion bulbs are absent (Suter and Snipes, 1995). The deficiency is 
greater in homozygous animals as is reflected by the severity of the phenotype. 
Immunolocalisation studies show reduced levels of MAG and Po in golgi associated 
vesicles in some Schwann cells (Heath et al., 1991), PMP-22 immunoreactivity is also 
seen to co-localise with lysosomal markers (Notterpek et al., 1997). 
More subtle abnormalities are seen in the relationship between Schwann cells and axons 
in the T/ mouse (Robertson et al., 1997). These include the morphology of the terminal 
loop of myelin and the position of the Schwann cell body relative to the centre of the 
internode. No onion bulbs are observed of the type described in Tr, however 
abnormalities in the basal lamina of TrJ Schwann cells are seen - layers of collapsed 
basement membrane possibly representing processes extended by Schwann cells that 
were later withdrawn. 
1.6.5 Identifying the Site of the Mutation 
The identification of the affected gene in the trembler and trembler J phenotype was 
preceded by a number of discoveries. In a series of experiments, Aguayo et al. (1977) 
demonstrated that the likely primary target of the defect was the Schwann cell. When Tr 
nerve grafts were introduced into a normal mouse host, the axons degenerated leaving 
the non-neural component. Subsequently abnormal myelin representative of the Tr 
phenotype was found at the site of the graft. In the reciprocal experiment, when normal 
Schwann cells attempt to remyelinate Tr axons the typical myelinated phenotype was 
observed. Schwann cells from sympathetic nerves of the Tr mouse, which are ordinarily 
non-myelinating and show no abnormality in the mutant mouse, were also grafted into 
the site of normally myelinated axons. Again the trembler phenotype was seen, 
suggesting that the defect exists in all Schwann cells (Perkins et al., 1981b) 
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The chromosomal position of the trembler and trembler J mutation were shown to map 
to mouse chromosome 11, which has synteny with human chromosome 17 the site of the 
CMT duplication. In addition the gene for the peripheral myelin specific gene of PMP-
22 has also been shown to reside on chromosome 11 (Suter et al., 1992a). Analysis of 
the sequence of the PMP-22 gene in the mouse mutants discovered the presence of a 
point mutation in each that was thought to be the likely cause of each phenotype. 
In the TV mouse a guanine to adenine substitution results in a change from glycine to 
aspartic acid at amino acid 150. This introduces a charged amino acid into the putative 
fourth transmembrane spanning domain of the PMP-22 protein which may affect its 
structure and function (Suter et al., 1992a). The TV7 mutation has a thymine to cytosine 
alteration at nucleotide 190 that results in a leucine to proline substitution at amino acid 
position 16 in the first putative transmembrane spanning domain of the protein (Suter et 
al., 1992b). The transmembrane spanning regions of the PMP-22 gene are the most 
strongly conserved, suggesting that they are important in PMP-22 function, and this is 
reflected in the phenotype resulting from their disruption. The mechanism of action of 
the mutation is unknown. The mutated protein may be unable to incorporate correctly 
into the plasmamembrane preventing the development of compact myelin. Alternatively 
the mutation may affect conformation changes to the protein structure interupting the 
normal interactions of the protein with itself or other proteins. 
The mutations in TV7 have been shown to alter the post-transcriptional regulation of the 
PMP-22 protein. Notterpek et al. (1997) described the upregulation of the lysosomal 
pathway in the mice. This lead to the hypothesis that the mutated form of the PMP-22 
protein was successfully glycosylated and then incorporated into the plasma membrane 
where it is unstable. Autophagy and/or endocytosis is then upregulated in the Schwann 
cells to remove the myelin proteins. It has recently been shown that the mutated protein 
never reaches the plasma membrane but is arrested in the vesicles of the intermediate 
compartment. 
A number of groups have shown that a minor portion of the wild type PMP-22 protein is 
targeted to the plasma membrane, while a second population is retained in the 
endoplasmic reticulum where it is rapidly turned over (Naef et ah, 1997; D'Urso et al., 
1998; Naef and Suter, 1999; Tobler et al., 1999). Tobler et al (1999) and Naef and Suter 
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(1999) investigated the effects of different point mutations on the transport of the PMP-
22 protein, including that of the trembler-J mutation. It was found that with all 
mutations found in the putative transmembrane spanning domains, regardless of the 
severity of disease seen as a consequence, no PMP-22 protein was found in the plasma 
membrane. The mutated proteins were found to remain in the endoplasmic reticulum or 
the vesicles of the intermediate compartment that are involved in transport from the 
endoplasmic reticulum to the golgi apparatus. 
When the wild type and a mutated form of the PMP-22 were co-expressed, a reduced 
amount of the wild type was inserted into the membrane. A proportion remained in the 
intermediate compartment with the mutated protein. This suggested interaction between 
the two and this was confirmed in Western blot studies that identified potential dimer 
formation by the wild type PMP-22 protein (Toblere/ al., 1999). 
What this data suggests is that point mutations result in the altered distribution of PMP-
22. When the gene is duplicated or deleted the balance of myelin proteins may disturb 
the physiology of Schwann cells. Changes in the stoichiometry of the myelin proteins 
could disrupt the interactions of PMP-22 with itself or with P 0 (D'ursoe/ al., 1999) and 
so affect the structure of compact myelin that typifies mutations of PMP-22. 
1.6.6 PMP-22 as the Primary Defect in CMT and HNPP 
Once PMP-22 had been identified as the site of the mutation in the mouse mutant 
models of peripheral neuropathy, it became a candidate for the gene responsible for 
human disease. Analysis showed that the human PMP-22 gene resides on chromosome 
17 and is complete in the CMT duplication (Matsunami et al., 1992; Patel et al., 1992; 
Timmerman et al., 1992; Valentijn et al., 1992a). In one family that displayed CMT the 
duplication incorporated only 460kb of chromosome 17. This region, while missing the 
majority of genes found in the more common duplication, does include the full PMP-22 
sequence (Valentijn et al., 1993) further implicating it as being significant. 
To further corroborate PMP-22 as the target gene, a number of families have been 
identified in which the CMT phenotype is caused by point mutations in the gene -
commonly in the putative transmembrane spanning regions. In one family the exact 
mutation seen in trembler-J has been identified (Valentijn et al., 1992b; Roa et al., 
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1993b,c). A 2 base pair frame shift in the first translated exon has been associated with 
HNPP (Nicholson et al., 1994). And two point mutations have been identified with the 
more severe DSS phenotype (Roa et al., 1993a). 
The search for mutations in other myelin genes lead to the discovery of the site of 
mutations responsible for CMT-1B and CMT-X. The importance of genes such as Po 
has been described. Giese et al. (1992) produced transgenic mice with a disrupted Po 
gene. The resulting mice show deficiencies in motor co-ordination and tremors with 
occasional seizures. A severe but incomplete loss of myelin in the PNS is seen. The 
mutation site in CMT-1B has been localised to chromosome 1, the site of the human Po 
gene. Missense mutations within the extracellular domain have been identified in the 
CMT-1B patients (Hayasaka et al., 1993a,b). A 3 base pair in frame deletion has also 
been implicated (Kulkens et al., 1993). Again mutations are occuring in functionally 
significant sites, since the extracellular domain of Po is implicated in the homophilic 
interactions that maintain the myelin sheath. 
The gene that carries the mutation for the X-linked form of CMT has been found to 
encode the gap junction protein Connexin 32, Cx32 (BergofFen et al., 1993). Cx32 is 
expressed in a number of different tissues (Dermietzel and Spray, 1993), however the 
effects of mutations within it are restricted to the PNS. In the PNS Cx32 expression is 
restricted to the Schmidt-Lanterman clefts and the paranodal loops of the myelin sheath 
(BergofFen et al., 1993a). 
In addition, mutations in the gene for Krox-20 have demonstrated the involvement of 
this transcription factor in the disease process. 
1.6.7 Transgenic Mouse Studies 
The conformation of PMP-22 as the disease causing gene was achieved with the 
production of a number of transgenic animals. Overexpression of the gene and 
disruption of it gave rise to phenotypes corresponding to those seen in the human and 
mouse condition. 
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A rat model produced by Sereda et al. (1996) with three additional copies of the PMP-22 
gene shows symptoms compatible with those of Charcot Marie Tooth disease. 
Heterozygous animals developed an abnormal gait and suffered tremor and transient 
seizures from 2 months of age. A loss of muscle strength was seen and the rats failed 
standard behavioural assays for motor performance. A decrease in the conduction 
properties of both sensory and motor nerves was observed. The myelin sheath in the 
peripheral nervous system was thin or absent and at 2.5 months onion bulbs began to 
form. The progressive nature of this model manifests itself in extensive onion bulb 
formation by 6 months of age. Motor nerves and large calibre axons were mainly 
affected. Myelin debris was occasionally observed. 
An increase in the severity of phenotype was observed in a mouse model in which an 
additional 16 copies of the PMP-22 gene was incorporated (Magyar et al., 1996). Whilst 
Schwann cells and axons had associated in the correct manner and a basement 
membrane was present, no compact myelin was formed. A two fold overexpression of 
PMP-22 mRNA was found, whilst levels of other myelin protein mRNAs were severely 
reduced. This increase in the amount of mRNA is in part due to an increase in the 
number of Schwann cells found. The abnormal proliferation of Schwann cells seen in 
the trembler and trembler-J mice was mirrored here. Behaviourally by 2 weeks of age 
mice show shivering, followed by an unsteady gait. By 2-3 months muscle atrophy 
occurs. Nerve conduction velocities are reduced. In the homozygous animal a complete 
loss of myelin was seen. Homozygotes never developed a normal gait and were 
paralysed by 4 weeks. Many died or had to be sacrificed before this time. 
Overexpression of the human PMP-22 cDNA in transgenic mice has a less pronounced 
effect on Schwann cell development but the study demonstrates the apparent dose 
sensitivity of PMP-22 expression. Mice with two additional copies of the gene displayed 
a normal phenotype and little effect was seen. Animals with four copies of the human 
gene showed some hypomyelination at adulthood and an electrophysiological defect. 
However, no behavioural abnormalities were found. When seven or more copies of the 
human gene were incorporated a severe dysmyelinating phenotype was observed with an 
39 
Chapter 1: Introduction 
abnormal gait and progressive paralysis. The differences between the severity of effects 
seen with the introduction of the human versus the murine gene may be due to 
inefficient functioning of the human gene in the mouse environment (Huxley et al., 
1996;1998) 
Mouse models of HNPP have also been produced. The disruption of the PMP-22 gene 
gives rise to a line of mice that show behavioral, electrophysiological and morphological 
abnormalities. Adlkofer et al. (1995) produced a mouse with such a null mutation. 
Heterozygous mice, with only one copy of the correct gene were phenotypically 
indistinguishable from wild type litter mates. Some individuals showed sporadic walking 
difficulties. They showed near normal nerve conduction velocities yet some myelin 
deficiencies occurred. The numbers of tomacula increased from 24 days to 10 weeks old 
and occasional onion bulbs were seen. No significant changes in axon number were 
observed. Homozygous mice begin to show walking difficulties with progressive 
paralysis of the hind limbs by post-natal day 14. Occasional tremor and convulsions 
were seen. Electrophysiological studies show a slowing of the NCV and increased motor 
latencies. At 24 days myelin thickenings, tomacula were observed, and the 
accompanying axons appeared compressed. Early stages of demyelination were seen, 
and large calibre axons were devoid of myelin. By 10 weeks of age tomacula were rare 
and onion bulbs became more prominent. Myelin degeneration was also seen. 
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1.7 Aims and Objectives 
The peripheral myelin protein 22 has previously been implicated as an important 
component of the peripheral myelin sheath. It is localized to the Schwann cell and its 
expression follows that of other myelin proteins as it increases from birth concomitant 
with the extensive myelination of the peripheral nerves. Interaction between it, and the 
major myelin protein P0, is thought to maintain the compact structure of the mature 
myelin. When cells transfected with either protein were grown together, the two proteins 
were seen to co-localise at apposing membranes suggesting an interaction between them 
(D'Urso et al, 1999). In the disease state, disruption of either component that prevents 
the two proteins interacting or that alter the correct stoichiometry between them, result 
in abnormalities of myelin formation and behavioural phenotypes charactersied by 
tremors. 
As highlighted previously, the regulation of PMP-22 is complex. Two alternative 
promoters PI and P2 give rise to alternate transcripts identified by the presence of non-
translated exons la or lb respectively. The differential regulation of these promoters 
results in a defined pattern of expression. Activity of the PI promoter identified by the 
presence of the exon la transcript is responsible for the expression of PMP-22 in 
Schwann cells of the peripheral nerve and is intimately involved in the myelination 
process. Exon lb containing transcripts predominate at sites of non-neural expression of 
PMP-22. 
The aim of this project was to produce a transgenic mouse that would express the 
reporter gene - green fluorescent protein (GFP) specifically in Schwann cells of the 
peripheral nervous system. The relevance of PMP-22 to disease, both in murine mutants 
trembler and trembler-J and the human peripheral neuropathies, combined with the 
myelin specific nature of the PI promoter made it an interesting candidate to study the 
regulation of the expression of a reporter gene within the transgenic mouse system. This 
would allow the study of both PMP-22 expression and regulation during development 
and myelin formation and the myelination process itself. 
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The aim was to use the mouse model to address a number of issues. Despite the presence 
of a number of regulatory elements typical of a tissue specific promoter that is strongly 
regulated, the PI promoter conferred only limited promoter activity in driving 
expression of a reporter gene in vitro (Suter et al. 1994). Within the in vivo environment 
it was hoped that the necessary signals would be present that would allow correct 
regulation of the PI promoter. Description of the transgenes expression pattern during 
development will confirm the PI promoter region as containing all the necessary 
elements for tissue and temporal specific regulation of PMP-22. In vitro study of 
Schwann cells derived from the transgenic mouse could be used to assess the influence 
of transcription factors or hormones on the regulation of the promoter. 
The highly visual nature of the reporter gene will allow study into the dynamic 
behaviour of Schwann cells and neurons. Previous studies in which the description of 
the elaboration of the myelin sheath has been determined have relied on detailed electron 
microscopic examination. The absence of a requirement for co-factors and substrates of 
the GFP reporter gene will allow the visualisation of these processes in real time. 
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Chapter 2. Materials and Methods. 
This chapter aims to give a detailed description of the materials and methods used 
throughout the following chapters. Al l chemicals used were of an analytical or 
molecular grade and were purchased from Sigma or BDH unless otherwise stated. 
2.1 Solutions 
Antibody Dilution Buffer 
10%HIGS 
lmg/ml bovine serum albumin 
0.5%Triton-X-100 
made up in PBS 
Genomic DNA Extraction Lysis Buffer 
50mM Tris-HCl pH8 
lOOmMEDTA 
0.5% SDS 
2x HEPES Balanced Salt Solution 
280mM NaCl 
lOmM KC1 
1.5mM Na 2HP0 4 .2H 20 
12mM dextrose 
50mM HEPES, pH 7.05 
Luria Bertani (LB) media 
1 % peptone 
0.5% yeast extract 
r /oNaCl, pH7 
PBS 
137mMNaCl 
8.5mMNaH2P04.12H20 
1.5mMKH 2P0 4 
2.7mM KC1 
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Plasmid DNA Extraction Solution 1 
50mM Tris-HCl pH 7.5 
lOmM EDTA 
lOOug/ml RNase A 
Plasmid DNA Extraction Solution 2 
0.2M NaOH 
1%SDS 
Plasmid DNA Extraction Solution 3 
1.32M potassium acetate pH 4 
Plasmid DNA Extraction Solution 4 
80mM potassium acetate 
8.3mM Tris-HCl pH 7.5 
40uM EDTA 
55% ethanol 
SOC Bacterial Growth Media 
2% peptone 
0.5% yeast extract 
lOmM NaCl 
2.5mM KC1 
lOmM MgCl 2 
lOmM MgS0 4 
20mM glucose, pH 7 
Southern Blot Solutions: 
Denaturing Solution 
1.5M NaCl 
0.5M NaOH 
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100% Denhardts Solution 
2% BSA 
2% Ficoll 
2% polyvinylpyrollidene 
Neutralising Solution 
l.SMNaOH 
0.5M Tris-HCl pH 7.2 
0.001MEDTA 
Pre-Hybridisation Solution 
5x SSPE 
5x Denhardts Solution 
0.5% SDS 1 
lOOug/ml sonicated salmon sperm DNA 
20x SSC buffer 
3M NaCl 
0.3M sodium citrate 
100 x SSPE 
3.6M NaCl 
0.2M Na2P04 
0.02M EDTA 
Superbroth 
33g peptone 
20g yeast extract 
7.5gNaCl 
l g glucose in 11 
l x T A E Buffer 
0.04M Tris-acetate 
0.001MEDTA 
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T.E 
lOmM Tris-HCl 
ImMEDTA pH 8 
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2.2 Isolation of Plasmid DNA 
2.2.1 Mini - Prep Method 
This procedure is a modification of that of Birnboim and Doly (1979) and Ish-
Horowicz and Burke (1981) as cited in Sambrook et al. (1989). A single colony of 
transformed bacteria was grown overnight in 5ml of Luria Bertani (LB) media with 
appropriate antibiotic selection. 1.5ml of the overnight culture was taken and the 
cells harvested by centrifugation at 12,000g for 1 minute. The supernatant was 
discarded and the cells resuspended in 200ul of resuspension solution (Solution 1: 
50mM Tris-HCl pH 7.5, lOmM EDTA, lOOug/ml RNase A). 200ul of lysis buffer 
(Solution 2: 0.2M NaOH, 1% SDS) was then added and the solutions mixed by 
inversion until the suspension became viscous indicating cell lysis. 200ul of 
neutralising solution (Solution 3: 1.32M potassium acetate, KOAc pH 4) was then 
added and the solutions mixed by gentle vortexing. The sample was centrifuged at 
14,000g in a bench top microfuge for 1 minute to pellet bacterial debris. The 
supernatant was transferred to a clean 1.5ml microcentrifuge tube and an equal 
volume of phenol:chloroform:isoamyl alcohol (25:24:1) added. Following 
centrifugation at 14,000g for 10 minutes the aqueous phase was removed and DNA 
precipitated by the addition of 2 volumes of 100% ethanol and 0.1 volume of 3M 
sodium acetate (NaOAc) as described below (section 2.3.1.1). 
Alternatively 500ul of Promega Magic Mini-Prep DNA purification resin were added 
to the supernatant removed after the addition of solution 3. This was incubated at 
room temperature for 5 minutes with occasional inversion. The solution was then 
pipetted into a syringe barrel attached to a Magic Mini-Prep column. The solution 
was injected into the column then washed through with 4ml of column wash solution 
(Solution 4: 80mM potassium acetate, 8.3mM Tris-HCl pH 7.5, 40uM EDTA, 55% 
ethanol). The column was centrifuged for 1 minute at 12,000g and then air dried for 
5 minutes. Following transfer to a clean 1.5ml microcentrifuge tube the DNA was 
eluted with lOOul sterile milli Q water pre-heated to 60°C. This was added to the 
column which was incubated for 5 minutes at room temperature prior to elution by 
centrifugation at 12,000g for 1 minute. 
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2.2.2 Midi-Prep Method 
A fresh 5ml overnight culture of transformed bacteria in LB was subcultured at 1 in 
200 into 200ml of LB and grown overnight at 37°C with antibiotic selection. Cells 
were pelleted by centrifugation at 6000g for 20 minutes (in a JAM rotor suitable for 
use with Beckman J2-HC centrifuge) and resuspended in 10ml of solution 1. They 
were then lysed with 10ml of solution 2 and neutralised with the same volume of 
solution 3. The sample was centrifuged for 20 minutes at 16,000g and the 
supernatant removed to a clean tube where an equal volume of isopropanol was 
added and the solution mixed by inversion. DNA was pelleted by centrifugation at 
14,000g for 20 minutes and allowed to air dry before resuspension in 2ml of T.E. 
(lOmM Tris-HCl and I m M EDTA pH 8), after which 10ml of Promega Wizard 
MidiPrep DNA purification resin was added. The slurry was run into a Wizard 
MidiPrep DNA purification column and washed with 30ml of column wash solution 
4 followed by 5ml of 80% ethanol. The column was spun briefly to aid drying and 
allowed to air dry before DNA was eluted. 1ml of T.E. was added to the column, this 
was then incubated at room temperature for 5 minutes before being spun for 1 minute 
at 2500 rpm to recover the DNA solution. The elution step was repeated to ensure 
DNA recovery was maximised. 
2.2.3 Cesium Chloride Purification of Plasmid DNA - Continuous Gradient 
500ml bacterial cultures were grown up to an OD60o of 0.5-1.0 in superbroth (Howe, 
1973; 33g peptone, 20g yeast extract, 7.5g NaCl, l g glucose in 11) 
Bacteria were pelleted by centrifugation at 6000g for 20 minutes and the cells lysed 
using 20ml of solutions 1, 2 and 3 as described in section 2.2.2. Following 
isopropanol precipitation the DNA pellet was resuspended in 4ml of T.E. 
For every 1ml of DNA solution l g of CsCl was added and for every 10ml of this 
solution 0.8ml of ethidium bromide (lOmg/ml) was added. The solution had a final 
density of 1.55g/ml with an ethidium bromide (EtBr) concentration of approximately 
740(ig/ml. The solution was centrifuged for 5 minutes at 8000g to separate bacterial 
proteins that form a scum layer at the surface. The DNA solution was removed and 
placed in Beckman Quick seal centrifuge tubes suitable for a Beckman Ti65 rotor. 
The density gradients were then centrifuged at 45,000 rpm in a Beckman VTi65 ultra 
centrifuge for 16 hours. 
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Two distinct bands of DNA were visualised using a transilluminator (UVP Inc.). The 
upper band consisted of bacterial chromosomal DNA and nicked circular plasmid 
DNA while the lower band contained the closed circular plasmid DNA. A 21 gauge 
hypodermic needle was inserted in to the top of the tube to allow air to enter. After 
the side of the tube had been wiped clean with a swab of ethanol an 18 gauge needle 
was inserted, bevelled side up, through the side of the tube beneath the layer of 
closed circular plasmid DNA which was then withdrawn. 
2.2.3.1 Removal of Ethidium Bromide 
EtBr was removed from DNA samples by isoamyl alcohol extraction. An equal 
volume of isoamyl alcohol was added, the sample vortexed and centrifuged at 1500 
rpm for 3 minutes in a bench top centrifuge. The lower aqueous phase was 
transferred to a clean microcentrifuge tube and the step repeated 4 or 5 times until 
both phases were clear. The solution was subsequently dialysed over 24-48 hours 
against several changes of T.E. to remove the CsCl. The purified DNA was 
quantitated spectrophotometrically as described (section 2.4.1). 
2.3 Genomic DN A Extraction Methods 
2.3.1 Phenol Chloroform Extraction 
2-4mm sections of mouse tail were incubated in 0.7ml of lysis buffer (50mM Tris-
HCl pH8, lOOmM EDTA, 0.5% SDS) with lOul of 25mg/ml Proteinase K for at least 
4 hours at 55°C until digested. An equal volume of phenol pH 7.5 was added and the 
sample shaken vigorously. Following a centrifugation step of 10 minutes at 12,000g 
the aqueous phase was removed to a clean microcentrifuge tube and 0.6ml 
phenol:chloroform:isoamyl alcohol (25:24:1) added. The sample was mixed and 
centrifuged for a further 5 minutes at 12,000g. The aqueous phase was again 
removed and the DNA isolated from it by ethanol precipitation as described below. 
2.3.1.1 Ethanol Precipitation 
DNA was precipitated by the addition of 2 volumes of 100% ethanol and 0.1 volume 
of 3M sodium acetate (NaOAc) pH 4.8. The sample was mixed and incubated at 
-20°C for at least 30 minutes then centrifuged at 12,000g for 10 minutes. The DNA 
pellet was washed with 70% ethanol with a 5 minute centrifugation at 12,000g. The 
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supernatant was discarded and the pellet air dried and subsequently resuspended in 
T.E. Following genomic extraction, DNA was resuspended at 4°C overnight or at 
65°C for one hour. 
2.3.2 Promega Wizard Genomic DNA Purification 
Genomic DNA was extracted using the Promega Wizard Genomic DNA Purification 
system following the manufacturers instructions. Briefly a 2-4mm tail sample was 
incubated at 55°C for at least 3 hours in 600ul of EDTA/nuclei lysis solution (500ul 
of nuclei lysis solution was added to 120ul 0.5M EDTA chilled on ice before use) 
with 17.5p.l of 20mg/ml Proteinase K solution. Following this 200uJ of protein 
precipitation solution was added to the sample and the solution vortexed for 20 
seconds. The sample was incubated on ice for 5 minutes before the precipitated 
protein was pelleted by centrifugation at 13-16,000g for 4 minutes at room 
temperature. The supernatant was transferred to a clean tube, and 600ul of 
isopropanol added. The tube was gently inverted until threads of DNA could be seen. 
The DNA was pelleted at 13-16,000g for 1 minute in a bench top centrifuge. The 
supernatant was discarded and the DNA washed in 600ul of 70% ethanol. Following 
repeated centrifugation the DNA pellet was air dried and subsequently rehydrated in 
50(0.1 of T.E. at 4°C overnight, or 65°C for one hour. 
2.3.2.1 Modification of Wizard Genomic Purification for the Extraction of 
Genomic DNA from Cultured Cells 
Adherent cells were trypsinised from the surface of the culture dish. The cells were 
then collected by centrifugation at 13,000g for 10 seconds. The supernatant was 
removed leaving the cells in 10-50ul of residual media. The pellet was resuspended 
in 200ul of PBS. Following the addition of 600ul of nuclei lysis solution the mixture 
was pipetted to lyse the cells. Protein precipitation solution was then added and the 
procedure progressed as described in section 2.3.2. 
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2.4 Quantification of DNA Solutions 
2.4.1 Spectrophotometric Determination 
The absorbencies of diluted aliquots of DNA samples were determined at 260nm on 
a Beckman DU7500 spectrophotometer. An absorbance of 1.0 at 260nm is equivalent 
to a concentration of 50(j.g/ml of double stranded DNA and from this DNA 
concentrations could be calculated. 
2.4.2 Qualitative Analysis of DNA Solutions 
The optical density of each sample was also measured at 280nm. A ratio of 1.8 - 2.0 
between OD260 and OD280 was indicative of an uncontaminated DNA sample. 
2.4.3 Comparative Determination of DNA Concentration 
Comparison of the DNA sample with that of known concentrations of digested X 
DNA on an agarose gel gave an estimate of the DNA concentration. 
2.5 DNA Manipulations 
2.5.1 RNase A Treatment 
RNA was removed from DNA solutions by the addition of RNase A to a final 
concentration of 20|ig/ml. Denatured RNA was subsequently removed by ethanol 
precipitation (section 2.3.1.1). 
2.5.2 Restriction Endonuclease Digestion of DNA 
Plasmid DNA was digested at concentrations of 10-lOOng/ul in a total volume of 10-
50(0.1 with 5 units of restriction endonuclease, 0.1 volume of the appropriate lOx 
enzyme buffer made up to the final volume with sterile water. The reaction was 
incubated at the recommended temperature, for the majority of restriction enzymes 
this is 37°C, for one hour. 
For Southern Blot analysis of genomic DNA a total of 1 Ojag of DNA was digested in 
a 50-1 OOul volume with 40 units of restriction enzyme for 4-5 hours at the 
recommended temperature. For further analysis by gel electrophoresis the digest was 
subsequently concentrated by ethanol precipitation as previously described (section 
2.3.1.1) and resuspended in a volume of 30(4.1 T.E. 
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2.5.3 Electrophoretic Separation of DNA Fragments 
Gel electrophoresis was performed using 1-2% agarose gels ( lx TAE buffered, 
0.04M Tris-acetate, 0.001 M EDTA). The concentration of agarose was varied 
according to the size of fragment to be analysed (Sambrook et al., 1989). Generally, 
0.8% agarose gels were used. These efficiently separate linear DNA between 0.8-
10.0 kb. PCR fragments were isolated on 1.2% gels giving a resolution of 0.4 -6.0 kb 
size fragments. 
DNA fragments were visualised using a trans-illuminator (UVP Inc.) or Gel Doc 
1000 imaging system (Biorad). 
2.5.3.1 DNA Fragment Isolation: Qiaex II Agarose Gel Extraction 
DNA to be recovered following electrophoresis was removed in the smallest possible 
volume of agarose and isolated by the following protocol. 
The Qiagen Gel Extraction kit was used according to the manufacturer's guidelines. 
Briefly, 3 volumes of buffer QX 1 was added to 1 volume of agarose. This was 
incubated at 50°C for 10 minutes with lOul of Qiaex II particles. The sample was 
centrifuged for 30 seconds and the supernatant discarded. The pellet was 
resuspended in 500ul of buffer QX1 and spun for 30 seconds at 14,000g in a bench 
top microfuge. The pellet was then washed twice in the supplied buffer PE and 
allowed to air dry for 10-15 minutes. The pellet was resuspended in 20ul of T.E., 
spun for 30 seconds and the DNA solution removed to a clean microcentrifuge tube. 
The elution step was repeated to ensure maximum recovery of DNA. 
2.5.4 End Filling of DNA Fragments 
The 3' recessed ends of a restriction fragment were converted to blunt ends by the 
following method which utilises the 3' - 5' exonuclease activity of the Klenow 
fragment of DNA polymerase I (Sambrook et al., 1989). The DNA fragment 
(maximum of 500ng) was incubated in a final volume of 50ul with 5ul of lOx 
Klenow buffer (130mM KP0 4 , 6.5mM MgCl 2 , ImM dTT, 0.032mg/ml BSA), 1.4ul 
of stock dNTP's (each at 1.2mM) and 2 units of Klenow enzyme per lug of DNA. 
This was incubated at room temperature for 30 minutes, EDTA was added to a final 
concentration of lOmM, and incubated for 10 minutes at 75°C to inactivate the 
enzyme. Buffer and enzyme contaminants were then removed using a simple 
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modification of the method given in section 2.5.3.1. from which the incubation at 
50°C for 10 minutes was omitted. 
2.5.5 Dephosphorylation of Plasmid Vector DNA 
Dephosphorylation of vector DNA prevents its re-circularisation during ligation. Up 
to 20ug of vector DNA was incubated with 5ul of lOx dephosphorylation buffer and 
lu l of calf intestinal alkaline phosphatase (CIP) in a final volume of 50ul at 37°C for 
30 minutes. The enzyme was then inactivated by the addition of EDTA to 5mM and 
incubation at 75°C for 10 minutes. Buffer and enzyme contaminants were then 
removed using the modification of the Qiagen Gel Extraction kit described in section 
2.5.4. 
2.5.6 Ligation of DNA 
Bacteriophage T4 DNA ligase was used to ligate together DNA fragments and 
linearised plasmid vector with either compatible cohesive or blunt termini. The 
fragments of insert and vector DNA were mixed at a molar ratio of 3:1 respectively 
with a total combined amount of lOOng of DNA. A 0.1 volume of lOx ligation buffer 
(0.66M Tris-HCl pH 7.5, 50mM MgCl 2 , 50mM DTT, lOmM ATP [stock ATP 
solution lOOmM disodium salt, pH 7.0 adjusted by addition of 0.1 volume of Tris-
HCl pH 9.5 and stored at -20°C]) was added with 1 unit of T4 DNA ligase for 
cohesive termini. For blunt ended termini 3 units of ligase were added. The reaction 
was then incubated at 4°C overnight. The ligation mixture was then used to transform 
competent E. coli cells as described in section 2.5.8. 
Control reactions were carried out in tandem to assess the efficiency of each stage of 
the protocol. Ligation reactions that omitted the addition of T4 DNA ligase were 
performed to ensure that in the initial stages the DNA components were fully 
digested. Any transformant colonies resulting from this reaction would indicate that 
some circular DNA remained. Reactions were carried out in which vector DNA only 
was added to the reaction. In one instance the non-phosphorylated vector DNA was 
used. In another only the CIP treated, dephosphorylated vector was present in the 
reaction. Comparison of the number of transformed colonies in each will give an 
indication of the efficiency of the dephosphorylation reaction. Finally a control to the 
transformation step was performed in which known circular plasmid DNA was 
transformed. This ensured that the competent cell aliquot used was viable. 
53 
Chapter 2: Materials and Methods 
2.5.7 Competent Cells 
2.5.7.1 Calcium Chloride Competent Cells 
The method employed was a variation of that used by Cohen et al. (1972) as cited in 
Sambrook et al. (1989). Briefly a 5ml aliquot of LB media was inoculated with a 
single colony of E.coli and incubated overnight at 37°C with appropriate antibiotic 
selection. This was subcultured at a 1 in 100 dilution in 11 of LB broth and grown 
until the optical density at 600nm (OD60o) reached between 0.5 and 1.0. The cells 
were chilled on ice for 10 minutes and pelleted at 4000g for 5 minutes at 4°C. The 
pellet was then resuspended in 50ml of ice cold sterile CaCb (lOOmM, pH 8) and 
stored on ice for 15 minutes before the centrifugation step was repeated. The cell 
pellet was resuspended in 6.66ml of ice cold CaCb (lOOmM, pH 8) and dispensed 
into 0.1ml aliquots. These were kept on ice until immediate use (within 24 hours) or 
alternatively snap frozen in 20% glycerol in liquid nitrogen and stored at -80°C for 
subsequent use. 
2.5.7.2 Electrocompetent Cells 
One litre of LB was inoculated with a single colony of fresh E. coli and incubated at 
37°C until the OD60o was 0.5 - 1.0. The culture was chilled on ice for 15-30 minutes 
then the cells pelleted at 6000g for 15 minutes at 4°C. The pellet was resuspended in 
one litre of ice cold sterile distilled water. The chilling and centrifugation step was 
repeated and the cell pellet resuspended in 0.51 of cold sterile water. Following a 
further cycle of incubation on ice and centrifugation the subsequent cell pellet was 
resuspended in 20ml of 10% glycerol. A final centrifugation was performed and the 
cells were resuspended in 2-3ml of 10% glycerol. 50ul aliquots were frozen on dry 
ice and stored at -80°C for up to 6 months. 
2.5.8 Transformation of Competent Cells with Circular Plasmid DNA 
2.5.8.1 Calcium Chloride Transformation 
An aliquot of CaCh competent cells was resuspended in 900(4.1 of ice cold sterile 
0.1M CaCL;. A lOOul aliquot was removed from this and up to lOOng of the plasmid 
DNA added. The aliquot was incubated on ice for 30-90 minutes before being heat 
shocked at 43.5°C for 45 seconds. The cells were then placed on ice for 2 minutes 
before the addition of 900ul of SOC (2% peptone, 0.5% yeast extract, lOmM NaCl, 
2.5mM KC1, lOmM MgCl 2 , 10mM MgS0 4 , 20mM glucose, pH 7), and then 
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incubated at 37°C for at least 30 minutes to allow cell recovery. lOOul of the cell 
suspension were spread across the surface of solid LB plates (LB with 1.5% agar 
with antibiotic selection appropriate to the cell strain and plasmid DNA) and the 
inverted plates were then incubated overnight at 37°C. The remainder of the 
transformed cell suspension was centrifuged briefly in a bench top centrifuge to 
pellet the cells. The majority of the supernatant was removed leaving approximately 
lOOul, the remaining cells were subsequently resuspended in this volume and plated 
on solid LB with antibiotic selection and incubated at 37°C overnight. 
2.5.8.2 Electro-Transformation 
lng of DNA was added to 40u.l of electrocompetent cells which were subsequently 
incubated on ice for 60-90 seconds, transferred to a chilled cuvette (2mm gap width) 
and electroporated (Bio-Rad Gene Pulser electroporator set to 2.5kVolts, 100 Ohms 
with a capacitance value of 2.5). An indication of transformation efficiency was 
established by noting a time constant of approximately 4.7. Following 
electroporation 1ml of SOC was added and the cells were allowed to recover at 37°C 
for an hour. Aliquots were then plated on LB as described above (section 2.5.8.1) 
and grown at 37°C. 
2.5.9 Blue/ White Selection Screening. 
This technique is used to identify recombinant, successfully ligated clones within 
appropriate vector backbones. A series of plasmid vectors have been developed that 
contain the sequence for the first 146 amino acids of the P-galactosidase gene. When 
transformed into appropriate host cells containing the carboxy terminal of the P-
galactosidase gene the components can associate via a-complementation to form an 
enzymatically active protein (Ullman et al., 1967). In the presence of the substrates 
P-D-isopropyl-thiogalactopyranoside (IPTG) and 5-bromo-4-chloro-3-indolyl-P-
galactopyranoside (X-Gal) such Lac Z+ bacteria exhibit a blue colour (Horwitz et al., 
1964). The insertion of a foreign DNA fragment into the lacZ gene of the plasmid 
gives rise to an amino terminal incapable of a complementation and will result in 
white bacterial colonies. 
The ligation reaction was transformed into appropriate bacterial host strains such as 
JM109. Previously prepared solid LB plates with the correct antibiotic selection were 
spread with 50ul of 50mg/ml X-Gal and lOOul of 0.1M IPTG. These components 
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were allowed to absorb into the plate for at least 30 minutes before the transformed 
cells were plated out. 
2.6 DNA Sequencing 
Plasmid DNA for DNA sequencing was prepared using the Promega Wizard 
miniprep kit as described previously (section 2.2.1). Sequencing of double stranded 
plasmid templates was performed by the dideoxy-sequencing method of Sanger et al. 
(1977) using the fluorescent dye linked universal primers SP6 and T7. Custom 
primers were used in conjunction with the Applied Biosystems Taq dideoxy 
terminator cycle sequencing kit. Sequencing was performed in both directions using 
either an Applied Biosystems 373 DNA Sequencer or an ABI Prism 377 XL DNA 
Sequencer. 
2.7 Transfection Protocols 
The ability of plasmid constructs to express the desired gene can often be assessed by 
introducing the plasmid into an appropriate cell type. This can be achieved by any of 
the appropriate methods. 
2.7.1 Calcium Phosphate Transfection 
24 hours before transfection cells were harvested and plated at a density of lx lO 5 -
2xl0 5 cells/cm2 in 35mm culture dishes and incubated at 37°C in a 5% C0 2 
atmosphere. For each dish HOul of DNA (40ug/ml in T.E.) were added to 125ul of 
2x HEPES buffered saline or HBS (280mM NaCl, lOmM KC1, 1.5mM 
Na 2HP0 4 .2H 20, 12mM dextrose, 50mM HEPES, pH 7.05, filter sterilised through a 
0.22 micron filter). Subsequentlyl5.5ul of 2M CaCl2 were added dropwise with 
gentle mixing. Following incubation at room temperature for 20-30 minutes the 
DNA precipitate formed was resuspended by trituration and added to the media 
above the cells. After incubation of the cells with the DNA complex for at least six 
hours (optimised for each cell type), the cells were washed with PBS and fresh media 
added. The cells were assayed for expression of the transfected construct 48-72 hours 
later. 
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2.7.2 Lipophilic Transfection Reagents - Fugene 
24 hours before transfection the cells were plated at l -3x l0 5 cells/35mm dish. For 
each dish 97ul of serum free culture medium was placed in a tube, and 3u1 of Fugene 
(Boehringer-Mannheim) were then added directly and the solution left to stand for 5 
minutes. Care was taken to avoid contact with the walls of the tube and so avoid 
absorption of the reagent to the plastic. The complex was then added dropwise to a 
second tube containing l-2ug of the DNA to be transfected and gently mixed. 
Following a 15 minute incubation at room temperature the mixture was slowly 
introduced to the media above the cultured cells. Unless necessary for subsequent 
experiments the reagent was not removed from the cells prior to assay for the 
expression of the construct. 
2.7.3 Lipophilic reagent - Lipofectamine 
Cells were subcultured 24 hours before transfection as described previously (2.7.2). 
For each 35mm culture dish l-2ug of DNA were suspended in a final volume of 
lOOul with serum free media. In a second tube lOul of the transfection reagent 
Lipofectamine (Life Technologies) was added to 90ul of serum free media. The two 
solutions were combined and incubated together for 15-45 minutes before 0.8ml of 
serum free media were added. Media was removed from the cells and replaced with 
lml of the DNA containing solution. Cultures were incubated with the DNA 
complex for 6 hours at 37°C, 5% C0 2 before it was replaced with 2ml of growth 
media. The cells were assayed for expression after 48-72 hours. 
2.7.4 Transfection via Electroporation 
Cells were trypsinised from the culture dish and suspended at a density of 2-5x106 
cells/ml. lOug of DNA in a volume of less than 40ul was added to 400ul of the cell 
suspension. This was placed in a 4mm cuvette and pulsed at 220-300V (Genetronics 
BTX, Electro Cell Manipulator), optimised for each cell type, lml of growth media 
was immediately added and the cells re-plated in a 35mm culture dish. 
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2.8 Southern Blotting Techniques 
2.8.1 Denatured Sonicated DNA 
Salmon sperm DNA was suspended in water at a concentration of lOmg/ml and 
sheared by repeatedly being passed through a 17 gauge hypodermic needle. The 
DNA was then denatured in a boiling water bath for 10 minutes followed by 
quenching on ice for 5 minutes before use or storage at -20° C. 
2.8.2 Preparation of Radiolabeled Probes. 
DNA fragments were labelled with [ 3 2P] dCTP 10u€/ul (Amersham) using the 
random primer method of the Amersham "Rediprime" labelling kit. 25ng of probe 
DNA was diluted to a final volume of 45ul with T.E. and denatured in a boiling 
water bath for at least 5 minutes. The volume was adjusted i f necessary to 45ul and 
was added to a Rediprime kit aliquot. 5ul of [32P]-dCTP (10u€/ul) was added and the 
reaction incubated at 37°C for 20-30 minutes. The labelled DNA was then denatured 
once more in a boiling water bath for 5 minutes and quenched on ice for a further 5 
minutes. This was then added directly to the pre-hybridisation solution (section 
2.8.4). 
2.8.3 Transfer of DNA to Nitrocellulose Membranes 
The following method is a modification of that of Southern (1975). DNA was 
transferred from an agarose gel to a Hybond-C nitrocellulose membrane (Amersham) 
following the procedures below. The agarose gel containing the DNA samples was 
photographed with a fluorescent calibration rule. The genomic DNA within the 
agarose gel was depurinated in 0.25M HCL for 15 minutes then rinsed twice with 
distilled water. The gel was soaked in an excess volume of denaturing solution (1.5M 
NaCl, 0.5M NaOH) for 45 minutes followed by two distilled water rinses and then 
soaked in neutralising solution (1.5M NaOH, 0.5M Tris-HCl pH 7.2, 0.001M EDTA) 
for 45 minutes with gentle shaking. After further distilled water washes the gel was 
then blotted overnight. 
A platform was placed over a reservoir of 20x SSC buffer (3M NaCl, 0.3M sodium 
citrate). A wick of 3MM Whatman filter paper was placed over this, its ends 
extending into the reservoir, and soaked with buffer. The agarose gel was placed, 
well-side down on top of the filter paper, and any air bubbles were gently removed. 
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A piece of pre-wetted nitrocellulose membrane, cut to the correct size was then 
placed onto the gel avoiding air bubbles. Once in place the membrane was not 
moved. Two additional pieces of buffer soaked Whatman 3MM filter paper and a 
stack of absorbable hand towels all cut to the same size as the gel were then placed 
over the membrane. The ensemble was then covered with a 0.5kg weight and left for 
at least 16 hours to allow DNA transfer after which time the apparatus was 
dismantled. The membrane and gel were removed together, placed membrane down 
on a piece of clean filter paper. The position of the wells was marked on the 
membrane before the gel was discarded. The membrane was washed in 2x SSC 
before air drying. The DNA was fixed to the membrane by baking at 80°C for 2 
hours. 
2.8.4 Hybridisation of Radiolabeled Probes to Southern Blots. 
Hybridisation was carried out in a Techne Hybridisation tube in a Techne Hybridiser 
HB-1 oven. The membrane was incubated in 25ml of pre-hybridisation solution (5x 
SSPE [lOOx SSPE: 3.6M NaCl, 0.2M Na2P04, 0.02M EDTA] 5x Denhardts solution 
[100% Denhardts: 2% BSA, 2% Ficoll, 2% polyvinylpyrollidene], 0.5% SDS and 
lOOug/ml sonicated salmon sperm DNA pre-heated to 65°C), for 6 hours at 65°C. A 
denatured 32P-dCTP radiolabeled probe was then added and the filter hybridised 
overnight. 
The probe solution was removed and the filter washed twice with pre-heated 
2xSSPE, 0.5% SDS for 10 minutes at 65°C. This was followed by one wash with 
lxSSPE, 0.5% SDS and a higher stringency wash with O.lxSSPE, 0.5% SDS both at 
65°C. The level of non-specific hybridisation was assessed using a Geiger counter 
following each wash. Finally the filters were wrapped in clingfilm and hybridisation 
bands detected as described below. 
2.8.5 Detection of Hybridised Bands 
The filter was enclosed in clingfilm and exposed to Fuji RX-100 X-Ray film within 
an Amersham Hypercassette at -80°C for at least 48 hours. Following this the 
position of the filter was marked on the photographic film which was subsequently 
developed in Ilford Phenisol High Contrast film developer and fixed with Kodak 
Unifix diluted according to manufacturer's instructions. I f the signal detected was 
weak the filter was exposed to film for up to five days. The distance of the molecular 
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weight markers from the well was determined from the image of the original gel 
calibrated with a fluorescent ruler, and compared to the position of the radioactive 
band on the film to resolve the size of any hybridising fragments. 
2.9 General Tissue Culture Techniques 
2.9.1 Aseptic Techniques 
All tissue culture work was carried out in a designated tissue culture unit. Solutions 
were prepared with autoclaved water and filter sterilised before use. Al l experiments 
were performed in a class I I Microflow Biological Safety Cabinet and items 
sterilised with 70% ethanol before entry into the hood. 
2.9.2 Subculturing Cells 
Confluent flasks or 35mm culture dishes (Greiner) were subcultured as follows. The 
growth media was removed and replaced with sterile PBS to wash the remaining 
media from the cells. This was removed and replaced with 1ml or 0.3ml respectively 
of 0.25% trypsin. The cells were returned to a 37°C incubator, 5% CO2 (LEEC) and 
observed until they detached from the base of the culture vessel. An excess volume 
of serum containing media was then added and the cells harvested from the media by 
centrifugation at 1000 rpm for 5 minutes. The cell pellet was washed with growth 
media. A further 1ml of fresh media was then added and the cells dissociated into 
single units by trituration through a fine pipette tip or hypodermic syringe. The cell 
density was then calculated as described below before aliquots were plated. 
2.9.3 Cell Counting 
To determine the density of viable cells prior to plating, equal volumes of 0.6% 
trypan blue and the cell suspension were mixed. An aliquot was removed and 
injected into the chamber of a gridded haemocytometer. Under a stereoscopic 
microscope the number of viable cells, those that have not taken up the blue dye, in 
the five subdivided sectors were counted. The average was taken from this and 
multiplied by 2 to account for the dilution factor to determine the number of cells x 
104/ml. The density at which cells were then plated was dependent upon the cell type 
and subsequent procedures. 
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2.9.4 Treating Coverslips for use in Tissue Culture 
Coverslips were immersed in excess xylene for 24 hours with gentle agitation. This 
was replaced with acetone for 30 minutes and then 100% ethanol for 24 hours. 
Coverslips were washed several times in distilled water until they washed clear and 
then further soaked in distilled water for 1-2 hours. They were then immersed in 
100% ethanol for at least 1-2 hours before use, and were subsequently maintained in 
100% ethanol. 
2.9.4.1 Brief Treatment of Coverslips 
Coverslips were treated with xylene as above overnight. This was replaced with 
acetone for 30 minutes and then 100% ethanol for 60 minutes before washing with 
distilled water. Coverslips were soaked first in distilled water for 1 hour then 100% 
ethanol for at least 1 hours before use. Coverslips were stored as above (2.9.4). 
2.9.5 Collagen Coated Coverslips 
Treated coverslips were coated with collagen and poly-d-lysine before use. Collagen 
Type I from rat tail (Sigma) was dissolved at 0.5mg/ml in 0.1% acetic acid and 
stored in 1ml aliquots at -80°C. Equal volumes of poly-d-lysine (Sigma, lOOug/ml 
filter sterilised) and the prepared collagen were mixed and IOOu.1 spread across the 
surface of each coverslip. This was allowed to air dry before being sterilised with UV 
light for 30 minutes. 
2.9.6 Alternative Substrates for Coating Coverslips 
Clean coverslips were coated with lOOul of collagen (0.25mg/ml), poly-lysine 
(50ug/ml) and laminin, components of the endogenous basal lamina and allowed to 
air dry. The commercially available, growth factor reduced basement membrane, 
Matrigel (Becton Dickenson) was diluted to a concentration of 0.148mg/ml with a 
consistency suitable to lay a fine film across the surface of the coverslip. Excess was 
applied to the coverslip, after an hour this was removed and the coverslip was 
allowed to air dry. 
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2.10 Conditions for the Maintenance of Cells In Vitro 
A number of common cell lines have been used to express different plasmid 
constructs through transfection protocols. These are described below, with the 
conditions needed for their successful culture. 
2.10.1 SCL4.1/F7 
This transformed Schwann cell line was produced by pulsing primary rat Schwann 
cells with the mitogen, cholera toxin (Haynes et al, 1994). 
The cells are maintained in DMEM with low glucose and glutamax (Gibco) 
supplemented with 10% foetal bovine serum (FBS, Sigma). See Figure 2.10 C 
2.10.2 Primary Myoblasts 
Primary rat myoblasts were provided by colleagues. They were prepared following 
the trypsinisation and collagenase digestion of the hind limb muscle of neonatal rat. 
Cells were cultured on 1% gelatin coated plates to 90-95% confluency in DMEM 
containing 10% FBS and 2mM glutamine. 
In preparation for transfection of the myoblasts the cells were pre-plated to remove 
any residual fibroblasts from the culture. Confluent flasks of the cells were 
trypsinised one day prior to the scheduled transfection and pre-plated in a 60mm 
petri dish with no gelatin coat for 25-30 minutes. Presumed fibroblasts adhered to the 
substrate leaving a suspension of myoblasts that were then collected and plated on 
gelatin coated dishes. See Figure 2.10 D 
2.10.3 Fibroblasts 
Primary human skin fibroblast cultures were donated by colleagues within the 
laboratory. Their growth media comprised DMEM with glutamax and 10% FBS. 
Figure 2.10 E 
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2.10.4 COS-7 
COS-7 cells are derived from the CV-1, African Green monkey kidney cell line. 
They have been transformed by an origin-defective mutant of SV40 (Gluzman, 
1981). These cells are widely commercially available. 
They are maintained in Dulbecco's modified eagle's medium (DMEM) with 
glutamax (Gibco) and 10% foetal bovine serum (FBS, Sigma). See Figure 2.10 F. 
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Figure 2.10 
Phase contrast images of cell types used throughout. A and B. Primary co-culture 
from the dorsal root ganglia with neuronal and Schwann cell outgrowth. Scale bar 
200um and 50um respectively. C. SCL4.1/F7 transformed Schwann cell line. D. 
Preparation from neonatal rat muscle showing the presence of myotubes. E . Primary 
skin fibroblasts. F. COS-7 cell line derived from the kidney of the Green monkey. 
Scale bar 200um 
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2.11 Preparation of Primary Cells 
The use of animals in all procedures was carried out in accordance with Home Office 
guidelines under the project licence 60/2093 and personal licence 60/6195. 
2.11.1 Schwann Cells Isolated from the Sciatic Nerve of Neonatal Animals. 
This method is based on that of Brockes et ah, 1979. 
2.11.1.1 Preparation of the Cells. 
Newborn mice of between 4 and 5 days old were sacrificed by cervical dislocation. 
The lower abdomen was serilised with 70% ethanol and the skin over the leg 
retracted to reveal the sciatic nerve beneath the muscle. The sciatic nerve was 
removed from each pup from the lumbar spine to the knee joint and transferred to 
Hanks balanced salt solution (HBSS, Sigma). 
When all the nerves had been collected they were removed from the HBSS and as 
much as possible of the residual media was removed. Spring scissors were used to 
mince the nerves to 0.5mm lengths and the tissue was then placed in a sterile 1ml 
tube. 
The tissue was incubated with 0.5ml of collagenase B (lmg/ml, Boehringer-
Mannheim) at 37°C for 5 minutes. The collagenase was removed and replaced with 
lml of 0.25% trypsin and further incubated at 37°C for 15-20 minutes. 
The enzyme activity was arrested by the addition of 0.1ml heat inactivated FBS. The 
tissue was further dissociated by trituration with a 21 or 23 gauge hypodermic 
syringe. The contents were allowed to settle for one minute then the supernatant was 
removed to a sterile universal tube with 2ml of growth media (88ml DMEM, 10ml 
FBS, 2ml 0.25M glutamine, per 100ml). The suspension was centrifuged at 1,600 
rpm for 3 minutes. The cell pellet was resuspended in growth media and split 
between 3 coated 35mm dishes. These were incubated at 37°C in a 5% C0 2 
atmosphere. Cell counting is not necessary at this point as the culture contains a 
mixed population of cells. 
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2.11.1.2 Post Plating Maintenance of the Cultures 
After one day in culture 1 um cytosine arabinoside was added to prevent the growth 
of fibroblasts. 
After 3 days in culture the media was replaced with fresh growth media. At 5 days 
post plating a further lum of cytosine arabinoside was added. This was removed two 
days later, and the cells subsequently maintained in growth media. 
2.11.2 Dorsal Root Ganglion Preparation of Schwann cells and Neurons in co-
culture. 
This protocol is based on that of Wood et al, 1976. 
A 15 day pregnant mouse (day of plugging day 0) was sacrificed by cervical 
dislocation. The abdomen was sterilised with excess 70% ethanol and an incision 
made through the skin and body wall to reveal the uterus. Following an incision 
through the cervix and detachment from the ovaries the uterus was removed to a petri 
dish containing HBSS. 
The uterine walls were separated and the embryos released. They were immediately 
decapitated to ensure humane death. 
The internal viscera of each embryo was removed allowing ease of access to the 
spinal column. A pair of fine forceps was used to split the vertebrae along the length 
of the spine. From here the spinal cord could be lifted out with the ganglia intact. 
Under a dissecting microscope the ganglia were picked from the spinal cord and 
plated in coated 35mm culture dishes with 2ml of plating media (90ml basal media, 
10 ml FBS, 50|_il nerve growth factor [Sigma], per 100ml. Basal media, 500ml MEM 
[Gibco], 1.19g HEPES, 2.5g d-glucose adjust to pH 7.4, add 1.1 g NaHC0 3 then filter 
sterilise). Any remaining ganglia, which failed to separate with the spinal cord, were 
removed from between the vertebrae with fine forceps and plated out. In general 8-
12 ganglia were plated in each 35mm culture dish and three dishes could be prepared 
from 1 animal. 
24 hours following plating the media was removed and replaced with 2ml of defined 
media (98ml of basal media, 1ml 200mM glutamine, 1ml N2 supplement, Gibco per 
100ml.). 
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2.11.2.1 Dorsal Root Ganglion Neuron Cultures. 
Cultures of pure neurons can also be prepared from dorsal root ganglia cultures. 
Ganglia were removed from embryos at 15 days of pregnancy, El5 as described 
above. One day after plating lOuM of the antimitotic reagents uridine and 
fluorodeoxyuridine were added to the media above the cells. The following day the 
media was replaced with defined media for 2 days. I f Schwann cells were still 
present the anti-mitotic step was repeated. Bare neurons were maintained in defined 
media with nerve growth factor. 
2.11.2.2 Removal of the dorsal root ganglia. 
On occasion the neuronal cell bodies were removed from the co-cultures to give rise 
to cultures predominated by Schwann cells. The ganglia were removed by excision 
with a pulled Pasteur pipette tip. The debris was removed and fresh media was 
added. The cultures were monitored to ensure that all neuronal material had been 
removed. 
Control experiments showed that within 2 days of removal the axons were found to 
have degenerated. Incubation of the cultures with NF68 monoclonal antibody to 
neurofilament showed the loss of all neuronal processes, (section 2.12). 
The ganglia removed in this manner were capable of seeding new co-cultures 
following re-plating. 
2.11.3 Crude Dissection of Different of Organs 
Basic dissection of the heart, lung, liver and skeletal muscle from the hind limb of a 
transgenic embryo were carried out. The resulting pieces of tissue were dissociated 
by trituration through a fine bore syringe needle. The cell suspension from each was 
plated in serum containing plating media on collagen/poly-lysine coated cover slips 
(section 2.9.5). 
2.11.4 Dissection of the Sciatic Nerve from Neonatal Mice 
Neonatal mice were humanely sacrificed by cervical dislocation and the sciatic 
nerves removed. Briefly the skin was pulled back to expose the muscles of the hind 
limb. Fine forceps were used to gently part the individual muscles and expose the 
sciatic nerve. The nerve was separated from surrounding connective tissue and then 
removed from the lumbar spine to the knee joint. In older, larger animals a piece of 
67 
Chapter 2: Materials and Methods 
sterile cotton was pulled underneath the exposed nerve at one end and was tied 
around the nerve. Once the opposing end of the nerve had been severed from its 
attachment this prevented the nerve from recessing into the muscle. In younger, 
smaller animals this proved technically difficult and it was easier to maintain a hold 
on the fibre during the first cut. Once the opposite end was detached the nerve could 
then be removed and placed in PBS. One nerve from each mouse was gently teased 
apart using fine forceps until individual fibres were present. These were mounted in 
PBS and overlayed with a coverslip. This was then sealed with nail varnish. In this 
state the nerves were viable for analysis by confocal microscopy for approximately 
48 hours. The remaining nerve was mounted in Tissue-Tek O.C.T Compound 
(Sakura) and frozen in liquid nitrogen before storage at -80°C. 
2.12 Immunostaining Procedures 
2.12.1 General Immunostaining Method 
Primary cultures were washed twice with 2ml of phosphate buffered saline (PBS) at 
room temperature for 5 minutes before fixation in 2ml of 95% ethanol/5% acetic acid 
for 10 minutes at -20°C. Two subsequent PBS washes were followed by the addition 
of lOOul 10% heat inactivated goat serum (100% HIGS [ICN Biomedicals]: Goat 
serum was heat inactivated at a solution temperature of 65°C for 30 minutes. 
Dilutions to a final concentration of 10% were performed with PBS and stored in 
lml aliquots at -20°C) at room temperature for 15 minutes. 200ul of primary 
antibody (1:100 dilution with antibody dilution buffer [10% HIGS, lmg/ml bovine 
serum albumin (BSA), 0.5% Triton-X-100] made up in PBS) were added to the 
coverslip with an incubation of 60 minutes at room temperature or overnight at 4°C. 
This was removed with four PBS washes before the addition of 200ul of fluorescent 
labelled secondary antibody (diluted 1:100 with antibody dilution buffer). The cells 
were incubated for 30 minutes in the dark at room temperature and then washed as 
before with four PBS washes. Coverslips were mounted on microscope slides with 
Mowiol (Calbiochem). 
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Commonly used secondary antibodies: 
Tetramethyl-rhodamine-isothiocyanate (TRITC), Kirkegaard and Perry Inc. 
Alexa-fluor 546, Molecular Probes. 
2.12.2 Paraformaldehyde Fixation and Immunostaining 
Primary cultures were washed twice with PBS and fixed with 4% paraformaldehyde, 
made up in PBS, for 20 minutes at room temperature. Post fixing was carried out 
with 100% methanol for 5 minutes at -20°C or sodium metaperiodate and L-glycine 
in PBS for 20 minutes at room temperature. Cells underwent two PBS washes before 
the addition of lOOul of 10% HIGS. Immunostaining was continued as described 
above (section 2.12.1). 
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3.1 Introduction 
3.1.1 Selecting the Appropriate Promoter 
Peripheral myelin protein 22 (PMP-22) has been demonstrated to provide a crucial 
role in the formation and maintenance of the peripheral myelin sheath. Its temporal 
expression pattern is equivalent to that of other myelin proteins rising from birth and 
modulated by loss of axonal contact during nerve injury. Following nerve crush 
injury it has been well documented that proteins involved in the maintenance of the 
myelin sheath are downregulated. PMP-22 was originally identified using a strategy 
based upon the differential expression of transcripts following nerve crush injury. 
The cDNA sequence for two molecules CD25 and SRI 3 were identified (Spreyer et 
al., 1991; Welcher et al., 1991). The two transcripts were shown to encode for the 
same 22 kD glycoprotein (Snipes et al., 1992) subsequently designated peripheral 
myelin protein 22 which was associated predominantly with myelinating Schwann 
cells of the peripheral nervous system. 
Comparison of the two species showed that the two transcripts were identical 
throughout the coding sequence, however the 5' untranslated regions were seen to 
vary markedly. Detailed characterisation of the human gene identified two putative 
promoter regions, PI and P2, upstream of two alternative non-translated exons 
designated exon la and exon lb respectively (Suter et al., 1994). The alternative 
transcripts in turn correspond to the CD25 and SR13 species (Spreyer et al., 1991; 
Welcher et al., 1991). The conservation of this gene arrangement in the rat PMP-22 
gene and the high degree of sequence homology within the non-coding exons 
between species indicated the importance of this region. 
3.1.1.1 Expression of the Alternative Transcripts 
Originally described as a protein associated with the nervous system, PMP-22 has 
also been found in a number of other sites. Detectable amounts of both transcripts 
have been found in a range of non-neural tissues including the heart, lung and 
intestine (Suter et al., 1994). In each instance preferential expression of the exon lb 
containing moiety was seen. Northern analyses of a similar group of tissues were 
able to identify high levels of exon lb containing transcripts but near or below 
detectable levels of exon la mRNA (Bosse et al., 1994). 
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In the Schwann cells of peripheral nerve however, the ratio between the transcripts 
was reversed, the predominant PMP-22 transcript was that of exon la, found at levels 
7 fold higher than that of exon lb (Bosse et al., 1994). 
3.1.1.2 Regulation of the PMP-22 Gene 
Expression levels of the total PMP-22 mRNA in the peripheral nervous system have 
been shown to be regulated both during development and following nerve injury 
(Spreyer et al., 1991; Welcher et al., 1991; Snipes et al., 1992; Kuhn et al., 1993). 
The contribution of the alternate transcripts to this has been investigated. 
3.1.1.2.1 Developmental Regulation 
During development the amount of PMP-22 protein in the peripheral nervous system 
is seen to rise with the increased rates of myelination. Further resolution of this 
expression pattern has shown that the PI promoter driven exon la transcript is 
strongly regulated during this time. At birth, exon la transcript levels account for 
approximately 30% of the total PMP-22 mRNA population. This steadily increases 
to a peak at 14 postnatal days of age, at which point exon la transcripts contribute up 
to 80% of the PMP-22 mRNA species (Bosse et al., 1994; Suter et al., 1994). These 
changes correspond to the developmental cessation of Schwann cell proliferation and 
the peak of myelination. 
In comparison, although exon lb transcript levels rise 7 fold following birth, levels 
peak at post-natal day 4 in a manner that does not correlate with the formation of 
myelin. 
The ratio between the two transcripts in the peripheral nervous system also alters 
developmentally, reflecting the shift in the pattern of expression during early post-
natal development. Five days after birth the ratio of exon la to exon lb in a normal 
mouse sciatic nerve is found to be 0.2. This rises to 1.4 at dayl5 and subsequently to 
2 at day 25, as exon la levels exceed those of lb (Garbay et al., 1995). 
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3.1.1.2.2 Regulation Following Nerve Injury 
Differential expression of the alternative transcripts is also seen following nerve 
injury. Northern analysis of the behaviour of the mRNA species following nerve 
crush shows the immediate decrease in both transcripts with very low levels detected 
2 days after the lesion. Subsequently, the exon lb transcript returns to control levels 
within one week post crush whilst exon la recovery begins in the second week and 
approaches normal levels at approximately 6 weeks after the initial lesion (Bosse et 
al., 1994). The pattern of expression for exon la PMP-22 transcripts closely 
resembles that of other myelin proteins following injury (Gupta et al., 1988; Kuhn et 
al., 1993). 
3.1.1.3 Promoter Structure 
Much of the work in dissecting the roles of each of the alternative promoters and 
their non-translated exons has been carried out by Suter et al. (1994). Using DNA 
sequencing, primer extension and RNase protection assays they were able to map the 
promoter and exon regions in the human PMP-22 gene. Analysis of the resulting 
sequence identified a number of regulatory components within each promoter that 
implicate possible roles for each. 
Elements associated with the regulation of tissue specific genes have been found 
within the PI promoter. 30 base pairs upstream of the mRNA cap site lies a TATA 
like sequence and at position -43 to -47 an inverted CCAAT box is found. The 
position of these motifs remains constant in the mouse PMP-22 PI promoter 
sequence. These regions are absent from the P2 promoter. The P2 regulatory region 
contains many G and C nucleotides. A section spanning -127 to 130bp of the 
sequence is identified as a potential CpG island (Van de Weetering et al., 1999), 
these are often associated with the promoters of house keeping genes (Larsen et al., 
1992; Cross and Bird, 1995). 
A number of recognition sites for various transcription factors can be found in each 
of the human promoters. The transcription factor NF1 has two binding sites in PI , 
-217 to-221 and -241 to -245 (Zhang and Miskimins, 1993). Overlapping consensus 
sequences for AP-2 and Sp-1 are present at -67 to -79 in P2 (Imagawa et al., 1987). 
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Sequence comparisons were carried out against the promoter regions of other myelin 
proteins. A number of elements of the myelin basic protein (MBP) promoter were 
also found in PI and P2. A motif downstream of the TATA sequence in promoter PI 
corresponds closely to a MBP enhancer element (Fors et al., 1993). In the mouse 
MBP gene this is found to be involved in the binding of the transcription factor NF1 
(Tamura et al., 1988; Aoyama et al., 1990). In addition, a similar sequence to that of 
the M l binding site of the MBP promoter (Aoyama et al., 1990) is found in the P2 
sequence. 
Within the PI promoter is a region that shares homology with a range of myelin 
protein promoters. The FP330 sequence identified in the proteolipid protein (PLP) 
promoter is also present in the protein zero (Po) promoter of rat, mouse and human. 
It can also be found in MOTIF B of the MBP promoter (Nave and Lemke, 1991) and 
corresponds to bases -78 to -67 of the human PI promoter. Analysis of the murine 
PMP-22 PI promoter sequence identifies each of these sites within the mouse 
promoter (Table 3.1.1.3). 
Functional studies of the rat PMP-22 promoters (Suter et al., 1994) have confirmed 
that both regions can confer promoter activity. 3kb of the upstream region of each 
non-translated exon were cloned into a plasmid vector containing the gene for 
bacterial chloramphenicol acetyltransferase (CAT) in both the forward and reverse 
orientation. The resulting plasmids were then transfected into primary Schwann cells 
and the hamster fibroblast line RJK88. The plasmid containing the forward 
orientation of the P2 promoter proved to be the most active in driving CAT 
expression, whilst PI promoter activity was much lower, however the structure of 
this region is still thought to suggest that it performs a regulatory role. 
The PI promoter has therefore been established as the Schwann cell specific 
promoter for the expression of PMP-22, a protein involved in the maintenance of the 
myelin sheath. PMP-22 is expressed as one of the early myelin proteins concomitant 
with Po but before MBP (Notterpek et al., 1999). Its use to drive the expression of a 
reporter gene should therefore give rise to the Schwann cell specific expression of 
that gene. 
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Mouse MBP 
Human PMP-22 
Mouse PMP-22 
Human PLP 
Human P 0 
Rat P 0 
Mouse Po 
Mouse MBP 
Human PMP-22 
Mouse PMP-22 
Enhancer -127 AACTGGCAAGGCGCCCACCCAG -106 
Promoter 1 -27 AACTGGAAAGACGCCTGGTCTG -6 
Promoter 1 -27 AACTGGAAAGACGCCTAGGACA -6 
FP330 -341 GGGCTCTCACTT -330 
Promoter GGGCTGTGAGGC 
Promoter -367 GGGCTCTCAGGC -356 
Promoter GGGCTCTCAGGC 
Motif B -455 GGGCTCTCAGGC -444 
Promoter 1 -78 AACCTCTCAGGC -67 
Promoter 1 -78 AACCTCTCAGGC-67 
Table 3.1.1.3 Comparison of conserved sequences in the promoters of myelin genes. 
Highlighted bases are conserved between motifs. Underlined sequences refer to NF1 
binding sites. 
3.1.2 The Reporter Gene - Green Fluorescent Protein 
Reporter genes are commonly used to assess gene expression and regulation (Alam 
and Cook, 1990). Applications include the study of promoter and enhancer elements. 
Reporter genes can be useful in normalising transfection reactions, or in the 
production of stable cell lines with selectable markers. Reporter genes have also been 
used to create transgenic mice in which cells expressing specific genes can be 
identified. 
Two of the most frequently used reporter genes are chloroamphenicol 
acetyltransferase (CAT) and the lac Z gene for P-galactosidase. When engineered 
into plasmids in which their expression is driven by a designated promoter factors 
that regulate the promoter and its use can be assessed by the changes in reporter gene 
expression. These enzymes catalyse reactions that can then be quantified by the 
amount of reaction products produced. To do this, substrates have to be provided and 
the tissue fixed (Silhavy et ai, 1972; Gorman et ai, 1982; Sanes et al., 1986; Ginot 
etal, 1989). 
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Recently, an alternative reporter gene has been described, the advantages of which 
include the lack of any need for substrates and co-factors. It can be assessed in live 
cells, with no need for fixing and staining protocols and is ideal for studying the 
dynamic movements of cells. This reporter gene is the green fluorescent protein. 
The Pacific Northwest jellyfish Aequorea victoria is seen to fluoresce in response to 
excitation with blue light. This process is mediated by a photoprotein, the aequorin 
species. Once activated by calcium binding (Shimomura et al., 1962) the aequorin in 
turn excites the green fluorescent protein (GFP, Morin and Hastings, 1971; Morise et 
al., 1974). 
Characterisation of the GFP protein has elucidated an extremely useful tool. The 
gene was cloned by Prasher et al. (1992) and Chalfie et al. (1994), it consists of 238 
amino acids and is 30 kDa in size. The chromophore is extremely stable to a range of 
stresses. Fluorescence remains in temperatures up to 65°C, pH 11, in solutions of 1% 
SDS and in the presence of 6M guanidinium chloride. It can also resist many 
proteases for a number of hours. A loss of fluorescence due to acid or base treatment 
or the presence of a denaturing agent can be recovered by neutralisation of the pH or 
removal of the agent (Chalfie et al., 1994). 
GFP absorbs blue light at 395nm wavelength with a smaller peak at 475nm, these 
peaks emit green light at 509nm and 540nm respectively (Morin and Hastings, 1971; 
Morise et al., 1974; Ward et al., 1980). The protein has a tendency to dimerise and it 
is the dimerised form that is able to interact with the primary photoprotein, aequorin, 
and that is predominant in fluorescent organelles of the jellyfish (Cubitt et al., 1995). 
The chromophore structure lies at the 3' end of exon I I of the GFP gene (Prasher et 
al, 1992). It is formed by the cyclisation of a tri-nucleotide sequence also found in 
the chromophore of the Renilla GFP (Prasher et al., 1992; San Pietro et al., 1993). 
Cyclisation of Ser65, Tyr66 and Gly67, with 1,2-dehydrogenation of the tyrosine 
residue creates the fluorescent species (Prasher et al., 1992; Cody et al., 1993). 
75 
Chapter 3: Producing the Construct 
3.1.2.1 Mutations in the Green Fluorescent Protein 
Mutations of the wild type protein to dissect the mechanism of fluorescence and to 
determine more advantageous forms have been extensive. Many mutations of the 
GFP protein result in the abolition of the chromophore or reduced fluorescence. 
Replacement of the Ser residue at position 65 with Thr, Lys, Leu, Val or Ala gives 
rise to species with a single absorption peak, the 395nm peak is lost and the 475nm 
peak has been shifted to longer wavelengths (Heim et al., 1995). One of these, the 
Ser65Thr mutation gives rise to a protein with a number of benefits. It has an 
excitation peak of 490nm and emits at 510nm. It has six fold greater brightness than 
the wild type protein, and it oxidises to the final fluorescent species at a four fold 
faster rate than the wild type (Heim et al., 1995). The mutated protein does not 
undergo photoisomerisation and photobleaching occurs more slowly (Cubitt et al, 
1995). This makes this GFP mutant particularly suitable for use as a fluorescent 
marker. 
A number of commercial variations of GFP are available, each tailored to different 
applications. The Clontech plasmid pEGFP-1 (Genbank accession number U55761) 
contains a red shift variant of the wild type GFP which shows an excitation 
maximum of 488nm and emission maximum of 507nm. The enhanced form of GFP 
(EGFP) contains two mutations, the Ser 65 Thr mutation and substitution of Phe 64 
to Leu. The coding sequence contains more than 190 silent base changes 
corresponding to human codon usage preferences (Haas et al., 1996). Kozak 
consensus transcription initiation sites and downstream polyadenylation signals 
ensure correct processing of the protein (Kozak, 1987). 
The pEGFP-1 vector lacks a promoter sequence, allowing it to be used to assess the 
activity of promoters and enhancer elements inserted into the multi-cloning site 
(MCS). 
3.1.2.2 Expression of the Green Fluorescent Protein 
The green fluorescent protein has been successfully expressed in a number of 
systems. Both prokaryotic and eukaryotic cells are seen to fluoresce with GFP 
expression indicating that its chromophore formation is species independent and does 
not require interaction with other gene products. The fluorescence must occur 
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through the use of ubiquitous cellular components or autocatalysis (Chalfie et al., 
1994). 
GFP has been expressed in E. coli and C. elegans (Chalfie et al., 1994) as well as 
many plant species (Sheen et al., 1995; Hu and Cheng, 1995). Drosophila 
melanogaster and zebrafish also successfully express GFP (Wang and Hazelrigg, 
1994; Peters et al., 1995; Amsterdam et al., 1995 as cited in Zhou et al., 1997). 
The expression of GFP in mammalian cells and as a reporter gene in transgenic 
animals has been reported, and these studies indicate some of the advantages of GFP 
as a fluorescent marker. 
Ikawa et al (1995a,b) have used the ubiquitous P-actin promoter to drive GFP 
expression in transgenic mice and were able to show that in these mice, embryos at 
the morula stage of development were already displaying GFP fluorescence. A 
similar study was repeated elsewhere with equivalent results (Takada et al., 1997; 
Okabee/a/. 1997). 
The tagging of GFP to a protein can provide detailed information about the dynamic 
interactions of that protein. For example a fusion construct of the glucocorticoid 
receptor with GFP allowed confocal time lapse microscopy to show the hormone 
dependant translocation of the receptor from the cytoplasm to the nucleus (Htun et 
al., 1996). 
Tissue specific direction of GFP expression has also been demonstrated. Glial 
fibrillary acidic protein (GFAP) is an intermediate filament used to identify 
astrocytes. The promoter region of GFAP was coupled to the GFP gene and was used 
to create a transgenic mouse (Zhou et al., 1997). The astrocytes in multiple regions 
of the brain were positive for GFP expression, providing a system in which dynamic 
changes in astrocyte morphology during development and injury can be followed. 
3.1.3 Defining the Transgene Construct 
Having identified a suitable myelin protein promoter with the desired expression 
pattern and a reporter gene that will give strong fluorescence and requires no 
manipulation or co-factors a strategy was determined to produce a plasmid vector 
containing these constituent parts that could be used to produce a transgenic mouse. 
The PI promoter of PMP-22 was to be isolated and used to drive the expression of 
EGFP in a temporal and tissue specific manner in a transgenic mouse line. 
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3.1.3.1 Production of the Transgenic Construct: A Summary of Procedures 
Isolation of the PI Promoter 
Primers were designed to the known 
sequence of the promoter. This was 
extracted by PCR from mouse 
genomic DNA. 
•TJ. 
Ligation into Intermediate Vector. 
The T overhang in pGEM T easy 
vector (Promega) enables ease of 
ligation of the PCR product. 
Restriction digest and DNA 
sequencing confirms the identity of 
the fragment. 
-0-
Production of the Construct. 
The PI region was excised and 
inserted into the MCS of pEGFP-1 
vector (Clontech). 
Successful ligation was assessed by 
restriction digest 
-0-
Expression Studies. 
Transfection experiments were used 
to determine the functional 
expression of the construct in a 
range of cell types. 
J3-
DNA Preparation 
Preparation of the DNA to a quality 
for use in microinjection. 
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3.2 Results 
3.2.1 Optimising the PCR Conditions 
Primers were designed against the published sequence from the NCBI Genbank data 
base, accession number AJ001035. This sequence was first submitted by Bosse et al. 
in 1994 and later published by the same group (Bosse et al., 1999). Primers were 
determined according to the following set of criteria. They must incorporate the full 
length of the required sequence and be of at least 18 base pairs in length. This 
ensures the high specificity of the primer to the template DNA. Since G/C and A/T 
binding occurs with different strengths, primers with equal numbers of both will 
ensure it binds with sufficient tenacity. For ease of the reaction, each of the two 
primers should anneal to the template at approximately the same temperature. 
Importantly primers were designed to prevent the formation of internal secondary 
structure that could inhibit binding of the primer to the desired sequence within the 
genomic DNA. 
Conventional polymerase chain reaction (PCR) techniques utilising a single optimum 
annealing temperature proved unsuccessful in isolating the PI promoter. In an 
attempt to extract the regulatory region from the mouse genomic DNA alternative 
protocols were adopted. 
Hot start PCR aims to prevent non-specific binding of primers at lower temperatures 
and so eliminate non-specific reaction products (Chou et al., 1992). By separating the 
reacting components either physically (Chou et al., 1992, Horton et al., 1994) or 
through enzyme modification (Kellogg et al., 1994, Birch et al., 1996) until the 
reaction temperature approaches that of the annealing temperature, non-specific 
binding is prohibited. Further advantage is given to specific priming when a 
touchdown PCR protocol is observed (Don et al., 1991; Hecker and Roux, 1996). In 
reducing the annealing temperature during subsequent rounds of amplification 
towards an optimum, it is hoped that less stable, non-specific binding that usually 
occurs at lower temperatures could be eliminated. 
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3.2.2 Isolating the PMP-22 PI Promoter 
For a single lOOul PCR reaction the following components were added to a 0.25ml 
sterile eppendorf tube maintained on ice: 
lx Taq DNA polymerase buffer (lOmM Tris pH 8.3, 50mM KC1, O.lmg/ml gelatin) 
dNTP's 0.2mM (dATP/ dTTP/ dCTP/ dGTP) 
0 . 5 - 2 . 5 m M M g C l 2 
100-250ng genomic DNA 
Forward and reverse primers at a concentration of 1 uM 
Sterile H2O to a final volume of lOOul 
Oligo Sequence 5' to 3' Position in Promoter PI 
Forward AGA ACT AGG GCC TCG AAC T -722 to -704 
Reverse GCC CAC AGC AGA CCA GAC T 62 to 80 
Table 3.2.2.1 Oligonucleotide primers directed against the PMP-22 PI promoter 
region. 
A number of duplicate reactions were carried out to optimise the MgCh 
concentration. The reaction was spun briefly to mix the components before the 
addition of lOOul of light mineral oil. The tubes were placed in a Techne PCH-3 
thermal cycler and the first round of denaturation and annealing was performed. 1.0 
unit of Taq DNA polymerase was then introduced to each reaction and the 
amplification step allowed to proceed. Cycling parameters were as follows: 
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Temp (°C) Time (seconds) 
Two cycles: denaturation 9TC 60 
annealing 68°C 45 
extension 72°C 45 
Two cycles: denaturation 92° 45 
annealing 67°C 45 
extension 72°C 45 
The annealing temperature was reduced by 1°C every second cycle until the optimum 
annealing temperature of 58°C was reached. 
Temp CO Time (seconds) 
Fifteen cycles: denaturation 92°C 45 
annealing 58°C 45 
extension 72°C 45 
One cycle: denaturation 92°C 45 
annealing 58°C 45 
extension 72°C 120 
Table 3.2.2.2 Touchdown PCR conditions for the isolation of the PI promoter from 
genomic DNA. 
Control reactions were performed in tandem to monitor contamination by foreign 
DNAs. These consisted of reactions with no template DNA, no enzyme and no 
primers. 
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3.2.3 Identification of the Reaction Product 
An aliquot of each PCR reaction was separated on a 1.2% agarose gel by 
electrophoresis (see section 2.5.3). A reaction product at the expected molecular 
weight of 0.8 kb was found and potential identification of the fragment as the PI 
PMP-22 promoter was achieved by restriction digest (Table 3.2.3.1 and Figure 
3.2.3.2). 
A second aliquot of the PCR reaction was run in a low melting point agarose gel, at 
1.2%, the 0.8kb band was excised and the DNA extracted from the gel following the 
protocol described in section 2.5.3.1. 
Enzyme Restriction Site Fragment Length 
A v a l 514 514,288 
Dpn l 125,580 125,455,222 
DraI 622 622, 140 
Eco NI 99 99,703 
EcoRII 316,500,591,757 316,184,91,166,45 
Eco RV 240 240,562 
Sac I 729,774 729,45,28 
Table 3.2.3.1 Identification of the 0.8kb PCR product by restriction digest. The table 
shows the restriction sites and the resulting fragment lengths of a number of common 
enzymes. 
3.2.4 Cloning of the Putative promoter into an Intermediate Plasmid Vector 
The 0.8 kb DNA fragment was then ligated into the pGEM T-easy vector (Promega) 
at 4°C overnight as described in section 2.5.6. This vector had been commercially 
prepared with thymine overhangs to allow straightforward ligation of PCR products 
in which the Taq polymerase has added 3' adenine residues. The ligation was 
electrotransformed into bacteria (section 2.5.8.2). Using the blue white selection 
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Figure 3.2.3.2 Analysis of the Putative PI Promoter 
a. Schematic demonstrating restriction sites within the PI promoter 
sequence, b. Restriction digest of the isolated 0.8kb PCR fragment. 
Lane 1, molecular weight marker, lambda DNA digested with Pst I . 
Lane 2 the uncut 0.8kb PCR fragment. Lanes 3-6 the PCR fragment 
digested with Dra I , Dpn I , Eco NI and Pst I respectively. 
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procedure (section 2.5.9) ten of the white colonies were streaked out on agar plates 
containing the appropriate antibiotics and grown over night. To identify clones 
containing the promoter insert a small amount of each resulting colony was 
introduced into the PCR reaction as a source of DNA. One positive colony was 
identified directly by PCR using the above strategy (section 3.2.2.2). DNA was 
extracted from this colony by the miniprep method (section 2.2.1) and enzymatic 
digest established the successful integration of the 0.8kb fragment (Table 3.2.4.1 and 
Figure 3.2.4.2). DNA sequencing with the universal primers T7 and SP6 (section 2.6) 
confirmed this fragment as the PMP-22 PI promoter region. 
Enzyme Restriction Site Fragment Length 
Forward Insertion 
Dra I 682, 2078, 2097, 2789 
EcoNI 159 
Eco RI 52, 872 
Pst I 28, 484, 890, 
Sac I 789,834,911, 
1396, 19, 692, 1713 
linearise 3820 
820, 3000 
356, 406, 3058 
45, 77, 3689 
Reverse Insertion 
Dra I 240,2078, 2097,2789 
Eco NT 763 
Eco RI 52,872 
Pst I 438 794, 890 
Sac I 88,133,911 
1859,41,651, 1269 
linearise 3820 
820, 3000 
356, 96, 3368 
45, 778, 2995 
Table 3.2.4.1 Restriction sites within the pGEM T-easy/PMP22 PI promoter 
plasmid. Details are given for the integration of the fragment within the plasmid in 
both the forward or reverse orientation. 
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Figure 3.2.4.2 Analysis of the Intermediate Plasmid pGEM-Pl 
a. Promega pGEM-T easy vector (3kb) contains T residue overhangs for ligation of 
PCR products, b. The 0.8kb PI PCR product was ligated into the insertion site. The 
fragment is later easily removed by digestion with flanking enzymes from within the 
multi-cloning site (MCS). 
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Fig 3.2.4.2c Restriction digest of the intermediate plasmid 
Digestion of the Pl-pGEM plasmid. Lane 1 molecular weight marker. Lane 
2 uncut intermediate plasmid DNA. Lane 3-6 plasmid DNA restricted with 
Eco NI, Eco RI, Not I , and Pst I respectively. 
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3.2.5 Producing the Promoter-EGFP Construct 
The promoterless pEGFP-1 vector (Clontech) was linearised through the multi-
cloning site with the restriction enzyme Eco RI. Concomitantly the PMP-22 PI gene 
was removed from the pGEM T-easy backbone by digestion with Eco RI. The 
restriction products from both reactions were run on a 0.8% agarose gel and the 
desired fragments from each extracted using the protocol described in section 2.5.3.1. 
Following dephosphorylation of the vector backbone with calf intestinal alkaline 
phosphatase enzyme (section 2.5.5), the compatible ends of vector and insert allowed 
cohesive ligation following the procedure in section 2.4.6 at 4°C overnight (section 
2.5.6). The ligation reaction was transformed via the calcium chloride method into 
bacterial cells (section 2.5.8.1). Successful ligation was assessed by PCR as 
described in section 3.5.2.2. The DNA from six positive colonies was digested with 
Pst I and Sac I to determine the orientation of insertion. A specimen with forward 
insertion was then digested fully to ensure the correct fragment had been 
incorporated (Table 3.2.5.1 and Figure 3.2.5.2). 
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Enzyme Restriction Site Fragment Length 
Forward Insertion 
Dral 
EcoNl 
PstI 
Sac I 
Hind III/Bam HI 
Hind I I I /Af l I I 
687, 1698,4140,4159 
155 
124, 480, 877 
39, 785, 830 
41,899 
41,1878 
1020, 2442, 19, 1490 
linearise at 4971 
356, 397, 4218 
746, 45,4180 
858,4113 
1837,3134 
Reverse Insertion 
Dral 
EcoNI 
PstI 
Sac I 
Hind III/Bam HI 
Hind I I I /Af l I I 
238, 1698,4140,4159 
761 
436, 29, 877 
39, 86, 131 
41, 899 
41,1878 
1460, 2442, 19, 1050 
linearise 4971 
356, 85, 4530 
47, 45,4879 
858,4113 
1837,3134 
Table 3.2.5.1 Restriction table of the PMP22 PI - EGFP plasmid. The restriction 
pattern of the plasmid digested in both the forward and reverse orientation of the PI 
promoter into the vector backbone is considered. 
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MCS 
pUC ori EGFP 
Dral 4159 
Dral 1693 Dral 4140 
SV40 poly A HSV poly A Aflll 1878 
F l on 
Kan/Neo 
SV40 on 
EcoRI Eco RI 
31 34 
Eco 47 HI Xhol Hind III Pst I Kpn I Sma I Age I 
Sac I Eco RI Bam HI 
Figure 3.2.5.2 Production of the final P I - E G F P construct. 
a. Plasmid map of the Clontech pEGFP-1 vector (4.2kb). This plasmid 
contains a multi-cloning site (MCS), the EGFP gene is found between 
base pairs (bp) 97-816 and a Kanamycin/Neomycin resistance gene. b. 
Expansion of the MCS of the pEGFP-1 vector showing the insertion of 
the PI promoter into the Eco RI restriction site. 
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Figure 3.2.5.2c Restriction digest of the final P l - E G F P construct. 
Lane 1 molecular weight markers. Lane 2 uncut Pl-EGFP plasmid DNA. Lanes 
3-8 show restriction of the plasmid with the following enzymes Dra I , Eco NI , 
Pst I , Sac I , Hind I I I and Bam H I , Hind I I and A f l II.The Hind I I I and Bam H I 
double digest releases the PI promoter (800bp). Restriction with Hind I I I and 
A f l I I excises the PI promoter, the EGFP gene and the SV 40 poly-A tail from 
the plasmid (1.7 kb). 
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3.3 Functional Studies of the Promoter Construct 
Following the successful cloning of the murine PI PMP-22 promoter into the pEGFP 
(Clontech) vector backbone, functional studies were carried out. These were devised 
to ensure that the fragment of 5' sequence that had been isolated would prove 
sufficient to be capable of driving the EGFP expression and that it could do so in a 
manner that retained the specificity seen in vivo. 
Previous functional studies of the human PI promoter region utilised 3.3 kb upstream 
of exon la to drive reporter gene expression. This was shown to be sufficient to 
confer limited promoter activity in both rat Schwann cells and the hamster fibroblast 
line RJK88 (Suter et al., 1994). 
3.3.1 Determination of the specificity of the construct across a range of cell types 
To study the potential promoter activity of the construct and to investigate the 
specificity of its expression, a range of transfection experiments were carried out. 
Each cell type was transfected with a positive control, a cytomegalo-virus promoter 
(CMV) driven EGFP construct (see appendix A4). The promoterless pEGFP-1 vector 
(Clontech) was used as a negative control, and the pPl- EGFP construct was 
introduced into each cell type for analysis of its expression. 
3.3.1.1 Evaluation of expression of the construct in the target cell type. 
The potential of the construct to express in the target cells was important to 
determine prior to the production of the transgenic mouse. To investigate this, the 
pPl-EGFP vector was transfected into Schwann cells present within the dorsal root 
ganglion co-culture (section 2.11.2). 
In addition a line of transformed Schwann cells were transfected and assessed for the 
expression of EGFP. Many cell lines have been developed from the Schwann cells of 
newborn and adult rat peripheral nerve using a variety of methods. While many 
differentiate to produce myelin when presented to axons both in vitro and in vivo 
(Boutry et al., 1992), the transformed Schwann cells lose the ability to regulate their 
own growth, and in some the myelinating capability falls with repeated passaging 
(Porter et al., 1987). Haynes et al. (1994) attempted to develop a Schwann cell line 
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develop a Schwann cell line transformed in such a way as to retain as many of the 
characteristics of the parent Schwann cells as possible. Neonatal Schwann cells were 
transformed via intermittent exposure to the mitogen cholera toxin, and the cell line 
SCL4.1/F7 was derived from this. These cells display many desired characteristics 
including the potential to produce myelin, calcium dependent substratum adhesion 
and the negative autoregulation of growth. 
3.3.1.2 Promoter directed expression of E G F P in other PMP-22 positive cells. 
Initial studies of PMP-22, while showing predominant expression of the protein in 
the Schwann cells of peripheral nerves, also identified many sites of non-neuronal 
expression (Spreyer et al., 1991; Welcher et al., 1991; Bosse et al., 1994; Suter et al., 
1994) . In order to determine fully the expression potential of our construct, 
transfection into non-neuronal cells known for their expression of PMP-22 was 
investigated. 
PMP-22 expression begins in the developing embryo and during midgestation, at 
14.5 to 16.5 days post coitus, is seen in the developing muscle (Baechner et al., 
1995) . Primary rat myoblasts were kindly donated by a colleague, (section 2.9.2). 
The cultured myoblasts were able to differentiate, forming myotubes following 
serum depletion or the addition of differentiating media (DMEM with 5% horse 
serum and 2mM glutamine). 
3.3.1.3 Expression of PMP-22 driven E G F P in fibroblasts. 
PMP-22 was originally identified as the growth arrest specific protein (GAS-3) in the 
fibroblast line NIH3T3 (Manfioletti et al., 1990). To investigate the potential of the 
PI promoter within fibroblast cells, primary human skin fibroblasts were examined 
for EGFP fluorescence following transfection with the construct. 
3.3.1.4 Appropriate specificity of the construct in an unrelated cell type. 
Up to this point from previous observations each cell type considered has the 
potential to express the PI driven EGFP protein. The PI promoter is thought to 
contain control regions that regulate its specificity of expression. To ensure this 
specificity had been maintained in the construct its expression in an unrelated control 
cell type was investigated. 
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The cell type utilised was the COS-7 cell line, derived from the African Green 
monkey kidney cell line CV-1. It has been transformed by an origin defective mutant 
ofSV40 (Gluzman, 1981). 
3.3.2 Transfection Reactions 
A number of transfection protocols are described in the materials and methods 
section (section 2.7). The transfection efficiency achieved with each cell type was 
optimised with each different regime using the positive control DNA. The optimal 
method of transfection is described below for each cell type. 
Primary mouse Schwann cells in dorsal root ganglia co-cultures (section 2.11.2) were 
transfected via the calcium phosphate method (section 2.7.1) for six hours. The 
transfection media was removed and the cells washed with PBS before the addition 
of fresh growth media. 
The transformed Schwann cell line designated SCL4.1/F7 (Haynes et ai, 1994) was 
transfected using the lipophilic reagent Fugene (Boehringer-Mannheim) as described 
in section 2.7.2. 
Prior to transfection primary myotubes were trypsinised from the culture dish and 
fibroblast numbers were depleted by pre-plating on a non-permissive substrate for 30 
minutes. The remaining, suspended cells, were replated on 1% gelatin coated dishes. 
Primary myotubes in their non-differentiated state were transfected via calcium 
phosphate for six hours. They were then allowed to differentiate through the 
depletion of serum from the media before the cells were assayed for EGFP 
expression. 
The remaining cell types, the COS-7 green monkey kidney cells and wild type 
primary skin fibroblasts were also transfected with the lipophilic reagent Fugene 
(section 2.7.2). 
48 hours following transfection cells were fixed in 4% paraformaldehyde (section 
2.12.2) and mounted in mowiol (Calbiochem). EGFP expression was visualised on a 
BIO-RAD Microradiance Confocal microscope. 
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3.3.3 Results 
All cell types were seen to express the positive control plasmid pCMV-EGFP 
following their specific transfection regime (Figure 3.3.3). The pPl-EGFP construct 
was successfully expressed in both primary Schwann cells and the transformed 
Schwann cell line. In addition PI driven EGFP expression was seen in both the 
primary myoblasts and primary fibroblasts. The control cell line, the COS-7 cells, did 
not express the construct as monitored by EGFP fluorescence. 
The transfection efficiencies of each cell type were assessed approximately. The 
primary cell types, Schwann cells, fibroblasts and myoblasts expressed the pCMV-
EGFP construct in approximately 1 -2% of cells. The transformed Schwann cells and 
COS-7 cells expressed the positive control plasmid with approximately 5% 
efficiency. In all cases the PI promoter driven expression of EGFP was less than that 
of the positive control. 
In all cell types the promoterless expression vector, pEGFP-1 (Clontech) failed to 
elicit GFP fluorescence. 
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Figure 3.3.3 Functional studies of the pPl -EGFP construct. 
A. Dorsal root ganglia co-cultures were transfected with the negative control vector 
pEGFP-1 promoterless vector. B. EGFP fluorescence in cells transfected with the 
positive control plasmid pCMV-EGFP demonstrated the successful introduction of 
the DNA. C . Transfection with the pPl-EGFP vector showed expression of the 
construct in a population of the cells in the DRG co-culture system. The Schwann 
cell line, SCL4.1/F7 was assessed for its ability to express the constructs D. 
SCL4.1/F7 cells transfected with the negative control plasmid, pEGFP-1 
promoterless control vector. E . SCL4.1/F7 cells expressed the positive control 
plasmid pCMV-EGFP. F . The Schwann cell line was also able to express the pPl-
EGFP construct. G. Primary myoblasts were transfected with the negative control 
plasmid, H. the positive control plasmid and I. the pPl-EGFP construct. J . In 
addition primary skin fibroblasts were assessed for EGFP expression with the 
negative control plasmid, K. the positive control plasmid and L . the pPl-EGFP 
construct. M. The control cell type, COS-7 cells, were transfected with the negative 
control plasmid pEGFP-1 promoterless vector, N. the pCMV-EGFP positive control 
vector and O. the pPl-EGFP construct. In all instances no fluorescence was seen in 
cells transfected with the negative control, and each cell type demonstrated EGFP 
fluorescence from the positive control plasmid pCMV-EGFP. Scale bar lOOum. 
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3.4 Discussion 
The literature provides strong evidence that the PI promoter of the PMP-22 gene is 
responsible for expression of the protein in peripheral nerve, specifically within the 
Schwann cells. Successful isolation of the PI promoter from murine genomic DNA 
with primers designed to the published sequence, has been achieved and confirmed 
by restriction digest and DNA sequencing. The incorporation of the PI promoter into 
the Clontech pEGFP-1 promoterless vector resulted in a construct with the potential 
to give rise to green fluorescent protein expression in a Schwann cell specific 
manner. The specificity of the promoter PI , exon la transcript expression seen in 
vivo is maintained in vitro with this construct. In a series of transfection experiments 
reporter gene expression was seen in the target cell type, both primary and 
transformed Schwann cells. In addition, expression of EGFP was observed in non-
neural cell types associated with PMP-22 expression, primary fibroblasts and 
myotubes. However, expression was not seen in an unrelated cell type, the COS-7 
cell. 
These data provided evidence that the isolated region did, as intended, confer 
promoter activity and retained specificity, and that it was suitable for microinjection 
with the aim of producing a transgenic line in which the reporter gene, EGFP is 
expressed in a Schwann cell specific manner. It could also be used to examine sites 
of non-neural PMP-22 expression for evidence of EGFP fluorescence. 
Despite the success of the pPl-EGFP construct in maintaining specificity in vitro 
other factors may influence the expression of the endogenous PMP-22 gene in vivo. 
It is possible that other regulatory regions exist further 5' and 3' of the PMP-22 gene 
than is incorporated here that control the pattern of expression. In addition the 
transgene construct does not contain the full length of the untranslated exon la. The 
untranslated exons are suggested as having an important regulatory role due to the 
conservation of their sequence between species. 
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4.1 Introduction 
The use of transgenic animals has been widespread and has been applied to a range 
of fields. It is commonly used to induce mutant phenotypes and to recover genetic 
defects. The expression of tissue specific reporter genes has allowed the study of the 
temporal and spatial expression pattern of proteins. A number of techniques exist to 
achieve insertion of foreign DNA into the genome of a mouse. Microinjection of 
DNA into the pronuclei of fertilised embryos relies upon non-homologous 
recombination of the transgene into the host genome at the single cell stage. I f 
incorporation takes place after cell division has begun the resulting transgenic 
founder wi l l be mosiac and not every cell wi l l contain the transgene. This method is 
advantageous over other methods such as adenoviral infection that can result in 
higher frequencies of multiple insertion site and mosaicism. 
The incorporation of DNA constructs into embryonic stem cells is a common method 
for producing chimeric mice. Electroporation is used to introduce the DNA into the 
cells that are then microinjected into a host blastocyst. The resulting transgenic mice 
wil l be chimeric and can be bred on to produce heterozygotes for the transgene. 
Embryonic stem cells allow targeted mutations that incorporate selective genes to be 
screened for successful integration prior to the injection into the blastocyst and in this 
way can increase the efficiency of success. 
4.1.1 The Preparation of DNA for Microinjection. 
The preparation of DNA to be used for microinjection, can have a great influence on 
the success of integration of the transgene. Prokaryotic vector sequences have been 
found to be inhibitory to transgene expression (Chada et al., 1985; Krumlauf et al., 
1985; Townes et al., 1985) and it is therefore necessary to remove as much of this 
sequence as possible from the DNA before microinjection. In addition investigators 
have observed a 5-fold greater integration rate of foreign DNA introduced in a linear 
form than as supercoiled plasmid DNA. No apparent relationship between fragment 
length and integration frequency was found (Brinster et al., 1985) in fact yeast 
artificial chromosomes carrying several hundred kilobases of mammalian DNA have 
been used to construct transgenic animals via the microinjection method (Peterson et 
al., 1993; Schedl et al., 1993). 
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Suitably prepared DNA may integrate into the genome as a single copy, or multiple 
copies of the gene may insert in head to tail tandem arrays (Brinster et al., 1981; 
Constantini & Lacy, 1981). Commonly, integration occurs at a single position, 
however on rare occasions multiple integration points are found (Lacy et al., 1983). 
The practical preparation of DNA is also crucial to the successful production of a 
transgenic line. The microinjection of high concentrations of foreign DNA (greater 
than lOug/ml) can be toxic to the embryo, resulting in a decrease in the number of 
embryos developing to the morula or blastula stage in culture (Brinster et al., 1985). 
An optimal DNA concentration range of l-2ug/ml has been used, with no correlation 
found between the concentration and the eventual copy number of the transgene in 
founder lines. The composition of the injection buffer is also important, high levels 
of ethidium bromide (above 5mM) and EDTA (greater than 3mM) can also reduce 
the rates of embryo survival and lower integration efficiency (Brinster et al., 1985). 
4.1.1.1 Protocol for the preparation of DNA 
PMP-22 PI-EGFP plasmid DNA was purified using Caesium Chloride and Ethidium 
Bromide gradients as described in section 2.2.3. The DNA was subsequently 
digested with the restriction enzymes Hind I I I and A f l I I to excise the required 
construct from the plasmid sequence. This region includes the PI promoter, the 
EGFP gene and the poly-A tail required for efficient transcription. The digest was 
run on a 0.8% agarose gel that did not contain ethidium bromide with appropriate 
molecular weight markers on either side. A section of the gel containing one lane of 
markers and an aliquot of the digested plasmid DNA was removed and stained in 
0.25mg/ml ethidium bromide for 10 minutes to allow location of the position of the 
desired band under UV light. This was then repositioned alongside the remainder of 
the gel and the region corresponding to the required fragment excised. 
The linearised DNA was recovered from the agarose gel using the Qiagen Gel 
Extraction kit, as described in section 2.5.3.1, and resuspended in injection buffer 
(lOmM Tris-HCl pH 7.4 and O.lmM EDTA pH7.4 prepared with milliQ distilled 
water).The concentration of DNA was determined by its spectrophotometric 
absorbance at 260nm wavelength, see section 2.4.1. The fragment was then identified 
by restriction digest. The DNA was subsequently diluted to 1.45ng/ul with injection 
buffer. To ensure that the DNA was free of all organic impurities it was passed 
through a 0.2p.m Millipore filter to remove any particulate matter. 
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4.1.2 The Production of Transgenic Mice 
A summary of procedures 
Hormone Treatment 
Increases the number of 
follicles within the ovary and 
stimulates their release. 
•TJ. 
Superovulated Female 
Capable of producing up 
30 eggs per cycle 
to 
X Fertile Stud Male 
Recovery of pre-Implantation Embryos 
Embryos are removed from the oviduct of 
superovulated females and the cumulus 
cells dissociated. 
Pronuclear Microinjection 
Injection of the DNA construct into the 
pronuclei of the fertilised embryo 
•TJ. 
Oviduct Transfer 
Implantation of fertilised microinjected 
embryos into pseudo-pregnant recipients. 
Fertile Female 
Vasectomy 
By cauterisation 
0 . 
Sterile Stud Male 
Pseudo-pregnant Females 
Receptive to fertilised 
embryos. Her own 
unfertilised eggs wil l 
degenerate 
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4.2 Preparation of Equipment for Microinjection 
The protocols described below for assembling the microinjection apparatus and the 
animal procedures necessary for successful microinjection are modifications of those 
described in Hogan et al. 1994. 
4.2.1 The Production of pipettes for Microinjection 
4.2.1.1 Handling Pipettes 
Handling pipettes were used to manipulate oviducts during embryo recovery and to 
move embryos between stages. Medium length capillary tubes were pulled manually 
in the edge of a blue flame to give a fine tip of approximately 5-8cm in length with 
an internal diameter of 120-180p.m. A diamond pencil was used to break the other 
end cleanly. 
4.2.1.2 Transfer Pipettes 
Transfer pipettes were produced as for the handling pipette and were used for 
transferring embryos into the infundibulum of the oviduct of the pseudo-pregnant 
female. Once complete, a mounting needle was heated until red hot in a bunsen 
flame and was then touched 1 cm from the end of the pipette. This softened the glass 
so that a bend could be created in the pipette tip. This was to allow it to be inserted 
easily into the neck of the infundibulum. 
The use of both handling and transfer pipettes was controlled through attachment to 
an aspirator tube and mouth piece (Sigma). 
4.2.1.3 Holding Pipettes 
Holding pipettes were used to maintain an embryo in position during injection. Long 
capillary tubes were pulled on a pipette puller and a diamond pencil was used to give 
the tip a straight break. A microforge was used to heat the pipette until the outside tip 
diameter was approximately 50 urn with an inside diameter of approximately 15pm. 
The holding pipette, once mounted in the apparatus was controlled by an oil driven 
micrometer syringe. The holding pipette itself was back filled with Fluorinert FC-77 
(Sigma) as mineral oil has been reported to damage the embryos (Hogan et al., 
1994). 
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4.2.1.4 Injection Pipettes 
Long capillary tubes with an internal filament were pulled on a pipette puller to give 
a pipette with a very fine taper to ensure the point o f entry into the embryo was not 
so large as to cause lysis. 
Before attachment to the manipulator a diamond pencil was used to break o f f 1cm o f 
the bottom o f the pipette. It was then inserted into a microcentrifuge tube containing 
D N A solution and the tip filled by capillary action with approximately 1 ul. 
4.3 Arrangement of the Microinjection Apparatus 
4.3.1 Microscopes and Objectives 
A n inverted Nikon Diaphot microscope with Normarski differential interference 
contrast optics (D.I.C.) and x4 and x40 objectives was mounted on a base plate upon 
a vibration free table between two Leitz micromanipulators (Figure 4.3). 
4.3.2 Control of the Holding Pipette 
A Leitz instrument tube, controlled by a micromanipulator, was attached via Tygon 
plastic tubing to a micrometer syringe with a mechanism for fine adjustment. The 
entire system was filled with light paraffin o i l and all air bubbles eliminated. The 
holding pipette was filled wi th Fluorinert electronic f lu id FC77 using a 26 gauge fine 
needle inserted into the end o f the pipette. This was then inserted into the instrument 
tube. The manipulator levels were altered to allow access to the injecting chamber. 
4.3.3 Control of the Injecting Pipette 
A n injection pipette loaded wi th D N A solution was attached to a Leitz instrument 
tube connected via Tygon tubing to an air fi l led ground glass 50ml syringe. The 
D N A solution was expelled by pressure applied to the syringe. When the pressure 
was released the syringe returned to its neutral position and D N A f low stopped. 
4.3.4 The Injection Chamber 
A drop o f M2 media (Speciality Media, Sigma) 2-4mm in diameter was placed on a 
glass depression slide coated wi th silicon (Sigmacote, Sigma). This was then covered 
wi th mineral oi l to prevent dehydration. The shape of the drop is important to ensure 
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Figure 4.3 Arrangement of the microinjection apparatus 
From Hogan et al. 1994. Arrangement o f microscope, base plate and 
micromanipulators for pronuclear injection. The central microscope is flanked by 
manipulators that control the holding and injection pipette. These in turn are 
controlled by a micrometer syringe and an air filled glass syringe respectively that 
regulate the suction stabilising the embryo and expulsion of the D N A solution. 
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ease of access to the embryos, i f it is too flat the addition o f the mineral oi l w i l l 
depress it further. I f however the bubble is too round then the embryos w i l l slide to 
the sides, in either case the embryos become diff icul t to manipulate. 
4.3.5 Correct Positioning of the Injection Chamber 
To correctly position the injection chamber the media drop was centralised on the 
microscope stage. A n M 2 filled holding pipette was moved against the bottom o f the 
slide and then upward towards the centre o f the drop. 
The holding pipette remained static at all times. Any necessary movement was 
brought about by manipulation o f the microscope stage. 
The loaded injection needle was positioned at a 5-10° angle f rom the injection 
chamber opposite the holding pipette and within the same plane. The fine tip o f the 
pipette was pulled to a closed point by the puller, in order to allow expulsion o f the 
D N A solution this point was broken by carefully sweeping it across the edge of the 
holding pipette. This could be repeated during injection i f the tip became obstructed. 
4.4 Animal Procedures Used to Produce Tansgenic Mice 
4.4.1 Fertile Stud Males 
Mice reach their sexual maturity at approximately 8 weeks o f age and can then be 
used for stud for up to one year. 
Studs were separated into individual cages several days before being presented to a 
female. This prevented fighting and avoided suppression o f testosterone synthesis 
and sperm count in litter mates by the dominant male. 
Following mating, sperm counts are reduced and so studs were rested for 2-3 days 
before further use. A 60-90% plugging rate among females was expected from the 
stud mice. Repeated failure to plug, unfertilised eggs and low sperm count were 
taken as indications o f overuse and the mice were replaced. 
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4.4.2 Sterile Stud Males 
Sterile stud males were used to induce pseudo-pregnancy in female recipients for 
oviduct transfer. Sexually mature mice were vasectomised and subsequently tested 
for sterility. This was denoted by observing a vaginal plug in the female that on three 
subsequent matings failed to result in pregnancy. A vaginal plug consists o f 
coagulated proteins f rom the male's seminal f lu id that dissolves within 12-14 hours 
following mating. 
Sterile stud mice were used every other night for up to two years. Any vasectomised 
mouse failing to plug a female 4 to 6 times consecutively was replaced. 
4.4.3 Superovulation 
In order to maximise the number o f embryos recovered, but to also l imit the number 
o f animals used as much as possible, a hormonal regime was adopted to increase the 
number o f eggs produced by each female. 
Superovulation was induced in 3 to 4 week old female mice by the administration o f 
exogenous hormones concomitant to those naturally released. This resulted in each 
mouse producing between 20 and 30 eggs, two to three times the number produced in 
a normal cycle. 
The female was first injected intraperitoneally (IP) with the commercial form of 
pregnant mares serum (PMS), Folligon (Intervet). Elements within this can substitute 
for the gonadotrophin, follicle stimulating hormone (FSH). FSH is produced by the 
anterior pituitary gland and acts upon those primary follicles receptive to it. The 
follicle cells surrounding the primary oocyte are stimulated to proliferate and form 
the f luid filled antrum. The low levels o f lutenising hormone (LH) present at this 
time stimulate the production o f a layer o f thecal cells surrounding the follicle. These 
cells produce androgens, which stimulate the follicle cells to produce oestrogens. 
Oestrogens initiate further follicle cell proliferation giving rise to a positive feedback 
loop. High oestrogen levels have a second consequence; they cause the follicles to 
lose their sensitivity for FSH and become receptive to L H . Following this there is a 
surge in L H levels secreted from the anterior pituitary that causes mature follicle to 
be released (see figure 4.4.3). 
During superovulation the amount o f endogenously released L H is insufficient to 
cause the release o f the excessive numbers o f mature follicles. To aid their release a 
second injection o f exogenous hormone is administered. The commercial form o f 
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Figure 4.4.3 Summary of the development and hormonal control of oocyte 
formation. From W . J . Larsen, Human Embryology (1993). 
1. The nucleus o f a primary oocyte within a primordial follicle remains at prophase 
of division I . A t this stage the follicle is approximately 20 microns in diameter. 2. In 
the pre-antral follicle glycoproteins secreted by the follicle cells form the zona 
pellucida. The surrounding layer is penetrated by extensions o f the follicle cells that 
connect to the oocyte via gap junctions. These links are thought to provide both 
developmental signals and metabolic support to the oocyte. 3. Gonadotrophin 
releasing hormone from the hypothalamus stimulates the anterior pituitary to release 
FSH and L H . The FSH stimulates the follicle cells o f receptive oocytes only, to 
divide and form the f luid filled antrum. The Antral follicle now spans approximately 
85 microns. 4. Stimulation o f the connective tissue o f the ovarian stroma by L H 
causes it to differentiate into the thecal layers. Thecal cells release androgens which 
are subsequently metabolised by the follicle cells to oestrogens which provide a 
number o f roles. They stimulate follicle cell division, the follicle cells in turn release 
more oestrogens. They also stimulate the uterine mucosa to begin preparation for the 
implantation o f fertilised embryos. There follows a surge in the levels o f L H which 
promotes nuclear maturation and the primary oocyte completes meiosis division I to 
become a secondary oocyte. 5. Sensitivity to FSH is lost and the high levels o f L H 
cause ovulation to begin. The secondary oocyte surrounded by the cumulus cells, 
once ruptured f rom the ovary moves towards the infundibulum o f the oviduct. The 
remaining follicle cells proliferate and become luteal cells o f the corpus luteum. I f at 
this point the female has mated the mechanical stimulation o f the vaginal walls 
during copulation w i l l cause the release o f prolactin f rom the pituitary which 
activates the corpus luteum to produce progesterone. This inhibits the release o f 
further FSH and L H and in doing so prevents the cycle f rom resuming. It also 
prepares the uterine tissue further for the implantation o f embryos and w i l l maintain 
the initial stages o f pregnancy. 
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human chorionic gonadotrophin (HCG), Chorulon (Intervet) was therefore 
administered at a time point corresponding to that o f endogenous release o f 
lutenising hormone (LH) and provided the additional stimulus required 
4.4.3.1 Influence of Age and Weight on Superovulation. 
The sexual maturity o f the female has been found to be a major factor in the success 
o f superovulation. The optimum age lies between 3 to 5 weeks, after the first wave o f 
follicle maturation has taken place. This increases the number o f follicles capable o f 
responding to the hormones to a maximum. 
The nutritional and health status o f the mice is also important. Underweight and sick 
mice with a retarded development w i l l yield reduced numbers o f eggs. 
4.4.4 Pseudopregnant Mice 
Mating a female in natural oestrus with a vasectomised male results in a 
pseudopregnancy. The mechanical stimulation o f the vaginal wall during copulation 
sends impulses to the hypothalamus which in turn causes the release o f prolactin by 
the pituitary gland. Prolactin induces the corpus luteum remaining following 
ovulation to produce progesterone. High levels o f progesterone inhibit the production 
o f FSH and L H and maintain conditions receptive for the implantation o f fertilised 
embryos in the uterine endometrium. The synthesis o f progesterone levels necessary 
to maintain pregnancy is then taken over by the placenta. 
Mice o f approximately 6 weeks o f age and weighing approximately 20g were used. 
Heavier mice were avoided as the fat pad surrounding the ovary would be large and 
would make implantation diff icult . 
Two females were placed with each sterile male as not all w i l l actually be in oestrus. 
Females ovulate every four to five days between three and five hours after the onset 
of the dark period. Males w i l l then copulate wi th these females at the midpoint o f the 
dark period, this being one to two hours after ovulation. Females were checked for 
vaginal plugs the fol lowing morning. 
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4.5 Procedures for Preparing Animals for Microinjection 
The following procedures were based on those described in Hogan et al. (1994). A l l 
protocols were carried out in accordance with the guidelines o f the Home Office 
Animals (Scientific Procedures) Act 1986. The genetic background of all animals 
used was (CBA x C57BL/10) F,. 
4.5.1 Vasectomy 
Anaesthesia was achieved by the intraperitoneal injection o f 0.3 - 0.35ml o f 2.5% 
Avertin (Aldrich). This gave 20 minutes o f anaesthesia as determined by a lack o f 
response to foot pinching. 
The abdomen was shaved and wiped with 70% ethanol to sterilise and prevent hair 
f rom entering the incision site. Excess ethanol was avoided as its evaporation could 
cause cooling o f the mouse, which is susceptible to hypothermia. 
A transverse incision was made through the skin across the abdomen at a level wi th 
the top o f the leg and repeated in the body wall . I f blood vessels were damaged 
bleeding was stopped by stretching o f the body wall wi th forceps. A stitch in the 
body wall (4/0 Vicryl wi th a round bodied needle) was left in position to aid location 
o f the body wall at the end o f the procedure. 
The fat pad attached to the testis was identified and pulled outside the body cavity. 
The testis were then laid to one side, the Vas deferens was visible beneath with a 
blood vessel running along one side. 
The connective tissue was pulled away to isolate the Vas deferens and a section was 
removed by cauterisation. Alternatively two ligatures were applied and the vas 
deferens severed between the two. This procedure was repeated on the second testis. 
As the body wall was lifted the testes were gently pushed back into the body cavity. 
A n absorbable suture, ie Vic ry l 4/0 was used to place three horizontal mattress 
stitches in the body wall . This was repeated in the skin wi th a silk suture, 5/0 Mersilk 
wi th a cutting needle. 
The male mouse was then ready for test mating to determine sterility 10 days later. 
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4.5.2 Superovulation 
Assuming a 12 hr, 07.00 - 19.00 hr light cycle 
D A Y 0 : 5 international units (i.u). (50 i.u./ml, made up in phosphate buffered 
saline, PBS) o f Folligon (Intervet) was injected interperitoneally (IP) at 14.00 hr. 
D A Y 2 : 5 i.u. (50i.u./ml, made up in PBS) o f Chorulon (Intervet) was injected IP at 
12.00, 46 hrs after injection o f the Folligon. The female was placed with a stud male, 
and mating was assumed to have occurred at 00.00 midnight. 
D A Y 3 : 09.00 hrs, evidence o f mating was sought via the presence o f a vaginal plug 
which was taken to correspond to 0.5 day post-coitus (p.c) . 
10 females were superovulated at any one time to ensure that enough embryos were 
produced for implantation into three or four pseudo-pregnant females. 
4.5.3 Recovery of Pre-implantation Embryos 
Pre-implantation embryos were recovered f rom the superovulated females between 
11.00 and 12.00 noon on day 3. Later during this day the cumulus cells that form the 
follicle begin to dissociate and the eggs become increasingly diff icult to recover. 
Superovulated females were humanely sacrificed by cervical dislocation. The 
abdomen was sterilised with ethanol and a large transverse incision made through the 
skin. Either side o f the skin was pulled back to reveal the body wall . The body cavity 
was then opened and the intestines pushed to one side to reveal the uterus. Each o f 
the uterine horns were checked for the presence o f seminal f lu id from the male. 
The ovary and oviduct were revealed by grasping the upper end o f the uterus and 
gently pulling in a caudal direction. They were then separated from the 
mesometrium. Holding the utero-tubual junction wi th forceps the oviduct was pulled 
away f rom the ovary. Fine scissors were used to isolate the oviduct f rom the uterus. 
The collected oviducts were placed in a 35mm dish o f M2 media (Speciality Media, 
Sigma) at room temperature. Each oviduct was then removed to a microdrop culture 
(20-40ul individual drops o f M2 media overlaid wi th mineral oil) . 
Under a stereo dissecting microscope (Nikon) the oviducts were manoeuvred into 
such a position as to enable access to the enlarged ampulla, the upper region o f the 
oviduct. This was identified by its striated epithelium and the presence o f the 
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embryos within it. Forceps were then used to tear the ampulla and gently coax the 
embryos out into the media. The oviducts were then discarded (Figure 4.5.3). 
Once the embryos from each oviduct were isolated the enzyme Hyaluronidase, (Type 
IV-S, Sigma) was added to a working concentration o f 300|ig/ml. This caused the 
break down of the cumulus cells revealing the embryos. The embryos were not 
exposed to the enzyme for more than 5-10 minutes to avoid toxic effects. To aid the 
dissociation o f the cumulus cells the embryos were agitated with the handling 
pipette. Cleaned embryos were subsequently removed to a second flooded dish o f 
M2 in preparation for injection. 
Subsequently the embryos were moved through three subsequent 100(4.1 wash drops 
o f M2 to remove traces o f the enzyme and discard cumulus cells and debris. The 
embryos were then kept in M l 6 media (Cell and Molecular Technologies Inc, 
Speciality Media) microdrop cultures in a 37°C incubator, 5% C 0 2 until ready for 
microinjection. 
4.5.4 Pro-nuclear Microinjection 
This procedure was carried out at approximately 14.00 on day 3 which was 
consistent with two or three hours before pronuclear fusion in the fertilised embryos 
prior to the first cell cleavage. 
Embryos were transferred from the M l 6 microdrop culture through an M2 wash and 
into the injection chamber. 
The stage was manoeuvred to allow an embryo to be picked up via suction onto the 
holding pipette. The embryo was then manipulated to an optimum position. This 
involved placing a pronucleus at the central axis in the hemisphere adjacent to the 
injection pipette. 
Either pronuclei was injected, however the male pronucleus was more often visible 
as the larger o f the two and was positioned closer to the surface o f the embryo. In 
addition, i t tended to have only one nucleolus. 
Once in place, the suction on the holding pipette was increased to stabilise the 
embryo during injection. The zona pellucida could be seen to be pulled into the 
opening o f the holding pipette. 
109 
Chapter 4: The Production of a Transgenic Mouse 
ovary 
fat pad 
oviduct 
Pull back uterus 
4 
Pull back 
Uterus 
Reposition forceps 
ovary 
Cut • i 
Poke hole in mesometrium close to 
oviduct with tip of closed forceps 
or scissors 
mesometrium or membrane 
carrying prominent 
blood vessel 
Cut between oviduct and ovary 
with fine scissors 
infundibulum 
eggs with 
cumulus cells 
-12 hr postovulation 
fat may be attached 
cut end of uterus 
swollen ampulla 
with ridges in epithelium 
coils of 
oviduct 
Figure 4.5.3 Recovery of preimplantation embryos 
From Hogan et ai, 1994. The ovary, oviduct and uterus are separated f r o m the 
mesometrium (A) and the oviduct is isolated (B). The embryos can be seen in 
the swollen, striated ampulla. Gentle tearing of this membrane releases the 
embryos (C). 
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The point o f the injection pipette was brought to above and just beyond the 
pronucleus and then manoeuvred, through vertical control o f the manipulator, into 
the same plane as the pronucleus. Before insertion, pressure was applied to the air 
f i l led syringe driving the injection needle to expel any media that had entered the tip 
o f the pipette. The tip was then drawn back level wi th the pronucleus and pushed 
through the zona pellucida and into the pronucleus avoiding contact with the 
nucleolus. The D N A solution was then injected through the manipulation o f the 
controlling air f i l led syringe at which point the pronucleus was seen to expand. 
Injected embryos were passed through an M l 6 wash and placed in M l 6 microdrop 
cultures in the incubator until ready for implantation. 
4.5.4.1 Common problems encountered During Pro-Nuclear Microinjection 
I The pronucleus was seen to expand in all directions following successful 
microinjection. I f the pronucleus did not expand a small drop o f D N A solution 
accumulated around the injection site indicating that the pipette had not penetrated 
the plasma membrane. I f the zona pellucida and cytoplasm of the embryo were seen 
to 'dimple' then the injection pipette was found to have not penetrated the embryo 
(figure 4.5.4). 
I I I f an injection pipette passed through the nucleoli o f the pronucleus on withdrawal 
the pronucleus was often also removed causing embryo lysis. In this event sticky 
material f rom the nucleoli could be seen adhering to the injection pipette and any 
pipette found to lyse two embryos in a row was discarded. 
H I Cell lysis occurred within 30-60 minutes and was identified prior to 
reimplantation. Healthy embryos were seen to have distinct perivitelline space 
between the egg and the zona pellucida while lysed cells filled the zona pellucida and 
the cytoplasm was homogenous. 
I V Unfertilised embryos identified by homogenous cytoplasm, no evident pronuclei 
and only one extruded polar body were unsuitable for microinjection. Recently 
fertilised embryos in which pronuclei were yet to form and older embryos in which 
the pronuclei had broken down and embryo division was about to commence were 
discarded. Embryos with three pronuclei were seen and discarded as non-viable, this 
appears to be a consequence o f superovulation. 50 - 80% o f embryos were expected 
to survive microinjection. 
I l l 
Chapter 4: The Production of a Transgenic Mouse 
polar body 
'A 
male pronucleus 
nucleoli 
female pronucleus 
zona pellucida 
polar body 
male pronucleus 
nucleolus 
membrane 
indented 
"bubble" of DNA 
female pronucleus 
nucleoli 
B 
Figure 4.5.4 Microinjection into the pronucleus. 
Taken f rom Hogan et al. 1994. Successful injection of the D N A solution into the 
pronucleus: The injection pipette is seen to penetrate the embryo, and as the 
D N A solution is expelled expansion of the pronucleus is seen (A) . Incomplete 
penetration of the embryo: I f the injection pipette fails to penetrate the embryo 
the plasma membrane is pushed inwards and as the D N A solution is expelled it 
forms a visible bubble of solution and the pronucleus does not expand (B). 
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4.5.5 Oviduct Transfer 
Injected embryos were implanted into the oviducts o f 0.5 day p.c. pseudo-pregnant 
recipient females. Approximately 30 embryos were introduced into each mouse, 15 
in either oviduct. O f these 30% were expected to survive resulting in litters o f around 
ten pups. 
The transfer o f embryos into females at an earlier stage o f pregnancy than at which 
they were removed has been found to give the embryos time to advance in 
development before being exposed to conditions favourable to implantation. 
A pseudo-pregnant recipient female mouse was anaesthetised with 0.35ml 2.5% 
Avertin per 20g mouse and placed on a petri dish l id and manoeuvred onto the 
dissecting microscope stage. 
Embryos were taken through two M2 media washes before being loaded into a 
transfer pipette filled wi th M2 media. Two air bubbles were drawn into the pipette 
followed by 15 embryos immediately adjacent to each other in a minimal volume of 
media. This was followed by a third bubble and a small volume o f M 2 . The pipette 
was then placed to one side to ensure the embryos were not disturbed. 
A small region o f hair f rom the back o f the recipient mouse was shaved between the 
bottom of the rib cage and the top o f the leg. The area was then sterilised with 70% 
ethanol avoiding excess. A 1cm longitudinal incision was made in the skin and any 
sub-cutaneous tissue was dissociated to allow free movement of the skin across the 
back. This was then wiped free o f any loose hair with 70% ethanol. 
The skin was moved to one side to identify the position o f the ovary through the 
body wall. It could be seen as an orange body with an associated white fat pad. The 
presence o f a nerve was also taken as a strong indication o f the correct position. 
An incision was made in the body wall , which was stretched to prevent bleeding and 
a stitch placed within it for location later. The ovary was then pulled out by the 
associated fat pad. A serrefine clip (Fine Science Tools) was used to hold the fat pad 
outside the body cavity and pull the attached ovary out to one side. 
Under the dissecting microscope the swollen ampulla and the bursa, a highly 
vascularised membrane covering the oviduct and ovary could clearly be seen (figure 
4.5.5). 
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Figure 4.5.5 Transfer of embryos to pseudo-pregnant females 
Taken from Hogan et al., 1994. The ovary and oviduct are surrounded by a vascularised 
membrane called the bursa. Following the application o f adrenalin to stop blood f l o w this 
membrane can be torn to allow access to the infundibulum. A pipette loaded with 
embryos was inserted into the infundibulum and the embryos were gently released into 
the oviduct. The position o f the embryos is marked by the position o f the air bubbles that 
were present in the pipette. 
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Two or three drops o f 0.1 % adrenaline (Sigma) were applied to the bursa to cause 
vasoconstriction and prevent bleeding. 
A tear in the bursa allowed entry to the infundibulum, the opening o f the oviduct, 
which lies between the ovary and the main body o f the oviduct, usually facing the 
tail. 
The loaded transfer pipette was inserted into the infundibulum and the embryos were 
gently blown into the ampulla. The presence o f the air bubbles within the oviduct 
confirmed correct positioning o f the embryos. 
The clip was removed, the body wall l if ted high and the ovary gently pushed back 
into the mouse. The skin and body wall were then stretched to the opposite side and 
the procedure repeated on the second oviduct. 
The body wall was closed with a vicryl suture 4/0 and the skin incision was sealed 
with a wound clip. 
A 2-300ul IP injection o f PBS following surgery was administered to prevent 
dehydration and raise blood pressure through an increase in blood volume. The 
mouse was placed in a box with warm bedding, tissue paper, and left undisturbed 
under a heat lamp until recovery o f the righting reflex and signs o f waking. 
4.6 Animals Used in the Production of the PMP-22 P l - E G F P Mouse. 
During the course o f the production o f the Pl-EGFP transgenic mouse a total o f 
twenty three superovulated females were used. The fertilised embryos recovered 
from these animals were microinjected with the D N A solution and viable embryos 
were implanted into pseudopregnant recipients. In all two hundred and forty viable 
embryos were implanted into eight recipients. Fi f ty embryos developed to term, and 
the pups were subsequently screened for the presence o f the transgene. 
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5.1 Identification of Potential Transgenic Founders 
Following the successful microinjection and re-implantation of 240 viable embryos the 
mice were left to progress through pregnancy. Of the total, f i f ty pups developed to term. 
The mice showed no developmental or physiological defects and were indistinguishable 
from wild type mice. Once they had reached the age of three weeks a 2-4mm tail biopsy 
was taken from each. DNA was extracted using the method described in section 2.3.2. In 
an attempt to identify potential founders the DNA was screened for the presence of the 
transgene. Initial dot blot assays gave ambiguous results, mice deemed positive by this 
method could not be confirmed by the method of PCR in any instance (data not shown). 
An alternative strategy was adopted, using primers designed against the EGFP sequence, 
absent from the endogenous genomic DNA, the polymerase chain reaction was used to 
screen for the presence of the transgene DNA. Three mice designated 4, 11 and 15 were 
found to have positively incorporated the transgene into their genome. A PCR reaction 
to screen for the ful l length construct was then undertaken (Table 5.1.1 and Table 5.1.2, 
Figure 5.1.3). A reaction product at the expected 1.8kb molecular weight was positively 
identified by restriction digest (Table 5.1.4, Figure 5.1.3). 
Oligo Sequence 5' to 3' Position in Transgene 
Forward AGA ACT AGG GCC TCG AAC T PMP-22 Promoter 
Forward AGC AAG GGC GAG GAG CTG TTC A EGFP Sequence 
Reverse TTG TAC AGC TCG TCC ATG EGFP Sequence 
Table 5.1.1 Oligonucleotides used to identify potential founder animals 
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Reaction Temp (°C) Time (seconds) 
0.8kb EGFP One cycle: denaturation 92°C 300 
fragment annealing 58°C 45 
extension 72°C 45 
Thirty cycles: denaturation 92°C 45 
annealing 58°C 45 
extension 72°C 45 
Final extension 72°C 300 
1.8kb fragment Two cycles: denaturation 92°C 60 
annealing 68°C 45 
extension 72°C 45 
Fifteen cycles: denaturation 92° 45 
annealing 58°C 45 
extension 72°C 45 
Table 5.1.2 PCR protocols used to identify potential founder animals from genomic 
DNA 
The polymerase chain reaction is known to be susceptible to contamination and false 
positives and so the potential founders were confirmed by Southern blot (section 2.8, 
Figure 5.1.5). 10|ig of genomic DNA from each was digested with the restriction 
enzyme Bam HI to separate any tandem arrays into individual full lengths of the 
construct. The DNA was run on an agarose gel and blotted to a nitrocellulose membrane 
The Hindll l /Afl I I fragment of Pl-EGFP was radiolabeled (section 2.8.2) and used to 
probe the nitrocellulose filter. 
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Enzyme Restriction Site Fragment Length 
Bspl20I 850 850, 725 
EcoNI 99 99, 1476 
EcoRI 810 810, 765 
EcoRV 240 240, 1335 
PstI 68, 424,815 68,356, 391,760 
Table 5.1.4. Restriction sites within the Pl-EGFP PCR product. Analysis of the 
fragment generated by the primers PMP-1 and TG-2 used to confirm the identity of the 
product. 
The Southern blot established the incorporation of the Pl-EGFP transgene into the 
genome of the three founder mice. It showed that the number of copies found in each 
differs. An equal volume of genomic DNA from each mouse was loaded onto the 
agarose gel. Using densitometric analysis it was shown that founder mouse 15 has 
incorporated the lowest number of copies of the transgene. The intensity of the 
hybridised band was 1.2 and 1.8 times greater in founder mouse four and founder mouse 
11 respectively. 
PCR analysis of Subsequent generations derived from the founder animals has shown 
that in each line the transgene was successfully transmitted to the F2 generation, 
indicating the stability of the transgene within the genome. 
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Figure 5.1.3 Identification of Founder Mice by PCR. Three mice were identified 
as having incorporated the 0.8kb EGFP gene into their genome a. Lane 1 
molecular weight markers. Lane 2 Male founder four. Lane 3 Female founder 1. 
Lane 3 Female founder 15. The full length transgene was isolated from the DNA 
of founder four and identified by restriction digest, b. Lane 1 molecular weight 
markers. Lane 2 1.7 kb PCR product. Lane 3 -7 PCR product digested with Bspl20 
I , Dpn I , Eco NI, Eco RI, Eco RV and Pst I respectively. 
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Figure 5.1.5 Positive Identification of Potential Founder Mice by Southern Blot. 
lOug of genomic DNA from each potential founder animal was digested with Bam HI 
and analysed by Southern Blot. Lane 1 and 2 mouse 4 uncut and digested DNA. Lane 3 
and 4, and Lanes 5 and 6 mouse 11 and 15 respectively uncut and digested genomic 
DNA. a. The agarose gel was observed against a rule bar to enable identification of the 
corresponding molecular weights (lane M) on the membrane, b. The membrane was 
probed with the full length of the transgene insert, the Hind I I I /Af l I I fragment of the 
pPl-EGFP plasmid. Positive bands were seen in each digested lane at the correct 
molecular weight. In addition two additional bands were faintly observed (arrows), c. A 
subsequent blot of founder 4 shows clearer evidence of the additional bands. 
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5.2 Determining the Expression of the Transgene 
Following the identification of potential founder animals their ability to functionally 
express the EGFP protein (as described by EGFP fluorescence in the targeted cell type) 
was investigated. The co-culture of Schwann cells and dorsal root ganglion (DRG) 
neurons based on the method of Wood (1976) was commonly used in our laboratory at 
this time. Embryonic Schwann cells prepared by this method are able to myelinate and 
express the myelin proteins associated with more mature Schwann cells under the 
appropriate culture conditions. 
The founder mouse number four was most suitable for initial expression analysis. This 
male was used for breeding with non-transgenic females that could be sacrificed to study 
their embryonic progeny. Once mouse number four had reached sexual maturity it was 
allowed to breed with a wild type female. A vaginal plug was used to determine the time 
of mating. At embryonic day 15 (El5) the female was sacrificed and the embryos 
removed from the uterus and decapitated to ensure rapid death. The dorsal root ganglia 
were removed and cultured as described in section 2.11.2. A great number of litters from 
founder four and Fi offspring were studied and in many EGFP positive cells were 
observed. 
Within twenty-four hours of plating EGFP positive cells could be seen in cultures 
derived from three out of the ten embryos. Initially the fluorescent cells were 
predominantly within the ganglion and the immediate area surrounding it. Forty-eight 
hours after plating the positive cells had become more elongated and could be seen at 
greater distances from the ganglion (Figure 5.2.). Once the DRG axons had spread 
within the culture dish the fluorescent cells could be seen throughout. The positive cells 
were localised to specific regions of the dish, running in tracts throughout the culture 
(fig 5.2. c and d). 
In cultures derived from individual pups of the same litter, there was variation in the 
proportion of cells within each culture that were fluorescent. Expression ranged from 
those in which only one or two cells expressed EGFP within each plated ganglion to 
those in which approximately 30% of cells were fluorescent. 
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The DRG co-culture system contains Schwann cells, axons and fibroblasts. Of these, 
both axons and Schwann cells display polarity and long, slender processes. However the 
two can still be distinguished by morphological criteria. The cell bodies of the DRG 
neurons are located within the ganglion and their processes extend out from it. Schwann 
cells however are bipolar with distinct cell bodies and the EGFP positive cells found 
throughout the culture had these features. The processes of adjacent EGFP positive cells 
also generally ran in parallel, a morphology that more closely resembles that of Schwann 
cells than neurons. A small number of positive cells towards the periphery of the culture 
were more flattened with more numerous processes of shorter length. 
Studies showed that fluorescent cells were present within the ganglia as they were 
removed from the embryo, and that therefore the EGFP expression is not a result of the 
culture conditions or isolation of the cells from in vivo regulatory signals. 
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Figure 5.2 Transgenic Mice were Investigated to Determine their Ability to Express 
the Transgene. Dorsal root ganglia co-cultures of Schwann cells and neurons from El 5 
embryos of transgenic mice. In vitro the cultures were identical to that of wild type mice. 
A and B. The Schwann cells radiate out from the central ganglion. Scale bar 200um and 
50um respectively. C-F . Under excitatory light distinct cell bodies and elongated 
processes can be seen to express EGFP. (A and B phase contrast microscopy, C and D 
fluorescent confocal microscopy). Scale bar 100pm C-E and 50um F. 
123 

Chapter 5: Results 
5.2.1 The Site of Transgene Expression 
To confirm the identity of the cell type in which the transgene was being expressed 
positive co-cultures were incubated with antibodies against both Schwann cells and 
neurons. Co-cultures were fixed in 4% paraformaldehyde and incubated with the S-100 
monoclonal antibody (Sigma) or either of the neurofilament NF-68 or NF-200 antibodies 
(Sigma, section 2.11.2) and labelled with fluorescent secondary antibodies. 
The results showed that the EGFP fluorescence co-localised with the S-100 antibody 
(Figure 5.2.1.1). The full span of an individual Schwann cell labelled with S-100 could 
be difficult to detect, however the EGFP positive cell bodies were clearly identified with 
the S-100 antibody and some double labelled processes were also seen. 
The expression pattern of EGFP and the neurofilament (NF) antibodies were shown to 
be distinct (Figure 5.2.1.2). NF positive fibres were seen to originate at the ganglion and 
spread across the culture dish. No NF positive cell bodies were found away from the 
ganglion. At higher magnification the fluorescent processes of the transgene expressing 
cells can be seen to intertwine around those of the neurons (Figure 5.2.1.2). In many 
cases the fluorescent cells appeared in very close apposition to the neuron. 
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Figure 5.2.1.1 Immunostudies Identified the Positive Cells as Schwann Cells. 
Immunostaining of the DRG co-cultures with the S-100 antibody (Alexa-fluor 546 
secondary antibody, Molecular Probes) specific to Schwann cells in the PNS 
corroborated morphological identification of the cells. A. EGFP fluoresecent cell bodies 
can be seen to run in a swathe among other S-100 positive Schwann cells, bordered on 
one side by a group of fibroblasts (arrow). B. Only a proportion of the Schwann cells 
present is seen to fluoresce. Distinct localisation of the EGFP positive Schwann cells is 
seen. Scale bar lOOum. 
125 
i-
• 
Chapter 5: Results 
Figure 5.2.1.2 The Relationship between Transgenic Schwann Cells and Neurons 
was Examined. Anti-neurofilament antibody NF-68 (TRITC secondary antibody, 
Kirkegaard and Perry Inc.) was used to label neurons within the transgenic DRG co-
culture. Fluorescent confocal microscopy was able to show the fine interaction of the 
two cell types. A. The Schwann cell processes are seen to extend around the neuronal 
fibre as indicated by the arrows. Scale bar 40um. B. At times the Schwann cell is seen 
along the nerve fibre, at others it circumnavigates the processes. Scale bar 20um 
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5.2.2 Non-neural Expression of the Transgene 
In order to assess the expression pattern of the transgene outside of the nervous system a 
number of non-neural sites were investigated in at least three different transgenic 
embryos. Briefly sections of tissue were taken from an El5 embryo that was seen to 
express EGFP fluorescence. They were dissociated and plated into 35mm tissue culture 
dishes (section 2.11.3). Within twenty-four hours some cells had attached to the 
substratum and continued to divide. 
In the heart culture large sections of tissue that had adhered to the surface continued to 
beat independently for some time. However few cells migrated out of these regions and 
the cultures subsequently died. No evidence for EGFP expression was seen at this stage. 
The culture of cells from the lung, liver and skeletal muscle were maintained between 
one and three weeks before being fixed and mounted. In the culture derived from 
skeletal muscle of the hind limb a number of distinct cell types were observed. These 
included myotubes and bright cells with bipolar morphology. In addition unidentified 
cells with less defined morphologies that resembled fibroblasts were present. Six days 
after plating, once the cultures had become confluent they were assessed for the 
expression of EGFP using a Zeiss Axiovert inverted fluorescence microscope. A small 
number of cells showed weak EGFP fluorescence (Figure 5.2.2A and B). 
Morphologically these cells resembled Schwann cells seen in vitro, with clearly defined 
cell bodies and fine, elongated processes. Positive cells were found in isolated areas and 
were not diffuse throughout the muscle. Myotubes were not found to be positive for 
EGFP expression. 
In both the lung and liver cultures a number of different cell types could also be 
described on the basis of their morphology. Flattened cells similar to the fibroblast 
morphology were abundant. In addition in each were regions that appeared more 
organotypic in nature. The cells were together in clusters from which other cells 
migrated out. In these organotypic regions in both the lung and liver cultures a number 
of very faint EGFP fluorescing cells were seen (Figure 5.2.2C and D). Unlike the 
skeletal muscle culture these cells did not display a Schwann cell like morphology. The 
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Figure 5.2.2 Expression of the Transgene was Found in Non-neural Tissues. 
Previous reports of the contribution of the PI promoter and exon la transcript in non-
neural expression of PMP-22 have been confirmed. A and B. EGFP fluorescence was 
seen in cultures from the skeletal muscle. The morphology of the positive cells is 
reminiscent to that of Schwann cells. C and D. Fluorescent cells with a less defined 
morphology were found in cultures derived from the lung and liver respectively. Scale 
bar lOOum. 
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positive cells were large and flat with much cytoplasmic material. In the lung culture the 
cell nuclei were strongly fluorescent (Figure 5.2.2C). 
The Zeiss microscope possesses a mercury lamp as the source of illumination, white 
light is passed through specific filter blocks to provide light of the correct wavelength 
required to excite the fluorescent species of interest. In this way the intensity of the 
illumination and the sensitivity of the observation of the fluorescence cannot be 
enhanced. The level of expression of EGFP, the intensity of the signal was greater in 
Schwann cells from DRG co-cultures than the potential Schwann cells in the skeletal 
muscle culture. In turn the expression seen in the unidentified cell types of the lung and 
liver was substantially weaker again. 
5.2.3 Summary 
Three transgenic lines have been established with varied copy number of the transgene. 
Expression of the construct has been demonstrated in animals derived from founder four. 
In the remaining lines eleven and fifteen the transgene was shown to be transmitted to 
subsequent generations, but expression has not been seen in cells within the dorsal root 
ganglia cultures. Extensive study of founder line four has been carried out and a 
concerted programme of investigation into the remaining two lines should be undertaken 
to ascertain their ability to express the reporter construct. 
Within the dorsal root ganglia culture system, Schwann cells, axons and fibroblasts 
interact. The morphology of the positive cells was indicative of the expression of the 
transgene in its target cell type. That expression was restricted to Schwann cells within 
this system was confirmed using a monoclonal antibody against the S-100 protein that is 
specific to Schwann cells in the peripheral nervous system. Staining with the anti-
neurofilament protein NF-68 confirmed that neuronal cells did not express the transgene. 
In addition the expression of EGFP driven by the PI promoter has been described in a 
number of non-neural locations. EGFP expression in the skeletal muscle may in fact be 
derived from innervation of the muscle by the sciatic nerve. However in the lung and 
liver, whilst innervation cannot be ruled out at this stage the morphology of the cells 
expressing the EGFP is not consistent with that of Schwann cells. 
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5.3 Investigation of the Regulation of Transgene Expression In Vivo. 
5.3.1 Observation of Neonatal peripheral Nerves 
It was noted that in vitro within the outgrowth of each ganglion only a proportion of the 
Schwann cell population shows EGFP expression (section 5.2.1). It is possible that this 
is due to the developmental age of the cells as they are removed from the embryo. Once 
in culture the necessary signals required to initiate expression of the transgene may be 
absent. Since the transcription of PMP-22 through the PI promoter increases from the 
day of birth through the early postnatal period, analysis of Schwann cells from older 
animals could be expected to show enhanced EGFP fluorescence as a result of this 
developmental increase. 
The sciatic nerve is a major myelinated peripheral nerve of the hind limb. It is easily 
accessible and is clearly visible beneath the translucent muscles of neonatal mice. In 
order to follow the expression of the transgene during postnatal development the sciatic 
nerve was dissected from transgenic mice between the ages of five to forty days, (P5 to 
P40). 
A section from the tip of the tail of each newborn mouse was taken and the genomic 
DNA extracted from it (section 2.3.2). The DNA was then screened for the presence of 
the EGFP gene by PCR (section 5.1). Positive mice at different ages were taken and 
their sciatic nerves removed (section 2.11.4). 
When examined by phase contrast light microscopy the myelin sheath could be seen in 
many of the dissected nerves. A number of nodes of Ranvier were also evident as 
opposing myelin internodes abutted. The nerve fibers were then assessed for EGFP 
expression by fluorescent confocal microscopy. 
During the course of this experiment sciatic nerves were taken from animals of each line 
and across an age range that incorporated the timescale of upregulation of the PMP-22 
mRNA and protein. 
Mice from line four, which is known to express the transgene in vitro, were studied at 
P10, P15 and P21. During this time levels of PMP-22 expression continue to rise from 
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birth, with the peak of myelination occurring at approximately P21. No EGFP 
expression was seen in any of these animals. A comprehensive study of line eleven 
included investigation of nerves from animals from P14 the time of peak PMP-22 
expression to P40 and intermediate points in between. This follows the increase in 
myelin and myelin protein expression through its peak and beyond. Despite this at no 
time was EGFP fluorescence observed in any of these nerve fibres. Neonatal mice from 
line fifteen were studied at P5 and P10. In addition the sciatic nerves of an adolescent 
(ten weeks old) and an adult transgenic mouse were observed. Again no fluorescence 
was found in any instance. A summary of the mice used throughout this section of the 
study is found in Table 5.3.1.1. 
To confirm that the EGFP expression seen previously was not an artifact of the in vitro 
conditions in which the DRG co-cultures were maintained, Schwann cells were prepared 
from the sciatic nerve of P5 neonatal mice. The sciatic nerves were isolated as described 
(section 2.11.4) and a section from each mounted for immediate appraisal of EGFP 
expression. The remaining nerves were subsequently minced and treated enzymatically 
to dissociate the cells as described in section 2.11.1. This culture contains Schwann cells 
and fibroblasts. EGFP fluorescence was absent from the sciatic nerves at the time of 
removal from the animals, and subsequently following time in culture. This further 
indicates that the in vitro conditions are not determining the expression of the transgene 
(Table 5.3.1.2). 
5.3.2 Discrepancies in Expression within DRG Co-cultures 
Concomitant to this series of experiments consecutive dorsal root ganglion dissections 
derived from animals that had previously given rise to transgenic embryos, had failed to 
produce cultures that showed any EGFP expression. These additional discrepancies 
between the observed behaviour of the transgenic line, and the expected behaviour, 
suggested that these embryonic mice might also posses the transgene but fail to express 
it. To address this issue, during subsequent dissections, following plating of the DRG a 
section of tissue was taken from each embryo. The genomic DNA was extracted from 
this and analysed by PCR for the presence of the EGFP gene (section 5.1). 
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Founder Line Age Number of Animals Studied E G F P Expression 
4 P5 6 X 
P10 2 X 
P15 2 X 
P21 3 X 
11 P14 1 X 
P21 4 X 
P25 2 X 
P29 1 X 
P35 2 X 
P40 1 X 
4 weeks 1 X 
15 P5 1 X 
P10 1 X 
P15 3 X 
P21 2 X 
10 weeks 1 X 
adult 1 X 
Table 5.3.1.1 Neonatal animals investigated for expression of the transgene. Details 
of the number of neonatal animals and their ages from which sciatic nerves were isolated 
and analysed for expression of EGFP. In no instance was EGFP fluorescence observed. 
Date of Founder Line Number of Pups Expression on Expression 
Dissection Removal After Culture 
19.08.99 4 2 X X 
08.09.99 4 X X 
Table 5.3.1.2 Expression of the transgene in Schwann cells isolated from sciatic 
nerve. Sciatic nerves from transgenic mice of two litters were removed from p5 
neonates. Initial observation failed to find evidence of EGFP fluorescence. Schwann 
cells were prepared from the sciatic nerves and grown in culture. No subsequent 
expression of EGFP was seen. 
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A comparison could then be made between the fluorescent status of the Schwann cells 
from each mouse in culture and the genomic nature of each individual. 
Of the sixteen litters across all lines studied in this way fourteen contained mice that, 
although positive for the incorporation of the transgene failed to express EGFP in their 
Schwann cells, both as they were removed from the embryo and during subsequent time 
in vitro. A summary of each litter and the expression patterns of each embryos are given 
in Table 5.3.2. 
To insure against contamination of PCR reactions the results from three of these litters 
were confirmed. Duplicate dishes containing ganglia from each embryo were maintained 
and allowed to proliferate. Genomic DNA was purified from the monolayer of cells by 
the method described in section 2.3.2.1 and screened by PCR. Each sample repeated in 
this way corroborated the previous PCR result. 
5.3.2.1 Southern Blot Analysis of Litters 
Southern blot analysis of two litters from which mice both express the transgene and 
were non-expressing carriers was undertaken to determine i f there was any notable 
difference between the animals in the way in which the transgene was transmitted and to 
further substantiate PCR results. 
The male mouse 4.3, an Fi offspring of founder four had previously been shown to give 
rise to EGFP expressing embryos. A litter founded by this male was sacrificed at El5 
and the dorsal root ganglia cultured from the recovered embryos. Immediately following 
dissection one embryo designated 4.3/2 showed strong EGFP fluorescence. DRG from 
each embryo were cultured and subsequent examination showed very limited expression 
of the transgene, one or two fluorescent cells per ganglia in cultures from embryos 4.3/4 
and 4.3/7. 
Genomic DNA was extracted from tissue of all eight pups. Subsequent analysis by PCR 
identified five of these, including 4.3/2, 4.3/4 and 4.3/7 as positive for the transgene. In 
addition mice 4.3/1 and 4.3/5 also contained the EGFP gene. Primers spanning the full 
transgene sequence were utilised in a second PCR reaction to ensure that the full length 
had been incorporated (Figure 5.3.2.1). 
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A total of 10ug of genomic DNA from each pup was digested with excess amounts of 
the restriction enzyme Bam HI and the subsequent agarose gel was blotted to a 
membrane and probed for the presence of the transgene (section 5.1). 
The Southern blot confirmed that mice 4.3/1, 4.3/2, 4.3/4, 4.3/5 and 4.3/7 were positive 
for the incorporation of the transgene into their genomic DNA. In addition the restriction 
pattern of each is almost identical. Approximately equal amounts of DNA were loaded 
and transferred to the membrane. Without internal control DNA probes a specific copy 
number for each cannot be determined accurately. No obvious discrepancy was seen 
between either the PCR positive/EGFP negative mice and those that were positive for 
both or between the mouse that expressed strong EGFP expression and those that did 
not. 
This data has implications for the study of the transgene in neonatal animals, it means 
that at no time can it be certified that an absence of expression of EGFP at any time 
point during development is due to the regulation of the transgene. In each instance it is 
possible that the animal is not able to express the transgene. A mechanism for 
determining individuals that are able to express the transgene is needed before the 
analysis of the temporal pattern of EGFP expression can be achieved successfully. 
5.4 Investigation into the Transgene Expression Observed In Vitro 
The focus of this work was then returned to the study of the transgenic Schwann cells in 
vitro. Two key observations were explored. 
Variation in the extent to which Schwann cells from different embryos of the same litter 
express the transgene were observed, and the relative level of expression between two 
embryos could be determined from the ganglia as they were removed from the embryo. 
It was possible that this reflected a genetic characteristic of each embryo, but it could not 
be ruled out that individual embryos have developed at different rates. In vivo signals 
that upregulate the transcription of the construct in more advanced embryos may have 
been absent from this culture system preventing further stimulation of expression in less 
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1 2 3 4 5 6 7 8 9 10 
1 2 3 4 5 6 7 8 9 1011 1213 1415 1617 
bp 
4072 
3054 
2036 
1636 
1018 v. 
517 
b. 
Figure 5.3.2.1 Confirmation of the presence of the transgene fragment 
within the genome of mice that do not express E G F P . The initial PCR 
reaction was duplicated using primers against the full PI-EGFP sequence a. 
Lane 1 molecular weight markers. Lanes 2-9 DNA from embryos 1-8 
(disection 11.10.99) respectively. Lane 10 No DNA control reaction. This was 
further corroborated by Southern blot analysis of the mice. b. Lane 1 
molecular weight markers. Lane 2 and 3 DNA from embryo 1 uncut and 
digested with Bam HI . Lanes 4-17 DNA from embryos 2 to 8 uncut and Bam 
HI digested respectively. 
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developed embryos in culture. I f this were so, the effect of this signal is long lasting as 
the expression of EGFP in culture is not seen to decline with time. 
Schwann cells in DRG cultures radiate out from the ganglion and are orientated 
longitudinally along these lines. Observation showed that the positive cells within a 
culture were localised to defined areas. A number of fluorescent cells could be seen to 
lie within a swathe of cells (Figure 5.2.1). Occasionally these regions were bordered by 
fibroblasts (refer to Figure 5.2.1 A), others had no evident structural barrier that could 
account for this compartmentalisation of expression. 
In an attempt to determine the nature of factors that could influence both the expression 
of the EGFP protein and the spatial pattern of expression two components of the culture 
system that are intrinsically involved in the regulation of gene expression and 
myelination were considered. 
Axonal contact has been shown many times to influence Schwann cell behaviour and it 
is intimately involved in the regulation of the myelin proteins. PMP-22 is initially 
expressed in the cytoplasm of Schwann cells. Following axonal contact and the 
deposition of a basal lamina it is translocated to the plasma membrane (Pareek et al., 
1997; Notterpek et al., 1999). I f axonal contact is lost expression decreases and recovers 
when regeneration is complete (Spreyer et al., 1991; Welcher et al., 1991). In addition to 
the requirement of neuronal contact the formation of an organised basal lamina is 
intrinsic to the myelination system and has been reported to influence myelin protein 
regulation (Fernandez-Valle et al., 1993). 
Subsequent investigation aimed to determine the influence of these factors on the 
Schwann cells and transgene expression. 
5.4.1 Axonal Contact 
To determine i f the axonal presence in the DRG cultures was sufficient to cause EGFP 
expression the ganglia from each culture dish were excised. A glass pipette was pulled in 
a bunsen burner flame to a fine, clean point. This was then used to carefully cut around 
the ganglia severing the axonal processes from the neuronal cell bodies. The ganglionic 
masses were then removed. Parallel control co-cultures were immunostained with anti-
NF antibodies (section 2.12.2) at various time points following excision. At the earliest 
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time studied, 48 hours after ganglion removal, the axonal processes had degenerated and 
no NF staining was seen (Figure 5.4.1 and F). Occasional single neurons were found, 
and these were associated with individual neuronal cell bodies that were separate from 
the main ganglionic mass and persisted in the culture. 
Following axonal removal the cultures were followed for up to three weeks throughout 
which time EGFP fluorescence remained. Any change in the intensity or proportion of 
expression was not significant enough to be readily noted. In addition the morphology of 
the Schwann cells altered following axonal removal. The dense nature of the network of 
Schwann cells surrounding each former ganglion became more diffuse. The Schwann 
cells lost some of the bipolar nature of their morphology and processes became shorter 
and more numerous (Figure 5.4.1). The restricted distribution of the positive cells 
remained in part, although due to the altered morphology and the reduced density of the 
Schwann cells the periphery of such regions became less well defined. 
5.4.2 Basal Lamina 
Schwann cells are capable of secreting components of the basal lamina prior to the 
initiation of myelination. However only in the presence of neuronal contact and the 
secretion of collagen type IV, as afforded by the influence of serum and ascorbic acid in 
the culture medium, is this matrix organised into a ful l basal lamina. The tissue culture 
regime used here maintained the co-cultures in a chemically defined media that was not 
supportive for the formation of a basal lamina. With this in mind the use of the PI 
promoter to drive PMP-22 expression seen here, deduced through the expression of the 
EGFP reporter gene, is independent of a fully formed basal lamina. 
Typically DRG co-cultures are plated onto coverslips coated with collagen type I and 
poly-lysine. This provides a substratum to which the ganglia can adhere and axonal and 
Schwann cell outgrowth can occur. To investigate i f either of these components were 
preventing or stimulating the expression of EGFP, or indeed i f other proteins associated 
with extracellular matrices could influence the level or restriction of transgene 
expression, ganglia were plated on a range of different substrates. 
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Figure 5.4.1 The Removal of Axons From the DRG Co-cultures Affects the 
Morphology of the Remaining Schwann Cells. A and B. Schwann cells in DRG co-
cultures radiate out from the ganglion and are seen to run parallel to one another. 
Observation has shown that the pattern of fluorescent Schwann cells within such a 
system is restricted to localised areas. Scale bars 200um and lOOum respectively. C and 
D. Following removal of the neurons from the culture the Schwann cell morphology 
becomes less well defined. Bipolarity becomes less obvious and cells no longer orientate 
in the same direction. E and F. DRG co-cultures immunostained with the NF-68 
antibody and the TRITC fluorescent secondary antibody. The extent of the network of 
neurons can be seen in Fig E. The ganglia have been removed from the culture in Fig F, 
in this control experiment the excision of the DRG ganglia from the culture results in the 
degeneration of the neurons within 48 hours. Scale bar 100 urn. 
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Dorsal root ganglia were removed from two positively expressing embryos from 
different litters as described in section 2.11.2 and plated on collagen/poly-lysine coated 
coverslips. After 3-4 days in culture the extent of fluorescence was assessed and images 
taken for reference. Ganglia were then excised from the dish using a glass pipette pulled 
to a fine point in a bunsen flame and re-plated onto one of a range of substrates (section 
2.9.6). 
These experiments were designed to investigate the effect of different substrates on the 
pattern of expression of the transgene in cultures that were already expressing EGFP 
prior to the re-plating procedure. In an attempt to "turn on" the transgene in embryos 
positive by PCR but negative for the expression of the transgene, ganglia from such an 
embryo were also plated on alternative substrates to observe any induction in expression. 
On all substrates the Schwann cells were seen to retain EGFP expression (Table 5.4.2.1). 
A limitation of this series of experiments was the reduced ability of the DRG neurons to 
extend efficiently on a number of the extracellular components. This prevented axonal 
stimulation of Schwann cell proliferation. Therefore although the presence of EGFP 
fluorescence could be seen in Schwann cells within the transplanted ganglia, limited 
migration of cells into the culture dish meant that assessment of any change in the 
distribution of expression was restricted on the collagen only, poly-lysine only and 
laminin coated coverslips (Figure 5.4.2.2). Ganglia plated on coverslips that had no 
coating were also able to maintain EGFP fluorescence within the area of outgrowth. 
The Matrigel substrate proved permissive for the adherence and outgrowth of DRG 
neurons. Schwann cell proliferation was strong and the cells migrated throughout the 
radius of the axons. However the morphology of the Schwann cells was altered from that 
observed in the collagen/poly-lysine controls. Previously individual Schwann cells were 
bipolar with fine extended processes. The cell body was small and central and appeared 
three dimensional with phase contrast optics. Following plating on the Matrigel substrate 
many of the cells became flattened. The cells were no longer densely packed together, 
while contact remained between adjacent cells each was more diffuse than previously 
(Figure 5.4.2.3) 
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Figure 5.4.2.2 Fluorescence of the Transgene Remains in Ganglia Plated on a 
Range of Substrates. Dorsal root ganglia adhere poorly to alternate substrates and 
subsequent Schwann cell outgrowth is affected. A and B. When plated on a substrate of 
collagen the ganglion adheres and limited Schwann cell proliferation accompanies this, 
as is evident in the phase contrast image. A number of EGFP positive cells are seen 
within the ganglia as indicated by arrows when illuminated with excitatory light. C and 
D. Adhesion and some outgrowth of Schwann cells are seen when ganglia are re-plated 
on a laminin. Positive cell bodies with elongated processes are seen within the ganglion. 
E and F. Ganglia on the substrate poly-lysine show poor neuronal outgrowth and 
Schwann cell division. However expression of the transgene remains in positive 
Schwann cells. (A, C and E phase contrast optics). Scale bars A,C and E 200jim, B,D 
and F lOOum. 
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Figure 5.4.2.3 The Morphology of the Schwann Cells and the Pattern of E G F P 
Expression is Altered in Ganglia Plated on the Substrate Matrigel. The expression 
pattern of the transgene was investigated on a number of different substrates. A and B. 
Prior to re-plating the ganglia were assessed for the extent of expression on the normal 
substrate collagen/poly-lysine. C and D. Following re-plating on matrigel the 
morphology of the Schwann cells is greatly altered. The cells are now smaller and 
flattened. Many do not extend processes. In addition the observed level of fluorescence 
appears lower than that seen before the procedure was carried out. Scale bar lOOurn. E 
and F. Under phase contrast optics the morphology of the Schwann cells can clearly be 
seen. Although some remain stellate with higher magnification the flattened shape of the 
cell body surrounding the nucleus and the extended cytoplasm can be seen. Scale bar 
200um and 50um respectively. 
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Independent visual assessment of the level of fluorescence seen in Schwann cells 
replated on the Matrigel substrate indicated that the proportion of cells expressing the 
transgene appeared reduced. In addition the intensity was also diminished, although this 
may have been due to the increased area of the Schwann cell cytoplasm brought about 
by the change in morphology. 
At no time was fluorescence induced in Schwann cells from cultures of embryos that 
were positive for the transgene but had not expressed EGFP before re-plating. 
5.5 Summary 
Comprehensive observation of the peripheral nerves of transgenic mice from neonatal 
day 5 (P5) to adult failed to provide evidence for the expression of the transgene in vivo 
following birth. Investigation also showed that many embryos in which the transgene 
was present in the genome failed to give rise to fluorescent Schwann cells in culture. 
The influence of axonal contact and extracellular matrix components on the expression 
of the transgene and the restricted distribution of the positive cells was considered. The 
removal of axonal contact was not sufficient to alter the expression pattern of the 
transgene in any way. The restricted outgrowth of neurons and Schwann cells when 
plated on a number of components hindered the observation of expression within these 
cultures. That extracellular matrices can influence Schwann cells was demonstrated by 
the altered morphology of Schwann cells when plated on the matrigel substrate. The 
change in morphology appears also to be accompanied by a downregulation in the 
expression of the transgene by a number of Schwann cells. 
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6.1 Summary 
The PI promoter has been shown to drive the Schwann cell specific increase in PMP-22 
expression associated with myelination in vivo. In this study the PI promoter was 
isolated from mouse genomic DNA, and was then successfully incorporated into a 
plasmid vector to drive the expression of the enhanced green fluorescent protein. The 
cell specificity of the construct was demonstrated in a series of functional studies. The 
expression of the transgene was seen in both primary Schwann cells and the Schwann 
cell line SCL4.1/F7. In addition EGFP expression was demonstrated in diverse cell types 
associated with the non-neural expression of PMP-22. In an unrelated cell type, the 
COS-7 cell line, no expression was observed. 
The Hind III /Ail I I fragment of the construct that contains the promoter and reporter 
gene with regulatory regions was microinjected into pre-implantation fertilised embryos. 
Of 240 viable embryos that were re-implanted into pseudopregnant recipients 50 
developed to term, and of these 3 transgenic founder lines have been found that transmit 
the transgene through successive generations. Variation in copy number between them 
was evident by Southern blot analysis. 
Analysis of embryos from founder line four showed expression of the transgene in a 
Schwann cell specific manner with non-neural expression seen in the skeletal muscle, 
lung and liver. The Schwann cell expression was mosaic, not all Schwann cells from any 
one mouse were positive for EGFP expression. Comprehensive observation of the 
peripheral nerves of transgenic mice from neonatal day 5 (P5) to adult failed to provide 
evidence for the expression of the transgene in vivo following birth. Investigation also 
showed a further level of variation as many embryos in which the transgene was found 
to be present in the genome by PCR failed to give rise to fluorescent Schwann cells in 
culture. 
The influence of axonal contact and extracellular matrix components on the expression 
of the transgene and the restricted distribution of the positive cells was considered. The 
removal of axonal contact was not sufficient to alter the expression pattern of the 
transgene in any way. The restricted outgrowth of neurons and Schwann cells when 
plated on a number of components hindered the observation of expression within these 
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cultures. That extracellular matrices can influence Schwann cells was demonstrated by 
the altered morphology of Schwann cells when plated on the matrigel substrate. The 
change in morphology appears also to be accompanied by a downregulation in the 
expression of the transgene by a number of Schwann cells. 
6.2 Possible Causes of the Observed Variation of Expression 
The use of transgenic mice has been extensive since the technique was first developed. It 
is common to see variation of expression between different lines of animals 
micro injected with the same DNA fragment. Even with transgenic animals previously 
created to study myelin proteins there has been reported mosaicism. For example the 
expression of MBP promoter driven lacZ in transgenic mice was absent from most adult 
oligodendrocytes (Foran and Peterson, 1992). The rescue of the shiverer phenotype by 
the introduction of a functional myelin basic protein gene was also mosaic (Popkoe? al., 
1987; Readhead et al., 1987). In addition the expression of antisense MBP cDNA caused * 
variation between cells in the expression of endogenous MBP (Katsuki et al., 1988). 
Enhancer and repressor elements that regulate the expression of a particular gene can 
exert their influence from a great distance. Problems of expression have often been 
thought to be due to an absence of important 5' regulatory regions. 
Stable positional effects have also been considered to determine differences of 
expression between lines. The integration of an equivalent transgene within different 
sites can effect the resulting level of expression. A number of studies have described 
transgenic lines in which variation in the level of expression is seen both between lines 
and within individuals of the same line indicating some other method of restriction. 
Palmiter et al. (1984) produced a mouse in which the levels of expression of herpes 
simplex virus thymidine kinase varied by more than an order of magnitude between 
progeny of the same line. Dobie et al. (1996) investigated the expression of the P-
lactoglobulin gene in the mammary gland of transgenic mice and found variegation of 
expression, only a proportion of the cells expressed the transgene. Studies in Drosophila 
and yeast have provided insights into the mechanism of transgene silencing that can also 
be applied to mice. 
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6.2.1 Potential Influences on Expression Variation 
6.2.1.1 Multiple Insertion Sites 
A number of other possible factors that could influence the expression of the transgene 
must be considered. Differential expression in transgenic animals may be the result of 
multiple sites of insertion of the foreign DNA. For example i f a founder animal has 
integrated a transgene at two sites and only one of these is active then depending upon 
which set of tandem repeats the offspring inherits, it may or may not show EGFP 
expression. This would be evident by discrepancies in the copy number between the 
founder and the expressing and non-expressing offspring. 
Further indication of multiple insertion sites would be evident by the restriction pattern 
obtained by Southern blot analysis. I f different offspring inherit copies from different 
chromosomes the junctional fragments generated following digest of the genomic DNA 
would be different. 
In my mouse model an accurate determination of the copy number of the mice cannot be 
made at this point although there is no obvious gross difference in the copy number 
between individuals. To enable a precise comparison Southern blots would need to be 
hybridised with an internal probe of an endogenous gene. This could be used to equalise 
the amount of DNA loaded into each lane and correct for any discrepancies in the 
transfer process. 
The restriction pattern between offspring that have the transgene but differ in their 
expression of it gave identical bands on the Southern blot and appears the same as that 
of the founder. However the additional fragments were seen more strongly in the 
offspring than the founder animal. This is likely to be due to technical differences such 
as the quality and quantity of DNA, discrepancies in the blotting procedure or the 
activity of the probe. The restriction pattern is consistent both between individuals of the 
same litter and between litters. 
The additional bands are likely to correspond to junctional fragments, regions that lie 
between the Bam HI site of the terminal tandem repeats and the next Bam HI site within 
the genomic DNA on either side of the insert. Specifically these fragments are restricted 
to the DNA of positive animals and are therefore not non-specific bands that have 
hybridised to the probe or sections of the endogenous PMP-22 PI promoter. 
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It cannot be ruled out that subtle differences in the molecular weights of the restriction 
bands occur and that the resolution of the agarose gel masks this. The use of alternative 
restriction enzymes would address this problem. It is unlikely that with a range of 
enzymes the fragments isolated from genomic DNA would be equivalent across the 
mice. 
6.2.1.2 Sex Related Expression. 
A further obvious difference that may give rise to distinct populations of transgenic mice 
is their sex. As in humans, the presence or absence of the Y chromosome determines the 
sex of a mouse. Females lack the Y chromosome and have two copies of the X 
chromosome. In order to maintain equal dosage of genes expressed on the X 
chromosome between the two sexes one is inactivated in female mice. I f a transgene 
inserts on the paternal copy of the X chromosome that is then inactivated in an 
individual female offspring it wil l be unable to express the transgene. 
Alternatively i f the transgene has incorporated into the Y chromosome then only the 
male offspring can inherit it. However this would not explain in the present study the 
discrepancy of the animals that possessed the EGFP gene in their genome yet did not 
express it. 
Moreover table 5.3.2 describes the number of DRG co-cultures studied over a six month 
period. Often within a litter while a number of embryos had the transgene in their 
genomic DNA none of them expressed the EGFP protein. It is unlikely given the number 
of cultures studied that all of the mice that had the transgene and did not express it were 
of the same sex. Conversely, the infrequency with which mice express the transgene 
makes it unlikely that the determining factor is the sex of the animal. Equal numbers of 
male and female offspring would be expected, yet the figures for animals that express 
the transgene do not reflect that. 
The sex of a mouse can be determined at the embryonic stage. At the El 5 developmental 
stage the gonads of each sex can be found in a position relative to the kidneys. The male 
testes appear round in shape and at this stage in development are found deeper in the 
pelvic region that the female ovaries. The ovaries are more ovoid in nature and are 
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partially enveloped by the paramesonephric duct. The tissue appears "spotty" when light 
is shone through it. 
Identification of the presence the Y chromosome would also prove an indication of the 
sex of the individual. This could be achieved by amplification of a gene that is found 
upon the Y chromosome by PCR. For example the gene for a male specific 
histocompatibility antigen that is found on the Y chromosome gives a distinct restriction 
pattern in a Southern blot between male and female (Greenfield et al, 1996). The 
mRNA sequence for this protein is readily accessible in the Genbank database 
(accession number Y09222) and primers designed against it would allow identification 
of mice that have the Y chromosome. 
To determine the influence that the sex of a mouse has on the expression of the P l -
EGFP transgene, transgenic embryos could be analysed to determine their sex on 
dissection. In addition genomic DNA was extracted from embryos following a number 
of previous dissections. Suitable oligonucleotide primers could be employed with an 
appropriate PCR protocol to utilise this resource. 
6.2.1.3 Growth Arrest 
The regulation of PMP-22 and its alternate promoters in response to growth arrest has 
been extensively studied. The position through the cell cycle of individual cells within 
culture may be determining the expression of the transgene. While this possibility has 
not been investigated observation suggests that this is not the cause of the variability of 
expression. 
The relative level of expression within an embryo can be estimated as the ganglia are 
removed. I f one embryo has low numbers of positive cells immediately following 
dissection in comparison to another, then subsequent time in culture wi l l not alter the 
relative levels between the two. This suggests that the proportion of expressing cells is 
determined independently of tissue culture conditions. 
Within the DRG co-culture system Schwann cells are highly proliferative expanding 
throughout the culture. It is possible that a number of these are in a state of growth 
arrest, under which conditions it is suggested that PMP-22 is upregulated. However the 
variation in proliferation between cultures derived from individuals within the same 
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litter, maintained in identical culture conditions, is unlikely to be as great as the 
difference often observed between them in the levels of expression. 
The growth state of a cell can be determined by the nature of the molecules that are 
expressed at the nuclear membrane. For example in DRG co-cultures from transgenic 
embryos immunocytochemistry could be used to determine the presence of specific 
nuclear lamins associated with cell division at the nucleus of expressing cells. The 
incorporation of Bromodeoxyuridine (BrdU) into actively dividing cells, followed by 
their identification through antibody labelling of the BrdU would provide an alternative 
method of distinguishing between the growth states of cells. 
The maintenance of Schwann cells in low serum conditions (0.5% FBS) has been used 
to induce growth arrest. I f these conditions were to be imposed upon the co-cultures any 
alteration in the levels of expression may indicate a role for growth arrest in the 
expression of the transgene. 
6.2.1.4 Position Effect Variegation 
Work in Drosophila has shown that the position of a gene within different regions of the 
chromosome can affect the expression that is seen. Within eukaryotic cells the 
chromosomal material can take on a number of forms. Heterochromatin, found at the 
centromere and telomere of a chromosome appears deeply stained and condensed 
throughout the cell cycle and is relatively gene poor. By comparison euchromatin 
appears diffuse during interphase and is rich in functional genes. It was found that i f a 
gene was incorporated into a region of heterochromatin this brought about 
conformational change over the transgene that prevented interaction with the 
transcriptional machinery and so silenced the gene. Variation between individual cells is 
accounted for by differences in the extent of linear extension of the heterochromatin 
region (Martin and Whitelaw, 1996; Henikoff, 1998). 
The nature of the transgene also influences the silencing effect. DNA fragments tend to 
insert as linear head to tail arrays. It has been shown that arrays with high copy number 
tend to be focal points of heterochromatin formation. In Drosophila as few as three 
copies of a transgene have been seen to display a position effect variegation like 
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phenotype (Dorer and Henikoff, 1994). Garrick et al. (1998) investigated this effect in 
mice. A construct containing the P-globin promoter region and the LacZ reporter gene 
was used to produce multiple transgenic mouse lines. In addition the transgene 
incorporated a 34 base pair loxP site, the recognition site of the Cre recombinase enzyme 
of bacteriophage PI. The transgenic lines derived from this series of microinjections 
were examined for the expression of P-galactosidase in erythrocytes. Two transgenic 
lines were identified that displayed variable expression combined with a copy number of 
over 100. Oocytes derived from these mice were microinjected with a circular plasmid 
that possessed the Cre recombinase gene. This mediated recombination between loxP 
sites within the transgene array and removed the intermediate DNA as a circular 
episome. The copy number in these lines was therefore reduced. Analysis of the 
transgene expression following the reduction in copy number, indicated a strong 
increase in expression in comparison to the founder line. Since the site of insertion 
remained the same the high copy number was thought to have been the cause of the 
restricted expression. Subsequent studies showed that the transgene in the founder line 
was more resistant to DNase digestion than that in the mice with reduced copy number. 
This suggested that homolgous pairing between monomers within the transgene array 
were forming heterochromatin structures that were repressive to the expression of the 
transgene. 
The degree of variation was also found to be dependent upon other factors. It has been 
shown that age can effect the expression pattern. Robertson et al. (1996) found that 
among a line in which the level of variation of expression remained constant between 
offspring the developmental stage at which the reporter gene assay was carried out was 
significant. Compared to embryonic stages at later ages the proportion of cells that 
expressed the transgene was reduced. 
The influence of position effect variegation (PEV) can be overcome by other cis acting 
factors. Locus control regions (LCR) direct high levels of tissue specific expression of 
transgenes independent of the site of insertion. They act to open chromatin domains and 
allow trans acting factors access to a gene (Festenstein et ah, 1996). The LCR of the 
human CD2 gene has been identified and deletion studies have demonstrated the need 
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for a complete LCR to achieve high and non-variegated expression even when the gene 
is shown to be located in a centromeric region (Festensteine/ ai, 1996). 
The Pl-EGFP transgenic mouse shows mosaicism of expression. Within an individual 
animal not all Schwann cells show EGFP expression and within individuals of the same 
litter the extent of the variation is different. I f this were a stable position effect, with the 
surrounding genetic environment silencing expression it would be expected to do so 
consistently in all animals since they share the same site of insertion. However position 
effect variegation describes a situation in which variation occurs between mice of the 
same founder line, more accurately describing this mouse line. 
6.2.1.5 Fluorescence In Situ Hybridisation 
A valuable experimental tool that could illuminate many of the aspects that determine 
variegation is the use of fluorescence in situ hybridisation or FISH. This method utilises 
DNA or RNA probes that bind to specific sequences within the genomic DNA that can 
then be visualised by incubation with a fluorescent label. This allows identification of 
the site of that gene to a specific region of an individual chromosome. Cells obtained 
from easily accessible tissues or blood and are swollen hypotonically and then fixed on 
slides. The DNA is denatured and fixed in ethanol to prevent reannealing. It is then 
incubated with the specific probe labelled with reporter molecules such as biotin and 
allowed to hybridise. Following washing the slide is then incubated in fluorescent 
reagents such as fluorescent labelled anti-biotin antibody. The location of the transgene 
insertion site can be seen using fluorescent microscopy techniques, and combined with 
banding of the chromosomes the site can be identified (Trask, 1991). 
This technique could clarify many issues regarding the behaviour of the transgenic 
mouse. FISH using an EGFP probe against the chromosomes of the founder mouse 
would identify the chromosomal site of insertion, it would be evident i f more than one 
insertion site existed. Also through recognition of the chromosome in which it has 
inserted the issue of X-linked inactivation could be determined. Comparison of FISH 
results from transgenic Fi litters that display differential expression of the EGFP protein, 
could rule out the occurrence of gene rearrangements as the cause of the variation in 
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variation in expression. Once these possibilities have been disproved the issue of 
position effect variegation seems the likely cause of the discrepancy of expression of the 
transgene. FISH can also determine the position of the transgene within any given 
chromosome. The incorporation of the foreign gene into the centromere or teleomere 
regions that are rich in heterochromatin could be indicative of this outcome. 
6.3 Detailed Studies of the Transgenic Mouse Line 4 
Despite the variable expression pattern of the transgene within the mouse line a series of 
experiments were performed to determine the regulation of the Pl-EGFP construct 
within the transgenic line. 
6.3.1 Expression of the Transgene in the Target Cell Type. 
The ability to visualise EGFP expression in live Schwann cells provides an advantage 
over other methods of recognition. This system would allow the observation of the 
migration and interaction of non-myelinating Schwann cells with neurons against a clear 
background as only a proportion of these Schwann cells express the transgene. With 
changed culture conditions the progression of the Schwann cell as myelin formation is 
initiated and proceeds could be monitored, giving a dynamic visual display of 
myelination in vitro. 
Transgenic line four has been extensively studied in vitro. The preparation of co-cultures 
from the dorsal root ganglia of El 5 embryos allowed immunostaining and 
morphological identification of positively expressing cells as Schwann cells. 
The expression of the transgene could be seen within the ganglia at the time of removal 
from the embryo. This indicated the transcription of PMP-22 through the regulation of 
the PI promoter at embryonic day 15 or at some point prior to this time. Supporting 
evidence for the expression of PMP-22 in glial cells at this embryonic stage was found 
in the expression of EGFP in cells morphologically similar to Schwann cells, cultured 
from the skeletal muscle of a transgenic embryo. The crude nature of the dissection 
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technique means that it is possible that sections of the sciatic nerve were included in the 
preparation. 
Baechner et al. (1995) found PMP-22 expression in other cells of neural crest origin at 
this time and the myelin protein P 0 is also expressed in Schwann cells during 
development. Po expression is seen in Schwann cell precursors and at birth the levels of 
this protein are down-regulated in non-myelin forming Schwann cells and up-regulated 
in myelin forming cells (Lee et al., 1997). PMP-22 and P 0 show strong correlation of 
expression during myelination (Kuhn et al., 1993; Notterpek et al., 1999). In mature 
myelin P 0 forms homophilic interactions between molecules of opposing layers and 
maintains the compact nature of the sheath. An association between PMP-22 and P 0 has 
been shown in vitro. Cells transfected with Po were co-cultured with cells expressing 
PMP-22. Immunostudies showed that the two proteins co-localised at the opposing 
membranes of adjacent cells (D'Urso et al. 1999). The similarity of expression and the 
interaction between the two at this time is thought to demonstrate a functional 
significance of this relationship in compact myelin. It may be that this extends to the 
embryonic expression of both proteins in the Schwann cell precursor. 
The possible role of PMP-22 at this time is unknown. Expression of Po in neural crest 
cells is thought to be the earliest marker of the glial cell lineage. Its embryonic 
expression, suppression in non-myelin forming cells and its appearance following nerve 
injury has lead to the suggestion that it has a role in development and regeneration that is 
independent of myelination (Lee et al., 1997). PMP-22 has been suggested as a 
modulator of the cell cycle and one aspect of its expression is thought to be that of a 
growth arrest specific protein. However at this point in development Schwann cell 
proliferation rates are high as numbers are matched to those of axons. In addition 
investigations have suggested that it is the P2 and exon lb transcript that are associated 
with growth arrest whilst PI and exon la are involved in the myelination process (Bosse 
etal, 1994; Zoidl etal, 1995). 
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6.3.2 Non-neural Expression of the Transgene. 
The organs of three transgenic El5 embryos were assessed for the expression of the 
transgene. In only one instance in which the expression levels in the DRG co-cultures of 
the individual were high was non-neural expression seen. 
Non-neural expression of PMP-22 in the lung, liver, heart and skeletal muscle have been 
reported for the adult mouse (Spreyer et al., 1991; Welcher et al., 1991). During early 
organogenesis at 11.5 days pc high expression was seen in the capsule surrounding the 
liver. At 14.5 days p.c. or E14.5, expression was seen in the cartilage of the forming 
vertebrae. By E16.5 the neural crest derived connective tissue and skin of the face were 
expressing PMP-22. Parts of the skeletal system including the femur and vertebrae, 
muscle tissue such as the diaphragm and intercostal muscles, mesenchymal cells of the 
lung, all show PMP-22 expression at this time. No expression was reported in the heart 
or liver (Baechner et al., 1995). 
Morphological considerations suggest that the expression seen in the skeletal muscle 
culture of the Pl-EGFP embryo was restricted to Schwann cells from contaminating 
sciatic nerve. Immunolabelling with the Schwann cell specific S-100 antibody would 
demonstrate this. 
A small number of cells in lung and liver cultures were also positive for EGFP 
expression. These cells had a flattened morphology with large cytoplasmic areas. 
Subsequent analysis of these tissues may provide insight into alternative roles of PMP-
22. Previous studies of non-neural expression have utilised the whole organ and were 
unable to identify which individual cells were expressing EGFP. The fixation and 
sectioning of tissues such as the liver and lung from embryonic or adult transgenic mice 
may enable identification of the site of expression within each tissue. Determination of 
the cell type and lineage of positive cells may further illuminate the significance of 
PMP-22 expression at these sites. 
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6.3.3 Corroboration of the Transgene Expression with that of Endogenous PMP-22 
To ensure that the expression observed in El5 Schwann cells and embryonic organs 
genuinely reflects expression of PMP-22 further studies must be carried out. Reverse 
transcriptase PCR could be used to detect any PMP-22 exon la containing transcripts 
within the entire population of cells. A modification of the procedure in which total 
RNA is isolated from a single cell could be used to specifically identify expression 
within EGFP positive cells. Alternatively expanded co-cultures or ganglia on removal 
from the embryo could be fixed and immunolabelled with a PMP-22 specific antibody. 
Incubation with a fluorescent rhodamine secondary antibody would allow simultaneous 
identification of cells that express the PMP-22 protein and those that show EGFP 
fluorescence. 
6.3.4 Validation of the PI Promoter 
The initial analysis of the transgenic mouse line four indicates that the 1.8kb region of 
the PI promoter (Bosse et al., 1999) is sufficient to regulate the tissue specific 
expression of a reporter gene. Previously 3.3kb of 5' sequence to exon la have been used 
to drive expression both in Schwann cells and fibroblasts with limited promoter activity 
(Sutere/a/., 1994). 
The regulation of other myelin proteins has also been investigated through the 
production of transgenic mice in which specific promoters were used to drive reporter 
gene expression. The myelin basic protein (MBP) promoter has been extensively 
studied, and a number of transgenic lines have been produced with different lengths of 
the 5' untranslated region regulating gene expression (for review Ikenaka and Kagawa, 
1995). As little as 256 bp of the MBP promoter region has been shown to direct 
oligodendrocyte specific expression of reporter genes (Miura et al., 1989; Goujet-Zalc et 
al., 1993). Distinct Schwann cell expression however has not been seen with any 
construct implying the absence of an important regulatory region, although some 
expression was reported when up to 6kb of 5' sequence was used (Gow et al., 1992; 
Foran and Peterson, 1992; Friedrich et al., 1990). 
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6.3.5 Attempts to determine the regulation of the transgene during development. 
Within the DRG co-culture system employed in this study not all Schwann cells from an 
individual transgenic mouse expressed the EGFP protein. This may have been due to the 
developmental stage at which the Schwann cells were removed from the influence of in 
vivo signals. During post-natal development there is a great rise in the transcription of 
PMP-22 from the PI promoter (Suter et al, 1994). It was hypothesised that i f the 
transgene considered here was regulated correctly in a manner equivalent to that of 
PMP-22, examination of peripheral nerves from neonatal animals would show that 
expression of the transgene would increase during this time. The sciatic nerve was 
therefore removed from a series of animals, each identified as possessing the transgene 
by PCR analysis, and observed by confocal microscopy. In all animals from all founder 
lines and at ages ranging from postnatal day 5 to adulthood no expression of the 
construct was identified. In the DRG co-culture system embryos were also identified as 
positive for the transgene but that did not show EGFP expression. 
Southern blot analysis eliminated the possibility of contamination of the PCR reactions 
and also highlighted that the restriction pattern of all the offspring was the same, and no 
gross difference in the copy number was obvious between them. 
The site of the regulation of transgene expression may be further investigated through 
reverse transcriptase PCR to identify the presence or absence of EGFP mRNA in the co-
cultures of positive animals that do not show fluorescence. In addition a section of 
sciatic nerve from the animals used in the study of neonatal expression was embedded in 
Tissue-Tek and frozen at -80°C. mRNA material could be removed from these nerves 
and assessed for the EGFP transcript. 
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6.3.6 Analysis of the Transgene In Vitro 
6.3.6.1 In Vitro Myelination 
I f a mechanism similar to PEV is the cause for the variation of expression seen within 
the PI-EGFP transgenic mouse then there is no way to predict the likely expression 
pattern of any individual. This will restrict analysis of the regulation of the PI promoter 
region in vivo. However the El5 DRG co-cultures can be induced to myelinate i f 
maintained in the appropriate media. Commonly, following the initial dissection the co-
cultures are pulsed with anti-mitotic reagents to remove proliferating fibroblasts and 
Schwann cells. This results in a pure culture of DRG neurons. Concomitantly co-
cultures of transgenic, expressing Schwann cells are allowed to expand and the neurons 
are then removed to leave a pure population of Schwann cells. These can then be 
trypsinised from the culture dish and re-plated at a suitable density onto the pure 
neurons. The cultures are first maintained in defined medium that allows neuron 
stimulated proliferation of the re-seeded Schwann cells. It is then replaced with 
myelinating media, basal media with 10% FBS and 50ug/ml ascorbic acid. Within 7 
days myelin formation wil l begin and the cultures can be maintained for a number of 
weeks. 
In vitro myelination can be difficult to achieve consistently. The discovery of the 
influence of progesterone on both myelin formation and individual myelin protein 
expression has lead to culture methods that can increase that efficiency (Notterpek et al, 
1999). 
During injury of the peripheral nerve levels of progesterone remain high. The addition of 
progesterone inhibitors at this time impedes the subsequent remyelination of 
regenerating nerves that as a result show decreased myelin thickness. Myelination can be 
enhanced by the addition of exogenous progesterone with the sheath showing an 
increased number of lamellae. The overall percentage of myelinated fibres is not altered 
with varying levels of progesterone, so it is suggested that it is not involved with the 
initiation of myelin formation, but stimulates the ongoing production of myelin (Koenig 
etal., 1995). 
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The addition of progesterone to myelinating media has been shown to enhance the 
efficiency of myelination in vitro (Notterpek et al., 1999). It was found that this 
stimulated the expression of the myelin proteins MBP, P 0 and PMP-22 in Schwann cell 
co-cultures (Desarnaud et al., 1998; Notterpek et al., 1999). 
One advantage of the variation of expression among cells of one individual is that the 
ful l extent of an individual Schwann cell can be seen. The fine processes that extend 
from the Schwann cell body can be difficult to distinguish fully in dense three 
dimensional cultures. The absence of background fluorescence and the intensity of the 
EGFP signal enables the limits of a single Schwann cell to be identified. Confocal 
microscopy techniques could be used to follow the behaviour of a single Schwann cell 
over time and in a three dimensional manner to give clear and precise evidence of the 
manner in which the Schwann cell and neuron interact at this time. 
It would also be interesting to observe the expression of the transgene in other Schwann 
cells as the PI promoter is used more extensively as myelination proceeds. Although it 
would be difficult to quantify an increase in EGFP expression visually within an 
individual cell a series of semi-quantitative single cell RT-PCR reactions could monitor 
an increase in EGFP mRNA expression at different stages of the myelinating procedure. 
The expression of EGFP in Schwann cells at El5 may not represent the entire 
population that is able to do so. The initiation of myelination may induce EGFP 
expression in previously non-expressing Schwann cells. This may be a distinction 
between different stages of development among the population in vitro alternatively it 
may represent a novel role for PMP-22 in a population of Schwann cells that is 
independent of myelination. The immunostaining experiments that were suggested in 
section 6.3.3 would address this issue. I f the number of EGFP positive cells remains 
constant and PMP-22 immunolabelled cells are identified that do not express EGFP then 
the initial population of positive cells represents the extent of expression within that 
individual. 
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Some evidence has been obtained that the expression of the transgene can be influenced 
through study of the interaction of the non-myelinating Schwann cells with the 
extracellular matrix and the DRG neurons. The influence of both neurons and the 
extracellular matrix has been shown to have a profound effect on the expression of 
myelin proteins and the behaviour of Schwann cells. In an attempt to determine how 
influential these factors were on transgene expression in the Schwann cell they were 
disrupted and altered expression was searched for. 
6.3.6.2 Neuronal Influence on Expression 
Co-cultures immunolabelled with anti-neurofilament antibodies clearly showed the great 
extent of neuronal outgrowth across the tissue culture dish indicating that restricted 
axonal outgrowth was not underlying the low expression seen. 
Following the removal of the dorsal root ganglia from the co-cultures the remaining 
neuronal processes were shown to degenerate within 48 hours. Over time the loss of the 
neurons affected the morphology of the Schwann cells, however no decrease in 
expression was seen. That expression can continue without axonal presence was 
reiterated by the observation of potential fluorescent Schwann cells in the skeletal 
muscle culture. Due to the method of dissection axons in the sciatic nerve would have 
been severed from their cell bodies and would subsequently degenerate. 
It is unlikely that the persistent EGFP signal following axonal degeneration is a 
reflection of a stable population of EGFP protein. Clontech state the half-life of EGFP as 
twenty four hours and so it should prove dynamic enough to reflect changes in 
expression over such a course of time examined here. Removal of the neurons from the 
co-culture at an earlier stage and maintenance of the culture over longer periods of time 
should solidify the validity of this observation. 
The restricted distribution of the positive cells did not alter after the removal of axons. 
These observations suggest that the expression of EGFP in this population of Schwann 
cells was independent of axonal contact and myelination and that axonal influences did 
not restrict the expression of the transgene. 
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Schwann cells have been shown to be dependent upon many axonal signals. Precursor 
Schwann cells are dependent upon neuronal signals for survival, axonal contact is 
required by mature Schwann cells for the formation of myelin (Jessen et al., 1994; 
Lemke, 1996). PMP-22 was originally described as a protein that was differentially 
expressed following nerve crush (Spreyer et al., 1991; Welcher et al., 1991). Axonal 
degeneration causes downregulation of the expression of PMP-22, that recovers as 
regeneration and remyelination occurs. Specifically it was demonstrated that the myelin 
specific expression of PMP-22 was restricted to the exon la containing transcript that is 
driven by the PI promoter (Suter et al., 1994). 
However PMP-22 has been demonstrated in the cytoplasm of non-myelinating Schwann 
cells in co-culture with neurons. In myelinating co-cultures, MAG negative Schwann 
cells have been identified in which PMP-22 expression was found at the plasma 
membrane, this translocation of the protein is not normally seen in cells that are not 
forming myelin. And in addition MBP negative Schwann cells of the rat sympathetic 
tract have also been found to express PMP-22 (Notterpek et al., 1999). This indicates 
that neuronal contact and myelination do not strictly regulate the expression of the 
protein. However it does not preclude the possibility that neuronal and extracellular 
influence are still required at some level. 
It is possible that a neuronal signal is required to initiate expression at an earlier 
developmental stage. DRG dissection from embryos younger than El5 becomes 
progressively more difficult as the tissue becomes softer. In situ hybridisation of whole 
younger embryos with an RNA probe against EGFP may allow determination of the age 
at which expression begins this may then be related to the interactions that are occurring 
between axons and Schwann cell progenitors at that time. It may also be compared to the 
expression of the myelin protein Po during development to determine the extent of their 
interaction at this time. 
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6.3.6.3 Extracellular matrix regulation of Transgene Expression 
Extracellular matrix products have been shown to have a profound effect on the 
differentiation of the Schwann cell. Once Schwann cells have associated with axons and 
in the presence of the necessary factors the Schwann cell secretes a basal lamina before 
myelination proceeds. This extracellular matrix polarises the cell and allows myelination 
to continue (Bunge et al., 1986). The role of the extra cellular matrix in the initial stages 
of myelination that accompany changes in gene expression have been discussed in detail 
in section 1.3.2. 
Dorsal root ganglia co-cultures were maintained in a chemically defined media that was 
not permissive for the formation of a basal lamina due to the absence of serum and 
ascorbic acid. However Schwann cells have been demonstrated to secrete some 
extracellular proteins independent of axonal contact and myelin formation. Punctate 
labelling of laminin and heparin sulfate proteoglycan is seen in Schwann cells in non-
myelinating media, however they are not organised into a functional basal lamina 
(Cornbrookes et al., 1983). Furthermore since these factors are secreted locally by 
individual Schwann cells an attempt was made to investigate its role in restricting the 
expression of the transgene. The ganglia were plated on a number of substrates, however 
limited growth of the cultures prevented any direct comparison of expression levels and 
patterns before and after re-plating. On the Matrigel substrate successful culture was 
observed. This was shown to greatly affect the morphology of the Schwann cell and 
some evidence was found for a reduction in the number of Schwann cells that expressed 
EGFP. However the restricted regions of expression remained. 
Matrigel is a soluble basement membrane extract from the Engelbreth-Holm-Swarm 
tumor. Its major components are extracellular matrix proteins; laminin; collagen type 
IV; entactin and heparin sulfate proteoglycan. However these proteins are not organised 
into a functional matrix. 
The importance of the extra cellular matrix in determining the morphological shape of a 
cell has been demonstrated. Once a basal lamina has been established and expression of 
the myelin proteins begins, the Schwann cell undergoes a number of morphological 
changes. Undifferentiated Schwann cells with short processes and round nucleus, extend 
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the cellular processes and the nucleus elongates. In serum-free media conditions 
expression of the myelin proteins Po and MAG can be induced, however basal lamina 
formation is not. In the absence of a basal lamina the morphological alterations that 
normally accompany the change in gene expression do not occur (Femandez-Valle et 
al., 1993). The same report also found that with the removal of serum from the growth 
media Schwann cells in a DRG co-culture were able to express Po However 
maintenance in media with serum but no ascorbic acid resulted in suppression of Po 
levels. Subsequent addition of ascorbic acid to the media caused a rapid increase in P 0 . 
This was argued to show that the expression of this protein is linked to basal-lamina 
formation. 
The observation that manipulation of the extracellular matrix may be influencing the 
extent of the expression of the PI-EGFP transgene needs to be confirmed and expanded 
upon. 
Ganglia plated and maintained on clean coverslips would secrete extracellular 
components across the surface of the coverslip. I f the cells were later removed and the 
deposited extracellular matrix examined, localised variation in the factors secreted may 
become evident. Repeated cycles of freezing at -20°C followed by thawing to room 
temperature osmotically ruptures the cells and their debris can be removed by washing. 
Incubation of the coverslips with a range of different antibodies against matrix 
components would indicate any differences. 
In a preliminary experiment a co-culture from an embryo that expressed the PI-EGFP 
transgene in a large proportion of the cells was allowed to deposit extracellular matrix 
components onto the surface of a coverslip. Following the removal of the cells by 
repeated freeze thawing and adequate washing the coverslip was re-plated with ganglia 
from cultures in which the level of expression was low. In two of the four ganglia that 
were replated it appeared that expression was seen in a greater number of cells than 
previously. This experiment needs to be repeated before any statement can be made. 
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The mechanisms by which the extracellular matrix could affect the expression of the 
construct are complex. Upregulation of endogenous PMP-22 and consequently the 
transgene by the induction of myelination requires exact culture conditions and is 
difficult to achieve. An independent method of increasing expression levels that can be 
achieved more readily is the addition of forskolin to culture media. Forskolin is an 
activator of cyclic AMP that has been shown to increase the expression of a number of 
myelin proteins including PMP-22 and specifically the PI promoter driven expression of 
the exon la transcript (Suter et ah, 1994). The addition of forskolin to non^nyelinating 
cultures has been shown to raise the expression of PMP-22 (Notterpek et al., 1999). The 
exposure of the transgenic Schwann cell co-cultures to this agent will raise the 
expression in all cells. I f an increase in the number of fluorescing Schwann cells is seen 
this would provide evidence that the transgene can be regulated and in a manner that is 
representative of the endogenous promoter. 
These experiments may provide evidence for the regulation of the transgene however no 
mechanism is suggested by which the transgene expression is restricted. One alternative 
hypothesis is that in fact the restriction is not due to some physical factor that is 
influencing expression. The position effect variegation discussed in section 6.2.1.4 has 
been suggested to occur in a clonal manner (Dobie et al., 1996; Festenstein et al., 1996). 
The decision whether to express the transgene is thought to be made at an early stage in 
development and subsequent cells derived from that progenitor will also express the 
transgene. In this way the restricted expression pattern seen may reflect the existence of 
a small number of progenitor cells that have expanded within a localised area. 
6.4 Further Suggested Study of the P l -EGFP Transgenic Line. 
In the Pl-EGFP mouse line four the expression of the transgene has been demonstrated 
in the Schwann cells of the peripheral nerve albeit in a mosaic manner. In addition the 
transgene was observed in a number of non-neural sites that lends weight to the 
argument that the exon la transcript while predominating in the Schwann cell also 
contributes to the reported non-neural expression. This is this first instance in which the 
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use of the PI promoter has been attributed to individual populations of cells in these 
non-neural sites. Further investigation of their lineage and function may indicate 
potential alternative roles for PMP-22 in these cells. 
The mosaic expression pattern of the transgene in line four was further demonstrated 
when analysis showed that not every individual that possessed the transgene within their 
genome expressed it despite the assumed identical site of insertion throughout the line. 
Southern blot analysis showed no evidence for multiple insertion sites or rearrangements 
of the transgene between these offspring. Other suggestions include insertion of the 
transgene into the silenced X chromosome. These possibilities could all be addressed by 
fluorescent in situ hybridisation studies investigation of the line. 
The variation in expression between individuals of the same line is consistent with a 
mechanism similar to that of position effect variegation in which the silencing of the 
gene is affected by the site of insertion and the nature of the chromosomal material 
present at that site. The divergence between cells that express and those that do not is 
thought to be made early in development. I f all positive cells within a given area were 
derived from the same progenitor this would explain the restriction of expression that is 
seen in vitro. 
I f the expression of EGFP in the Schwann cells at El5 as they are removed from the 
embryo represents a true reflection of PMP-22 transcription then it has been 
demonstrated that this persists independently of neuronal contact and myelination. The 
extracellular matrix however may influence the regulation of this expression but does 
not alter the restricted pattern of expression. 
This transgenic mouse potentially provides an opportunity to study the influence of the 
extracellular matrix on the expression of the myelin protein PMP-22. It can also give 
rise to a novel in vitro system with which the myelination of axons by peripheral 
Schwann cells can be visualised. This could be extended to include study of the 
interactions between Schwann cells and neurons in the trembler and trembler-J 
phenotype. Point mutations within the transmembrane spanning domains of the PMP-22 
protein result in abnormal myelin formation in these mice (Suter et al., 1992a,b). A 
mating regime in which the PI-EGFP transgene is introduced into the trembler 
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background would give rise to Schwann cells that lacked PMP-22 expression with the 
potential to express EGFP. The rescue of such cells by adenoviral infection with 
functional PMP-22 cDNA would allow direct visualisation of their behaviour as they 
begin to express the myelin proteins and myelinate axons. 
Following nerve injury the restoration of function depends upon the regrowth of 
surviving axons and the guidance of these neurons to their correct target with 
appropriate synaptic connections. In the PNS successful regeneration can occur. 
Neurons are able to grow through the remaining environment which includes Schwann 
cells, extracellular matrix components and other non-neural elements that express 
trophic factors and critical cell surface molecules. In addition Schwann cells can provide 
a permissive substrate through which CNS axons can regenerate (Aguayo et al., 1990). 
Expansion of Schwann cells that express EGFP would provide a source of cells that 
would be suitable for use in transplantation studies. Injection into local sites of injury 
and subsequent examination of these by fluorescence confocal microscopy would allow 
ease of identification of the transplanted cells and aid study into their migration and 
behaviour in the central nervous system environment. 
In conclusion while the PI-EGFP transgenic mouse line has limitations with respect to 
the variation of expression of the reporter gene, it remains an exciting tool with which to 
visualise the dynamic behaviour of Schwann cells. Further investigation of its 
expression may suggest potential roles for PMP-22 both during development and in 
Schwann cells and non-neural tissues that are independent of myelin formation. 
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A l Preparing 4% Paraformaldehyde 
4g of paraformaldehyde were added to 45ml distilled water with one drop of 10M 
NaOH. The solution was heated to 60°C. Once dissolved 50 ml of 2x PBS were added 
and the solution and adjusted to pH 7.4. The final volume was made up to 100ml with 
dH 2 0. 
A2 Administration of Anaesthetics 
Avertin (Aldrich). Intraperitoneal injection of 0.3 - 0.35 ml of 2.5% Avertin ( per 20g 
mouse) produces around 20 minutes of effective anaesthetic, sub-cutaneous injection is 
not as effective. The lack of analgesia does not seem to have any adverse effect in the 
described procedures. Administration cannot be repeated as this can cause peritonitis. 
However there is no need for repeated use in these protocols. 
Preparing Avertin for use: 2-2-2-tribromoethanol (Aldrich T484012) 
Tertiary amyl alcohol (Aldrich 240486) 
lOg tribromoethanol + 10 ml amyl alcohol 
Shake well and filter sterilise. 
Dilute to a 2.5% solution in water and filter sterilise. 
A3 Freezing of Microinjected Embryos for Long Term Storage. 
Preservation of a transgenic mouse line can be achieved by the storage of frozen 
embryos that can be recovered at a later date. The Karolinska Institute (Sweden) have 
frozen the embryos of the MBP-EGFP mouse line until such a time as they are required. 
Pre-implantation embryos derived from the established transgenic line were removed 
from the oviducts of a pregnant female mouse. Following isolation the embryos were 
screened for abnormalities and healthy embryos were maintained in M2 media at room 
temperature. 
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Freezing straws were prepared; plugged at one end and loaded with 1M sucrose. An air 
bubble was introduced to mark the boundary between the sucrose and the embryos in the 
final setup. 
Embryos were allowed to equilibrate in M2 media containing 1.5M propylene glycol for 
15-30 minutes. Up to 20 embryos at a time were taken up and introduced into the straw. 
The straws were then cooled to -7°C in a cooling bath. The sucrose fraction was touched 
with forceps cooled in liquid nitrogen to begin cooling. Once the ice formation had 
spread to the propylene glycol, after a further 5 minutes the straw was frozen at a rate of 
0.3°C/minute to a final temperature of -30°C. The straws were then plunged into liquid 
nitrogen and stored until further use. 
A3.1 Thawing Frozen 8 Cell Embryos and Blastocysts 
The freezing straw is removed from liquid nitrogen storage and held in the air for 40 
seconds before being placed in a room temperature water bath for complete defrosting. 
The seal of the straw is removed and the entire contents expelled into a 35mm culture 
dish. After 5 minutes the embryos wil l shrunk considerably. They are then transfered to 
a dish of M2 media. Care is taken to maintain the zona pellucida surrounding the 
embryo intact. The embryos rapidly absorb water and resume normal appearance. 
Following at least three hours in culture the embryos are washed in fresh M2 media 
before re-implantation into the oviducts of a pseudo-pregnant recipient female mouse. 
A4 Producing the pCMV-EGFP Positive Control Plasmid 
A4.1 Introduction 
The CMV-EGFP vector was produced for use as a positive control when investigating 
the expression of the tissue specific constructs. The cytomegalovirus (CMV) promoter 
gives rise to high levels of constitutive expression in mammalian cells and so can be 
used to provide positive evidence that a particular cell type has been both successfully 
transfected and is able to subsequently express the reporter gene. 
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The human cytomegalovirus is a member of the herpes virus classification group and has 
a large double stranded genome of 240 kilobases. At the immediate early (IE) time after 
infection, 88% of the viral RNA present is derived from a single region of the genome. 
Of these immediate early genes at least one was proposed to be a promoter with the 
capability of regulating the expression of other viral genes. 
From this gene region the human CMV promoter was isolated (US patent no. 
5,168,062). The promoter contains the common TATA box and CAAT box regulatory 
regions and the active promoter is thought to extend for 465 bases, a region 
incorporating a series of nucleotide repeats essential for promoter activity. A total of 767 
bases are utilised in the Invitrogen plasmid. This includes the promoter sequence and an 
additional 295 bases with unknown function. 
4.1.1 Assembling the Vector - Summary 
The EGFP gene was excised from the pEGFP-1 vector (Clontech, refer to section 3.1.2) 
and inserted into complementary restriction sites in the multi-cloning site of the 
pcDNAlamp vector (Invitrogen). This produced a construct from which constitutive 
EGFP expression could be achieved. 
4.2 Results 
The EGFP gene was cut from the pEGFP-1 plasmid by a double restriction digest with 
the enzymes Hind I I I and Not I (Table A4.2.1). lug of plasmid DNA was digested with 
10 units of each enzyme in a final volume of 50ul for 3 hours at 37°C. The restriction 
reaction was run on a 0.8% agarose gel and the 0.8kb fragment corresponding to the 
EGFP gene was removed and purified from the gel (section 2.5.3.1). 
Concomitantly lug of the pcDNAlamp (Invitrogen) vector was also digested with Hind 
I I I and Not I in the same manner and the major 4.7kb fragment was extracted from an 
agarose gel as described in section 2.5.3.1. 
The pcDNAlamp vector backbone was dephosphorylated with calf intestinal alkaline 
phosphatase (section 2.5.5), the vector and insert were then ligated overnight at 4°C 
with T4 DNA ligase (section2.5.6). 
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Plasmid Enzyme Restriction Site Fragment Length 
pEGFP-1 Hind I I I and Not I 41 and 820 779, 3421 
pcDNAlamp Hind I I I and Not I 2964 and 3039 75,4726 
Table A4.2.1. Restriction of the two plasmids for the production of the pCMV-EGFP 
vector. 
Following calcium chloride transformation (section 2.5.8.1) three colonies were 
identified, DNA was extracted via the miniprep method (section 2.2.1) and restriction 
digest (section 2.5.2) identified two that had incorporated the insert (Table A4.2.2 and 
Figure 4.2.3). 
Plasmid Enzyme Restriction Site Fragment Length 
pCMV-EGFP Nde I linearise 5.6kb 
Hind II I and Not I 2964 and 3 743 779, 4821 
Dra I 1584, 2276, 3940, 692, 1664, 437, 
4377 2807 
Dra I and Not I 1584, 2276, 3743, 692, 1467, 197, 
3940, 4377 437, 2807 
Table A4.2.2 Restriction map of the pCMV-EGFP plasmid. Fragments highlighted in 
bold represent the excised EGFP fragment (779bp) and the CMV-EGFP sequence 
(1467bp). 
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Figure A4.2.3 The pCMV-EGFP Positive Control Palsmid 
a. The EGFP gene was inserted into the Hind I I I and Not I digested 
pcDNAl/Amp plasmid (Invitrogen). b. Restriction digest of the resulting 
plasmid pCMV-EGFP. Lane 1 molecular weight markers. Lane 2 uncut 
CMV-EGFP plasmid DNA. Lane 3-7 pCMV-EGFP DNA restricted with 
Bam HI , Dra I , Nco I , Pst I and double digest with Hind I I I and Not I 
respectively. Lane 7 represents the removal of the inserted EGFP gene 
(779bp.) 
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A4.3 Functional Study of Activity of pCMV-EGFP 
Once the construct had been prepared, its ability to drive EGFP protein expression in a 
ubiquitous fashion was assessed. Confluent cultures of COS-7 green monkey kidney 
cells were transfected with the purified plasmid as described in section 3.3.1.4. 
As seen in Figure 3.3.3 successful expression of the protein was demonstrated in a full 
range of cell types. 
Relevant Patent: 
US Patent and Trademark Office. Inventor Stinski, M.F. 1990 no. 5,168,062 Transfer 
vectors and microorganisms containing the human cytomegalovirus immediate early 
promoter regulatory DNA sequence. 
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Appendix B: Generation of an Alternative Mouse Model. The MBP-
E G F P Transgenic Mouse 
B l Introduction 
Like the peripheral nervous system, many neurons in the brain require a myelin sheath to 
enable them to function properly. In the central nervous system the task of producing the 
myelin sheath is performed by the oligodendrocyte. These cells are found in the white 
matter of the brain, where individual cells extend processes and myelinate many nerve 
fibres. 
B l . l Development of the Oligodendrocyte Lineage 
Much of the work investigating the development of the oligodendrocyte has been carried 
out in the rat optic nerve as this region of the CNS is relatively simple. It does not 
contain any neuronal cell bodies and has only three types of glial cell, type I and I I 
astrocytes, and oliogdendrocytes. Studies on optic nerve cultures have shown that two 
distinct lineages are involved in the formation of the glial populations in the optic nerve; 
oligodendrocytes and type I I astrocytes share a common precursor while type I 
astrocytes develop from a separate cell type (Raff et al., 1983; 1984). The common 
lineage of oligodendrocytes and type I I astrocytes may relate to function, in that both are 
found to contribute structurally to the node of Ranvier (ffrench-Constant and Raff, 
1986). 
The common precursor cell, the pre-02A, is derived from the subventricular zone of the 
forebrain and the ventral spinal cord (Levine and Goldman, 1988a,b). These small, 
round, glossy cells are distinguished antigenetically from later cell types as they are 
negative for the A2B5 antibody that binds to polysialoganglioside proteins (Eisenbarth 
et al., 1979; Gard and Pfieffer, 1990; Hardy and Reynolds, 1993, Asou et al., 1995). 
The precursor cells mature to become 02A progenitors; process bearing cells that are 
positive for the A2B5 antigen. These latter cells are highly proliferative and can 
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differentiate into either oligodendrocytes or type I I astrocytes (Levi et al., 1986). Both of 
the final cell types divide infrequently, i f at all, with the main expansion of the 
population arising from the initial proliferation of the progenitor cells (Skoff et al., 1976; 
Miller et al., 1985). In the rat, oligodendrocyes first begin to appear at the day of birth, 
and the 02A progenitor cells continue to divide and differentiate for at least the next two 
weeks (Skoff et al., 1976). Type I I astrocytes are thought to begin developing from the 
same progenitors at later stages (Miller et al., 1985). Experiments suggest that in the 
absence of signals from any other cell type the oligodendrocyte is the default pathway of 
differentiation for the 02A progenitor cell (Temple and Raff, 1985). 
In vivo the 02A progenitor cells continue to proliferate over a period of weeks. In vitro, 
proliferation stops and differentiation begins within two days. The outcome of the 
differentiation is determined by the environmental conditions, cells that are maintained 
in 10% foetal calf serum (FCS) differentiate into type I I astrocytes; in its absence 
oligodendrocytes are formed (Raff et al., 1983; Raff et al., 1984). The correct timing of 
differentiation in vitro can be restored by culturing oligodendrocyte precursors on a 
monolayer of type I astrocytes (Noble and Murray, 1984; Raff et al., 1985). The 
mitogenic factor released by these cells was found to be platelet derived growth factor 
(PDGF), which itself can be used to reset the timing mechanism (Noble et al., 1988; 
Richardson et al., 1988; Raff et al., 1988). 
Experiments with the daughter cells of a single precursor suggest that in addition to 
regulation by PDGF, an intrinsic timing mechanism occurs within the cell. When 
stimulated by PDGF to divide two isolated daughter cells from a common precursor will 
do so the same number of times before committing to differentiation (Temple and Raff, 
1986). Analysis of the proliferation rates at different temperatures also points to an 
underlying mechanism. Oligodendrocyte precursors cultured at 33°C divide slower than 
those at 37°C. However they stop dividing and differentiate after fewer divisions, so the 
cells are not "counting" the number of divisions but are measuring time in some other 
way (Gaoet al., 1997). 
While it has been demonstrated that the timing mechanism requires the presence of 
PDGF, in the absence of other factors it is not sufficient in itself to completely restore 
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the pattern of in vivo development. Precursor cells cultured in a medium that contains 
PDGF but lacking other elements, will continue to proliferate without subsequent 
differentiation. I f either thyroid hormone or retinoic acid is then added to the media, 
differentiation wil l begin (Barres et al., 1994). 
It is likely that any timing mechanism that controls the proliferation of cells and their 
division must in some way involve the cell cycle. The cell cycle is controlled by many 
factors including the cyclin dependant kinases (cdk), these are activated to regulate the 
different phases of the cell cycle at the correct time and in the right sequence (Morgan, 
1995; Lees, 1995). In turn they are influenced by cdk inhibitors, one of these, p27 has 
been associated with oligodendrocyte development. Levels of p27 accumulate within 
oligodendrocyte precursors with successive divisions, a threshold level may be the 
trigger for differentiation (Durand et al., 1997). Mice deficient in p27 have precursors 
that divide within the normal cell cycle time, but go through more divisions before 
differentiation than wild type (Durand et al., 1998). 
As differentiation proceeds the immature oligodendrocytes gain a surface molecule 
recognised by the 04 antigen. This precedes other markers such as the oligodendrocyte 
specific cell surface galactocerebroside (GalC) , (Raff et al., 1978). GalC expression is 
first seen at birth, subsequently A2B5 staining is lost while 04 antigenicity remains 
(Levi et ah, 1987; Curtis et al., 1988). 
B1.2 The Pattern of Myelin Protein Expression in the CNS 
As the oligodendrocyte begins to produce long processes these identify an appropriate 
axon and begin to ensheath it, wrapping layers of membrane spirally around the axon to 
form the internode. Each oligodendrocyte can form up to 60 internodes on a number of 
different axons (Matthews and Duncan, 1971). In contrast to the Schwann cells, 
oligodendrocytes do not rely absolutely on axonal contact and regulation to produce 
compact myelin. In vitro studies have shown that oligodendrocytes can accumulate 
myelin proteins in the absence of axons (Dubois-Dalqc et al., 1986) and these can be 
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actively assembled into structures resembling myelin (Poduslo et al., 1982; Bradel and 
Prince, 1983; Sarlieve, et al., 1983). 
The composition of myelin protein is also different from that in the PNS. Proteolipid 
protein (PLP), which accounts for approximately 50% of all CNS myelin protein is not 
found in the PNS. While the major structural protein of the PNS myelin, protein zero 
(Po) is absent from the CNS. In addition, the transmembrane spanning protein PMP-22 
is restricted to the PNS. The CNS and PNS however, both possess the myelin basic 
protein (MBP) family of proteins and the transmembrane myelin associated glycoprotein 
(MAG). 
In vitro studies have elucidated the pattern of myelin protein expression in the CNS. 
Oligodendrocytes are first seen at birth and are identified by expression of GalC (Raff et 
al., 1978). After five days myelin basic proteins are found in the brain (Roussel and 
Nussbaum, 1981). In cultured oligodendroctes, MBP is found in the cytoplasm of the 
oligodendrocyte 5 days after plating and within their processes by 10-15 days (Dubois-
Dalcq etal, 1986). 
The initial expression of MAG closely follows that of MBP, however it is present in the 
oligodendrocyte projections 9 days after plating. The expression of PLP begins later than 
that of MBP and MAG. It is seen first at 7 to 9 days in the cell body, and at 14 to 15 
days in the oligodendrocyte processes (Dubois-Dalcq, 1986). A similar delay in PLP 
expression in comparison to MBP is found in vivo (Campagnoni and Hunkeler, 1980). 
B1.3 Myelin Basic Protein 
Myelin basic protein is shown to be one of the first myelin specific proteins to be 
expressed in both Schwann cells and oligodendrocytes as the myelin sheath begins to be 
constructed. MBP constitutes 30% of the total protein isolated from CNS myelin. The 
myelin basic protein family comprises of several proteins ranging from 14 to 21.5kDa 
that are formed by the alternative splicing of the MBP gene (de Ferra et al., 1985; 
Takahashi et al., 1985; Newman et al., 1987). In the mouse and rat the major isoforms 
21.5kDa, 18.5kDa, 17kDa and 14kDa are present in the relative amounts of 1:10:3.5:35 
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(Barbarese et al., 1978). Antigenically they are all identifiable with an antibody raised 
against the smallest, 14kDa MBP isoform (Fritz and Chou, 1983). 
MBP proteins are synthesised on free polysomes in the cytoplasm (Campagnoni et al., 
1978, 1980; Colman et al., 1983) and following the development of the oligodendroglial 
processes are translocated to the plasma membrane (Verity and Campagnoni, 1988; 
Amur Umarjee et al., 1990). Once located at the site of myelin compaction MBP is 
intimately involved in maintaining the structure of the sheath. 
Bl.3.1 The MBP gene is part of a complex gene organisation 
The classical MBP gene in mouse contains seven exons stretched across 32kb of 
chromosome 18. Alternative splicing of these exons is responsible for the range of 
different MBP isoforms found (de Ferra et ah, 1985; Roach et al., 1985). However, a 
number of MBP immunoreactive transcripts exist in both rodent brain and glial cells that 
have not been identified as MBP isoforms (Barbareses and Pfieffer, 1981; Barbareses et 
al., 1983; Carson et al., 1983). 
Kitamura et al. (1990) isolated M41-MBP mRNA, believed to be derived from the MBP 
transcription start site. It codes for a 14kDa MBP protein, however, it has an extended 5' 
region in comparison to other MBP mRNA species. A number of other, similar clones 
were recognized and analysis of these have identified further exons that described a new 
gene (Campagnoni et al., 1993). The new region was designated Golli-mbp as the gene 
products are expressed in the o/igodendrocyte /meage in the brain and encompass the 
MBP gene. It spans 105 kb of chromosome 18 encompassing 11 exons, and describes 
two overlapping transcriptional units. The golli-mbp exons 5A and 5B that are at the 
beginning of the MBP transcript also combine with exon 5C to form the end of the 
BG21 gene. The complex exon 5 region comprises three distinct regions that are 
alternatively spliced and are able to confer promoter activity in their own right. 
The multiple products of this gene region are expressed in a temporal manner at 
different stages of differentiation of the oligodendrocyte lineage. It is thought likely that 
the golli-mbp gene products are involved during the differentiation of the 
oligodendrocyte prior to the elaboration of the myelin sheath. Subsequently the MBP 
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proteins are intimately involved in maintaining the mature myelin (Campagnoni et al., 
1993). 
Golli-MBP 1 2 
Exons 
3 4 5 6 
A B C 
7 8 9 10 i: 
A B 
MBP Exons 1 
A B 
3 4 5 
A B 
Figure Bl.3.1 Representation of the organisation of the Golli-MBP gene region. The 
classical MBP gene comprises of seven coding exons. This was later found to be part of 
a larger transcriptional unit the Golli-mbp gene. Not to scale. Based on Campagnoni et 
al., 1993 
Bl.3.2 The Structure and Function of MBP 
Developmental regulation of the expression of the different MBP isoforms, and distinct 
localisation of individual isoforms suggests diverse function within the family group. 
The exon I I of the MBP gene appears crucial in determining this. 
Immunofluorescence localisation of individually expressed transcripts has identified two 
populations of MBP proteins within the oligodendrocyte. Of the major myelin isoforms 
studied the 14 and 18.5kDa proteins were found at the plasma membrane whilst the 
transcripts of the 17 and 21.5kDa isoforms, that include information from exon I I were 
found throughout the cytoplasm and within the nucleus (Staugaitis et al., 1990; 
Allinquant et al., 1991). 
Developmental studies have also identified MBP within the cytoplasm and nucleus of 
immature oligodendrocytes (Sternberger et al., 1978; Hartman et al., 1979; Roussel and 
Nussbaum, 1981). These proteins have been confirmed as exon II-containing isoforms. 
They reach high levels of expression in immature oligodendrocytes and in the early 
stages of myelination, but as myelination proceeds expression then decreases (Barbarese 
et al., 1978; Carson et al., 1983; Jordan et al, 1989a). The levels of non-exon I I -
containing transcripts however increase and remain high following myelination. 
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Jordan et al. (1989b) studied the behaviour of the MBP isoforms following nerve injury 
and found a dramatic increase in the amount of the exon II-containing MBP transcripts 
at the lesion site. Specifically the MBP isoforms were seen in the perinuclear cytoplasm 
of the oligodendrocytes. A change in the ratio of exon I I and exon I containing 
transcripts signalled the increase in other MBP transcripts with a more diffuse 
distribution. 
The transport of the exon II-containing transcripts to the nucleus has been shown to be 
an active process (Pedraza et al., 1997). It is proposed that these early isoforms of MBP 
are involved in oligodendrocyte maturation, necessary before myelination can occur. 
Once the oligodendrocyte processes have formed, later MBP isoforms are produced and 
translocated to the plasma membrane (Verity and Campagnoni, 1988; Amur Umarjee et 
al., 1990). 
In mature oligodendrocytes MBP can be found at the site of the major dense line 
(MDL), an electron micrographic image that represents the apposition of the 
cytoplasmic faces of adjacent myelin layers (Omlin et al., 1982). The homozygous 
shiverer mouse produces very little MBP (Kirchner and Ganser,1980; Campagnoni et 
al., 1984) and fails to produce compact myelin. Electonmicrographs show a loss of the 
MDL (Privat et al., 1979; Rosenbluth, 1980a). A deletion in the MBP gene is 
responsible for the shiverer mouse phenotype (Kitamura et al., 1985; Roach et al., 
1985). This observation suggests that MBP is likely to be integral to the maintenance of 
the MDL of compact myelin, acting as an intracellular adhesion molecule. 
Bl.3.4 Transgenic Strategies to Determine the Function of MBP. 
A number of natural mouse mutants exist whose phenotype is seen to affect the nervous 
system. Two of these phenotypes have been shown to be related to mutations in the 
MBP gene, the shiverer mouse shi, and the myelin deficient mouse shimld. 
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Bl.3.4.1 The Shiverer Mouse 
The Shiverer mouse displays a coarse action tremor beginning at the end of the second 
postnatal week, and progressing with age. Convulsions begin after a few months and 
become increasingly severe leading to premature death at 90-150 days. Shiverer is an 
autosomal recessive mutation (Biddle et ah, 1973; Chernoff et al., 1981) characterised 
by an almost total lack of CNS myelin (Bird et al., 1978; Rosenbluth 1980a) with all 
MBP isoforms absent (Depouey et al, 1979; Kirschner and Ganser, 1980; Mikoshiba et 
al., 1981; Barbarese et al., 1983). The loss of the major dense line in the CNS further 
implicates the MBP gene as the site of this mutation (Privat et al., 1979). However in the 
peripheral nervous system of this mouse, functional myelin sheaths are present although 
they are often thinner than in wild type mice (Rosenbluth 1980b; Peterson and Bray, 
1984). 
Both the MBP gene and the shi mutation had been mapped to mouse chromosome 18 
(Sidman et al., 1985; Roach et al., 1985) and it has been shown that the MBP gene in 
fact is deleted from the second intron to 2kb 3' of the last exon in the shiverer mouse 
(Roach et al., 1985; Takahashi et al., 1985; Molineaux et al., 1986). 
Transgenic studies have caused both the induction and the rescue of the shiverer 
phenotype through manipulation of the MBP gene. Readhead et al. (1987) were able to 
rescue the mutant phenotype by incorporating the full length sequence of the MBP gene 
into shiverer mice. It has been shown that rescue can occur with the expression of only a 
single MBP isoform. Kimura et al. (1989) introduced a minigene encoding the 14kDa 
MBP isoform, driven by 1.3kb of 5' region into a shiverer mouse with restoration of 
myelin formation that in turn alleviates the tremoring phenotype. They have also shown 
recently that introducing the minor MBP isoform, the 17.5 kDa protein is also sufficient 
to rescue the shiverer phenotype (Kimura, et al., 1998). 
Conversely the shiverer phenotype can be induced through the expression of antisense 
MBP mRNA. Antisense mRNA is thought to bind to the sense mRNA preventing 
protein formation. This manipulation was found to convert the normal phenotype of 
heterozygous shi mice to a more severe homozygous shiverer phenotype. 
Immunohistochemical analysis of the brains of these mice showed mosaic loss of MBP 
expression and myelination (Katsuki et al., 1988). 
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Bl.3.4.2 The Myelin Deficient Mouse 
The myelin deficient mouse, shimld exhibits a phenotype similar to that of shi mice. 
Tremors begin at about day 12 and continue throughout life. Convulsive seizures begin 
at 1-2 months and lead to early death at 5-9 months (Doolittle and Schweikart, 1977). 
The CNS myelin of shimld mice is severley hypomyelinated (Doolittle and Schweikart, 
1977; Matthieu et al., 1981). Unlike shiverer however, all MBP isoforms are seen in the 
shimld mouse but at reduced levels and with abnormal developmental expression 
(Matthieu et al., 1984; Roch et al., 1986; Popko et al., 1987). 
The mutation in myelin deficient mice is a complex gene duplication that results in one 
intact copy of the MBP gene, and a second that contains an inversion (Okano et al., 
1987; 1988a; Popko et al., 1988). It is proposed that the inverted gene produces 
antisense mRNA of the MBP code and that this can form duplexes with the sense 
mRNA from the intact gene. This reduces the amount of MBP mRNA and therefore the 
protein (Okano et al., 1988b; Tosic et al., 1990). 
Transgenic mice have been produced in which the shi"'ld phenotype could be alleviated 
by introduction of further copies of the intact MBP gene (Popko et al., 1987). 
A number of different lengths of the MBP 5' untranslated region (UTR) have been used 
to drive reporter gene expression in different transgenic mouse lines created to study the 
expression of MBP (for review see Ikenaka and Kagawa, 1995). The use of lacZ as a 
reporter gene has allowed analysis of the temporal and spatial expression pattern of 
MBP throughout the CNS (Gow et al., 1992; Foran and Peterson, 1992; Wrabetz et al., 
1998). These transgenic animals, however, do not express the reporter gene in the 
Schwann cells of the PNS. Some regulatory element is lacking that is necessary for the 
peripheral expression of MBP. 
Detailed characterisation of the key regulatory regions within these promoter regions has 
identified a number of enhancer and repressor cis acting elements that affect the 
expression of MBP. 
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Bl.3.5 Characterisation of the Myelin Basic Protein Promoter. 
Kimura et al. (1989) were able to show that 1.3kb of the upstream sequence of the MBP 
gene were able to confer promoter activity sufficient to drive expression of an MBP 
"minigene". This contained the cDNA sequence for the 14Kda MBP species and was 
expressed to alleviate the murine shiverer phenotype. Initial analysis identified a distal 
and proximal region within the promoter (-253 to -54 and -53 to +60 respectively) that 
were capable of tissue specific transcription (Tamura et al., 1989). A core promoter 
within the proximal region was identified at bases -36 to +12, and the region between -
22 and -17 was shown to be important for efficient transcription in brain nuclear extract 
assays (Tamura et al., 1991, 1990). Additionally an activator sequence designated MB1, 
-14 to -50 was also found with a 10 base pair motif that increased transcriptional 
activity (Devine-Beach et al., 1991). 
The distal promoter region has been extensively studied. Miura et al. (1989) 
incorporated the 1.3kb promoter region into a plasmid containing the gene for lacZ, and 
carried out a series of deletions within the 5' region. The effects of these deletions were 
assessed by expression studies in a mouse neuronal/glial hybrid cell line, NG108-15 
(Amano et al., 1974) to determine regulatory important regions within it. 
Miura et al. were able to identify TATA and CAAT box regions at -34 and -85 
respectively and a GC rich region at -92bp. This compares with the position of the 
TATA and CAAT boxes in the rat and human found at -30 and -80 respectively in both 
species (Wrabetz et al., 1993). In addition the sequence for an NF1 transcription factor 
binding site was found to be located at -125 (Leegwater et al., 1986) and a sequence 
sharing homology with the SV40 enhancer core was found at -648 (Weiher et al., 1983). 
When a large fragment from -1318 to -254 was deleted from the promoter region the P-
galactosidase enzyme activity increased dramatically suggesting that within this region 
elements exist that repress MBP promoter function. Deletion studies also identified the 
region between bases -208 and -139 as a c/s-acting enhancer sequence. In addition 
bases -139 to -118 and -89 to -75 (which includes the CAAT box) were also shown to 
be required for efficient transcription as their removal lead to reduced promoter activity. 
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Wrabetz et al. (1993), in an investigation of the human MBP promoter, were able to 
show that as little as 149 bp upstream of the MBP gene were sufficient to drive 
chloramphenicol transferase (CAT) to a level of expression 8 fold greater than that seen 
with a promoterless control specifically in oligodendrocytes. Detailed investigation of 
this 149 base pair length identified both negative and positive cw-acting elements within 
it. 
A deletion of base pairs -149 to -108 gave rise to an increase in CAT expression, 
representing an in vivo negative effect on the functional activity of the promoter. This 
includes the -124 to -110 region previously identified as the consensus NF1 site. 
Aoyama et al. (1990) identified the sequence from -130 to -111 in the mouse MBP 
promoter, also containing the NF-I site, as a positive cis-acting element that is necessary 
for brain specific expression of MBP. The reasons for these conflicting results are 
unknown but they may be due to the extent of the deletions or the protocols used to 
assay the expression. The human and murine promoters have been shown to be 90% 
homologous (Kamholz and Wrabetz, 1992). 
The proximal section of the region under investigation, -102 to -95 shows positive 
functional activity and interrupts the motif GGAGCCG, an element that has also been 
identified in the PLP promoter (Berndt et al., 1992; Nave and Lemke, 1991; Kim and 
Hudson, 1990). Deletion of the TATA box region, -41 to -14 reduced CAT expression 
levels to that of the control. 
Wrabetz et al. (1993) proposed a mechanism of action for the positive and negative ex-
acting elements that they identified. They suggested that the positive elements may be 
required for MBP activation whilst the negative region restricts expression in a cell 
specific manner, a situation seen with the glycophorin B promoter (Rahuele? al., 1992). 
This idea is supported by the observation that the original promoter-149 to +81 was 
only capable of expression in oligodendrocytes. However when the negative acting 
element was removed the remaining promoter region was able to function in COS-7 
cells. 
For a summary of the regulatory elements within the MBP promoter see Table CI .3.5 
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Bl.3.5.1 Hormonal Influence on Expression 
Thyroid hormone has been shown to be vital for the development of the CNS with a 
critical active period at 10-15 days after birth. In its absence, retardation occurs and the 
processes of cellular differentiation within the brain are disrupted (Schwartz, 1983). In 
animals with hypothyroidism the process of myelination is also severely impaired, and 
there is a decrease in the final levels of myelin (Balazs et al., 1969). Farsetti et al., 
(1992) were able to show that in the same animals, despite having a normal timing of 
expression, the levels of MBP proteins were greatly reduced. In animals from which the 
thyroid was removed at 5-6 weeks of age the MBP levels subsequently decreased and 
were rescued by the administration of thyroxine. 
In mouse cerebral cell cultures thyroid hormone was found to effect the expression of 
MBP mRNA (Shanker et al., 1987) and further analysis of the MBP promoter region has 
identified a thyroid response element within it (Farsetti et al., 1992; 1997). In order to 
effect its regulation through the thyroid hormone response element, the thyroid hormone 
first has to form a complex with a thyroid hormone receptor. A number of different 
isoforms of the thyroid receptor have been found localised to the oligodendrocyte 
nucleus (Carlson et al., 1994). 
B1.4 Project Aims 
It can be seen that the MBP promoter region has been extensively studied and that many 
of its functional components have been determined. The production of the PMP-22 P l -
EGFP transgenic mouse was considered a high risk project and to ensure some level of 
result within the PhD an alternative transgenic mouse was proposed. This would be 
prepared by an institution that had expertise in the field of microinjection and transgenic 
production and so increase the probability of success. 
To this aim, a construct was prepared in which the proven activity of the MBP promoter 
was utilised to drive the expression of the EGFP reporter gene. This construct was then 
to be prepared for microinjection and sent to the Karolinska Institute in Sweden. The 
resulting transgenic line would be complimentary to the PMP-22 PI-EGFP mouse as it 
would be predicted to express EGFP in the central nervous system. 
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B2 Results 
B2.1 Optimising the PCR conditions 
Primers were designed against the published MBP promoter sequence from the NCBI 
Genbank data base, accession number M24410 (Miura et al., 1989). The primers were 
designed in accordance with the guidelines noted in section 3.2.1. 
Oligonucleotide Sequence 5' to 3' Position in Promoter 
Forward CAG ATC TTA TTC CTC ACC -1298 to -1281 
Reverse TGG TCC ATG GTA CTT GCT +105 to +122 
Table B2.1.1 Oligonucleotide primers designed to isolate the MBP promoter. 
The promoter was extracted from mouse genomic DNA by the polymerase chain 
reaction. The following reaction was set up in a 0.25ml microcentrifuge tube and 
maintained on ice. 
l x taq DNA polymerase buffer (lOmM Tria pH 8.3, MgCl 2 , 50mM KC1, O.lmg/ml 
gelatin) 
dNTP's 0.2mM (dATP/ dTTP/ dCTP/ dGTP) 
Forward and reverse primers at a concentration of 1 uM 
MgCl 2 0.5 to 2.5 mM range 
100-250ng genomic DNA 
Sterile H2O to a final volume of 100p.l 
A number of reactions were prepared in order to optimise the interaction between the 
primers and the DNA at different MgCb concentrations. 
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Each reaction was spun briefly to mix the components. The tubes were placed in a 
Techne PHC-3 Thermal cycler and the first round of denaturation was performed before 
the addition of 1.0 unit of Taq DNA polymerase. Cycling parameters were as described 
below: 
Temp (°C) Time (seconds) 
One cycle: denaturation 92°C 300 
Thirty cycles: denaturation 92°C 45 
annealing 50°C 45 
extension 72°C 45 
One cycle: extension 72°C 300 
Table B2.1.2 Description of the PCR protocol used to isolate the MBP promoter from 
genomic DNA. 
Control reactions were performed at the same time to ensure there was no contamination 
with unwanted DNA. These consisted of reactions with either no DNA, no enzyme or no 
primers. 
B2.2 Identification of the reaction products. 
An aliquot of each PCR reaction product was separated on a 1.2% agarose gel by 
electrophoresis. A reaction product at the predicted molecular weight of 1.4kb was 
found. Restriction digest of this product suggested that the MBP promoter region had 
been isolated (see Table B2.2.1 and Figure B2.2.2). 
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Enzyme Restriction Site Fragment Length 
Ava I 555,571, 1232, 1242 555, 16, 661, 10, 168 
Bsp 1201 963 963,447 
Dral 404, 741 404, 337, 669 
Dpnl 2, 142, 544, 1098, 1218, 2, 140, 554, 120, 156 
1374 36 
H i n f l 593, 1141, 1282 593,548, 141, 128 
PstI 641 641, 769 
Pvu I I 1190 1190, 220 
Smal 1242 1242, 168 
Table B2.2.1 Restriction sites within the MBP promoter. This table shows the restriction 
sites within the MBP promoter of a number of common enzymes, and the restriction 
fragment lengths that result from this. 
B2.3 Construction of an Intermediate Plasmid 
An aliquot of the PCR reaction was run in a low melting point agarose gel of 1.2% and 
the 1.4kb band was excised. The DNA was isolated from this using the protocol 
described in section 2.5.3.1. 
The purified DNA of the PCR fragment was then ligated into the pGEM T-easy vector 
(Promega) at 4°C overnight as described in section 2.5.6. Following electro-
transformation into XLI-Blue competent cells (section 2.5.8.2) positive colonies were 
identified by blue white screening (section 2.5.9). 
Ten of the potential positive colonies were streaked out and fragments of the colony 
were incorporated into a PCR reaction as the source of DNA. The PCR strategy devised 
to isolate the MBP promoter was utilised to identify the positive colonies (Table B2.1.2). 
188 
Appendix B: MBP-EGFP Transgenic Mouse 
593 
571 1190 1242 
555 1141 1232 
bp 2 142 404 544 641 741 963 1098 1218 1282 1374 
l I I L L U I I I I II I I I I I 
Dpnl Dpnl DralDpnl Pst I Bspl201 Dpn I Hinfl Dpn I 
Ava I Dra I Dpn I Ava I 
Aval Hinf I Ava I / Smal 
Hinfl Pvu II 
a. 
kb 
4.36 
2.32 
2.02 
0.56 
b . 
Figure B2.2.2 The Putative MBP Promoter 
a. Schematic demonstrating the restriction sites within the MBP promoter 
sequence, b. Restriction digest of the isolated 1.4 kb PCR product. Lane 1, 
lambda DNA digested with Hind I I I , lane 2 uncut fragment, lanes 3-6 PCR 
fragment digested with Bsp 1201, Dra I , Hinf I and Pst I respectively. 
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Of the ten initial colonies screened one was found to have successfully ligated the MBP 
promoter region into the vector backbone. 
5ml overnight LB cultures of the positive colony were grown and the plasmid DNA 
recovered by the miniprep method (section 2.2.1). Restriction digest of this gave 
corroboration that a positive insertion had occurred (Table B2.3.1and Figure B2.3.2). 
DNA sequencing results from the universal primers T7 and SP6 also confirmed the 
identity of the insert as that of the MBP promoter. 
Enzyme Restriction Site Fragment Length 
Forward Insertion 
Bsp 1201 10, 1025 
Dra I 466, 803, 2686, 2705, 3397 
EcoRI 52,1480 
PstI 703,1498 
Smal 1304 
1015, 3413 
337, 1883, 19, 692, 1497 
1428, 3000 
795, 3633 
linearise 4428 
Reverse Insertion 
Bsp 1201 10,509 
Dra I 
EcoRI 
PstI 
Smal 
731, 1068,2686, 2705,3397 
52,1480 
831,1498 
230 
499,3929 
337, 1618, 19, 692, 1762 
1428, 3000 
667, 3761 
linearise 4428 
Table B2.3.1. Determination of the Intermediate Plasmid. The MBP promoter-pGEM 
intermediate plasmid was restricted to ensure the correct insertion of the MBP promoter 
PCR fragment. This table shows the restriction sites and fragment lengths following the 
successful integration of the PCR product. 
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MCS 
Noel 2710 
Xmn I 2009 
Seal 1890 
a. 
14 20 26 
I 1 1 
64 70 
I I 
Apa I Sph I 
AatI 
Ncol Sac I Spel Not I 
Not I Eco RI Eco RI 
PstI Nde I Sac I 
Sail 
b . 
Figure B2.3.2 Intermediate plasmid. 
a. Promega pGEM-T easy vector 3kb. b. The MBP PCR product, 1.3kb 
was ligated into the insertion site. The fragment is later easily removed 
by digestion wi th flanking enzymes from within the multi-cloning site 
(MCS). 
191 
Appendix B: MBP-EGFP Transgenic 
1 2 3 4 5 6 7 
k b 
4.50 
2.84 
1.70 
1.16 
1.09 
0.80 
0.51 
c. 
Figure B2.3.2c Restriction Digest of MBP-pGEM 
Restriction digest of the intermediate MBP-pGEM vector in the forward 
orientation Lane 1, lambda DNA digested with Pst I , Lane 2 uncut vector. 
Lane 3-7, plasmid digested with Bsp 1201, Dra I , Eco RI, Pst I and Sma I 
respectively. Eco RI digestion releases the 1.4kb MBP promoter insert. 
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B2.4 Producing the Transgenic Construct 
The promoterless pEGFP-1 vector (Clontech) was linearised with the restriction enzyme 
Eco RI. At the same time the MBP promoter-pGEM T-easy vector was also digested 
with Eco RI to release the promoter region. The DNA entities were recovered following 
agarose gel electrophoresis and extraction via the protocol described in section 2.5.3.1. 
Following dephosphorylation of the vector backbone with calf intestinal alkaline 
phosphatase enzyme (section 2.5.5) the compatible termini of the vector and insert 
allowed cohesive ligation as described in section 2.5.6. Following electro-transformation 
positive colonies were identified by PCR (as described in section B2.1.2) for the 
presence of the MBP promoter. Of ten initial colonies investigated eight had 
successfully incorporated the promoter region. 
DNA was extracted from 5ml overnight cultures of these colonies and the DNA 
extracted by the miniprep method (section 2.2.1). Restriction digest identified two 
clones in which the insert had been ligated in the reverse orientation and six in which it 
had inserted in the forward direction (Table B2.4.1and Figure B2.4.2). 
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Enzyme Restriction Site Fragment Length 
Forward Insertion 
Bbsl 
Bsp 1201 
Dra I 
Pst I 
Sail 
1368 
1021, 1382 
462, 799,2188,4630, 4649 
699 
Site removed 
Hind I I I / Bam HI 41, 1389 
Hind I I I / Afl I I 41,2368 
linearise 5466 
361,5105 
337, 1389, 2442, 19, 1279 
linearise 5466 
uncut plasmid DNA 
1348,4118 
2327,3139 
Reverse Insertion 
Bbsl 
Bsp 1201 
Dra I 
Pst I 
Sail 
158 
505, 1382 
1064, 727,2188, 4630 
4649 
827 
Site removed 
Hind II I / Bam HI 41, 1389 
Hind II I /Af l I I 41,2368 
linearise 5466 
877, 4589 
337, 1124, 2442, 19, 1544 
linearise 5466 
uncut plasmid DNA 
1348,4118 
2327,3139 
Table B2.4.1. Restriction table of the pMBP-EGFP construct. The orientation of 
insertion of the MBP promoter into the pEGFP-1 vector backbone was determined by 
restriction digest. The restriction sites of a number of enzymes and the resulting 
fragment lengths are shown for either direction of insertion. 
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MCS 
Dm I 3339 
Dm I 3320 
a. 
pUC on EGFP 
SV40 poly A 
Fl ori 
HSV poly A 
Kan/Neo 
SV40 on 
Dm 1 878 
Aflll 1058 
Eco RI Eco RI 
• i 34 417 
l I 
Eco 47111 Xhol Hind III Pst I Kpn I Sma I Age I 
Sac I Eco RI Bam HI 
b . 
Figure B2.4.2 Production of the final construct. 
a. Plasmid map of the Clontech pEGFP-1 vector 4.2kb. Multi-cloningsite 
(MCS). b. Expansion of the MCS showing the insertion of the 1.3kb MBP 
promoter into the Eco RI restriction site. The EGFP gene is found between 
base pairs (bp) 97 to 816 of the pEGFP-1 vector 
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1 2 3 4 5 6 7 8 
kb 
4.50 
2.84 
1.70 
1.16 
1.09 
0.80 
0.51 
c. 
Figure B2.4.2c The final MBP-EGFP construct 
Restriction digest of the MBP-EGFP construct. Lane 1, lambda DNA 
restricted with Pst I . Lane 2 uncut plasmid DNA, lane 3-8 plasmid 
digested with Bbs I , Bsp 1201, Dra I ,Pst I , Sal and Sma I respectively. 
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B2.5 Subsequent Manipulation of the MBP Promoter 
The reverse primer for the MBP promoter extends into the protein coding region of the 
MBP gene and so includes the MBP translational start site. In addition the promoterless 
vector was purposely constructed to possess the necessary translational regulatory 
elements desired in a plasmid designed to investigate promoter activity. This meant that 
at this time the construct contained two transcriptional start sites. 
In the normal genetic arrangement, a transcriptional start site indicating the beginning of 
the RNA sequencing region follows a 5' promoter region containing regulatory regions 
such as a TATA box and CAAT box and transcription factor binding sites. This is then 
followed by a translational start site, which is positioned in correct alignment with 
Kozac sequences that aid protein translation. Two translational start sites would render 
the construct useless, as no functional protein is likely to be derived from it. 
A strategy was developed to excise the translational start site from the MBP promoter 
sequence. Regulatory elements within the MBP promoter were identified to ensure they 
were not inadvertently removed. In addition the organisation of the endogenous MBP 
gene was studied. Here the transcriptional and translational start site are located within 
47 bases of each other (Kamholz et al., 1988), as the translational start site is removed 
from the MBP region within the construct the two regions are brought to within 50 base 
pairs of each other. 
The strategy relied upon identifying two enzymes on either side of the site to be 
removed that only cut the vector once. A Bbs I site at the end of the MBP promoter 
region (bp 1367) and a Sal I restriction site located within the plasmid MCS (1497) both 
fulf i l l this criteria. 
Subsequently MBP-EGFP vector DNA was digested in a compatible restriction buffer 
with first Bbs I and then Sal I . To enable re-circularisation the protruding termini were 
filled in using Klenow enzyme as described in section 2.5.4. The DNA was purified 
from an agarose gel following the procedures in section 2.5.3.1. A blunt ended ligation 
was then carried out (section 2.5.6) and the reaction transformed into X L I Blue 
competent cells (section 2.5.8). A positive colony was identified as previously and 
confirmed by restriction digest (Table B2.1.2 ). 
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B2.6 Functional Studies of the Transgene 
To ensure the construct was functional, that it could be expected to express in vivo, a 
number of transfection experiments were carried out. Previous studies have already 
shown that 1.4 kb of 5' sequence is sufficient to drive oligodendrocyte expression of 
reporter genes (Kimura et al., 1989; Miura et al., 1989). Our studies were aimed at 
determining that the regulatory regions necessary for transcription and translation were 
in context and functional. 
The construct was transfected into primary Schwann cells isolated from DRG co-
cultures as described previously (section 3.3.2). In addition positive and negative control 
constructs were also introduced into the cells (section 3.3). Expression was also 
investigated in a control cell type the green monkey kidney cell line, COS-7 (see section 
3.3.2). 
B2.6.1 Results of Transfection Study 
Both cell types successfully expressed EGFP following transfection with the pCMV-
EGFP positive control DNA (see appendix A4). 
Schwann cells clearly showed expression of EGFP following transfection with the 
pMBP-EGFP construct (Figure B2.6.1). EGFP fluorescence was seen strongly in the 
Schwann cell body, with the limits of the Schwann cell processes also visible. Fewer 
cells were expressing the construct than displayed fluorescence with the constitutively 
expressing construct. 
In addition the control cell line, the green monkey kidney COS-7 cells also strongly 
expressed the pMBP-EGFP construct. In neither cell type was fluorescence seen with the 
promoterless EGFP plasmid control. 
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Figure B2.6.1 Functional studies of the pMBP-EGFP construct. 
A-C Transfection of primary Schwann cell co-cultures with the negative control DNA, 
the positive control pCMV-EGFP plasmid and pMBP-EGFP plasmid respectively. D-F 
Expression of these constructs in COS-7 cells, negative control, positive control and 
pMBP-EGFP plasmid respectively. Scale bar lOOum 
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B3 Production of a Transgenic Mouse expressing MBP-EGFP 
B3.1 Introduction 
The production of a transgenic mouse line in which the MBP promoter was used to drive 
EGFP expression was conceived as a contingency plan to run parallel to the primary aim 
of producing the PMP-22 PI-EGFP mouse. For this reason the MBP-EGFP construct 
was produced at the University of Durham and the DNA prepared for microinjection 
(section 4.1.1.1). It was then sent to the Karolinska Institute in Sweden where it would 
be microinjected into fertilised embryos in the same manner as that described in Chapter 
4. Tail biopsies from the subsequent pups were then to be sent to Durham for analysis 
and identification of transgenic pups 
B3.2 Microinjection 
The pMBP-EGFP plasmid was digested with the restriction enzymes Hind I I I and A f l I I 
this excised the 2.3kb fragment containing the MBP promoter, EGFP gene and SV40 
poly-A tail from the vector. The DNA was purified for microinjection as described in 
section 4.1.1.1. 
In the initial round of microinjection 50 pups resulted from 103 re-implantations. DNA 
was extracted from 2-4mm tail biopsies as described in section 2.3.2. 5\ig of DNA from 
each mouse was bound to nitrocellulose filter and screened with a PdCTP radiolabeled 
probe to the microinjected fragment (section 2.8). Potential founders were identified and 
PCR reactions with primers against the MBP-EGFP construct were used to confirm 
these (Table B3.2.1 and 3.2.2). The PCR reaction failed to identify any positive, 
potential founder mice. 
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Oligonucleotide Sequence Position in plasmid 
Forward MBP CAG ATC TTA TTC CTC ACC 57-74 
Reverse TG-2 TTG TAC AGC TCG TCC ATG 2109- 2126 
Table B3.2.1 The sequence of primers used to isolate the MBP-EGFP transgene. The 
forward promoter binds within the MBP promoter region. The reverse primer 
corresponds to the sequence for the EGFP gene. 
These conflicting results necessitated repeated analysis. Genomic DNA was extracted 
from a second section of tail for each mouse. 5ug of genomic DNA was digested with 
the restriction enzyme Bam HI. The samples were then run as a Southern blot (section 
2.8). The nitrocellulose filter was hybridised with a radiolabelled probe of the full MBP-
EGFP sequence (approximately 2.3kb, see section 2.8). The filter was then placed 
against autoradiograph film, negative results were obtained with all mice. 
A second aliquot of DNA was then sent to the Swedish institute for subsequent 
microinjection. From 5 further rounds of microinjection and re-implantation 43 pups 
were born and again DNA was extracted from tail biopsies as described previously 
(section 2.3.2). 
Analysis to detect the presence of the transgene began with PCR, using primers against 
the EGFP gene (see section 5.1). This identified a single mouse, designated 845-5, as a 
potential founder animal. This was confirmed by PCR against the full length construct 
MBP-EGFP (see Table B3.2.2). Digestion of the PCR product confirmed the fragment 
as the inserted MBP-EGFP construct (see Table B3.2.3 and Figure B3.2.4). 
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Temp (°C) Time (seconds) 
Two cycles: denaturation 92 300 
annealing 60 45 
extension 72 45 
Two cycles: denaturation 92 45 
annealing 59 45 
extension 72 45 
the annealing temperature was reduced by a further degree every second 
cycle until the optimum annealing temperature of 50°C was reached 
Fifteen cycles: denaturing 92 45 
annealing 50 45 
extension 72 45 
One cycle: extension 72 300 
Table B3.2.2 PCR protocol used to isolate the MBP-EGFP transgene from genomic 
DNA. The touchdown PCR method was used to isolate the MBP-EGFP transgene from 
genomic DNA of potential founder animals. Annealing was begun at 68°C and 
subsequently reduced during the following cycles to the optimum annealing temperature 
of58°C. PCR. 
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Enzyme Restriction Site Fragment Length 
Bam HI 1335 1335,735 
Bsp 1201 963, 1328 963,365, 742 
Dra l 404,741 404,337, 1329 
Pvu I I 1190 1190, 880 
Table B3.2.3 Restriction sites found within the MBP-EGFP promoter used to identify 
PCR reaction products from potential founders. 
The result was further validated by Southern blot of 845-5 (section 2.8). 5ug of the 
genomic DNA was digested with the restriction enzyme Bam HI and ran in an agarose 
gel. The gel was then blotted to nitrocellulose filter that was subsequently hybridised 
with a 32PdCTP labeled probe of MBP-EGFP. Autoradiographs showed the 
incorporation of the transgene in the genomic DNA of this mouse (Figure B3.2.5). 
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1 2 3 4 5 6 7 
Figure B3.2.4 Identification of Transgenic Mice. 
Genomic DNA from the four male offspring of founder 845-5 was screened for the 
presence of the MBP-EGFP transgene. a. Lane 1 molecular weight markers. Lane 2 
845-5 founder. Lanes 3-6 F l pups 845-5/1 to 845-5/4 respectively. Lane 7 No DNA 
control.The PCR product was identified by restriction digest, b. Lane 1 molecular 
weight markers. Lane 2 PCR product uncut. Lane 3-6 PCR product digested with 
Bam HI, Bspl20 I , Dra I and Pvu I I respectively. 
204 
1 2 3 4 5 6 7 8 9 1011 12 13 14 15 
3054 
2086 
1636 
1018 
a. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
3054 
mm 2086 in • 
1636 
0 8 
Figure B3.2.5 Southern Blot Analysis of the MBP-EGFP founder and F l 
male pups. 10 microgrammes of genomic DNA from each mouse was digested 
overnight with the restriction enzyme BamHI. a. Uncut and digested DNA was 
then run on an agarose gel and blotted to nitrocellulose membrane, b. It was then 
incubated with a radiolabeled probe. Lane 1 molecular weight marker. Lane 2-11 
male pup 1 to 4, founder 845-5, uncut and Bam HI digested DNA. Lane 12-15 
control DNA corresponding to approximately 1, 5, 10 and 50 copies of the 
transgene in the diploid genome. 
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B4 Maintenance of the Transgenic Line 
Due to the difficulties encountered during microinjection by the Karolinska Institute and 
the failure of incorporation requiring subsequent rounds of microinjection insufficient 
time remained for analysis of this transgenic mouse line. To maintain a colony of mice 
that at present would not be under active investigation would be prohibitively expensive. 
As an alternative the Karolinska Institute have frozen embryos derived from the male 
offspring of the original founder mouse for long term storage (see Appendix A3). In this 
way the transgenic line wil l be preserved until some future time when they may be 
analysed in full . 
B4.1 Analysis of the Transgenic Mouse Line 
To expand the transgenic population the founder mouse was mated with a wild type 
male. From the resulting litters tail biopsies were taken and sent to Durham for analysis. 
DNA was extracted from tail biopsies of four male pups of the Fl generation. PCR 
analysis identified two of these as positive for the EGFP gene and the whole MBP-
EGFP insert. This was confirmed by Southern blot as described above (section B3.2, see 
Figure B3.2.5). 
In order to estimate the number of copies of the transgene that had been incorporated 
into the genome of the founder mouse and her offspring, a number of standard amounts 
of the transgene DNA were investigated by Southern blot. The amount of DNA that 
corresponds to a single copy of the transgene within a stated amount of the full diploid 
genome can be determined. For example the transgene is 2330 base pairs in length 
within a single copy of the mouse diploid genome 6xl0 9 basepairs. In a total of 10|4,g of 
genomic DNA 3.9pg of the transgene fragment is equivalent to 1 copy of the transgene 
within the diploid genome. 
6xl0 9 = 2575 1 07.3 1 0,000,000 = 3.88pg equivalent to one 
2330 2575107.3 copy. 
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Alongside 5(j,g of genomic DNA from both the founder 845-5 and the Fi offspring, 3, 
15, 30 and 150pg of the transgene fragment (Hind I I I /Af l II) were loaded amongst a 
small amount of wildtype genomic DNA. This was equivalent to 1.58, 7.9, 15.8 and 79.0 
copies of the transgene respectively within 5ug of genomic DNA. Spectrophotometric 
analysis of the resulting bands found on the Southern blot (Figure B3.2.5) was used to 
estimate the copy number of the transgenic line. 
Assuming that equal amounts of genomic DNA were loaded onto the agarose gel, 
comparison of the optical density of the band that relates to 1.58 copies can be made 
with the bands from the transgenic mice. It is noted that the DNA from the Fi mouse 
845-5/3 had degraded. The results show that approximately 2 copies of the transgene 
have incorporated into the genome of the founder 845-5, and that the same copy number 
has successfully been passed on to the offspring 845-5/1 and 845-5/4 (Figure B3.2.5). 
Identity Optical Density Estimated Number of Copies 
3pg of the transgene 0.263 1.58 
15pg of the transgene 0.379 7.90 
30pg of the transgene 0.418 15.8 
150pg of the transgene 0.472 79.0 
Founder 845-5 0.362 2.2 
845-5/1 F, 0.350 2.1 
845-5/2 F, N/A N/A 
845-5/3 F, N/A N/A 
845-5/4 F, 0.352 2.1 
Table B4.1 Spectrophotometric determination of copy number. Analysis of the founder 
animal and its offspring by comparison of the density of the 3pg band. Limitations of the 
software cannot recognise increased density past a certain point. This means that a 
doubling of the optical density does not reflect doubling of the amount of standard DNA. 
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B5 Discussion 
The successful production of a construct in which 1.3kb of the 5' sequence of the myelin 
basic protein promoter was coupled to drive EGFP expression has been shown. The 
construct was shown to be functional in one of the target cell types, primary Schwann 
cells, and previous studies using this promoter region have shown its activity in 
oligodendrocytes (Katsuki et al., 1988; Kimura et al., 1989; Miura et al., 1989). In 
addition non-specific expression was seen in the control cell line, COS-7. 
This construct was incorporated into the genome of a mouse line by microinjection at 
the Karolinska Institute in Sweden. A single founder was identified by PCR and 
confirmed by Southern blot. The transgene was shown to be transmitted to the offspring 
of that founder by Southern blot. Spectrophotometric analysis has estimated that two 
copies of the transgene had incorporated into the founder line. To date no further 
investigation of the animal has been made. 
Initial analysis would need to determine i f EGFP expression could be detected in the 
white matter of the CNS. This could be achieved either by in vitro culture of 
oligodendrocytes from the brains of neonatal animals (as described by McCarthy and de 
Vellis, 1980), or through direct sectioning of the brain. EGFP fluorescence may be lost 
during the cryopreservation technique and so expression may have to be determined 
with the use of anti-GFP antibodies. 
Determination of the extent of expression both spatially and developmentally would also 
be necessary. Previously described transgenic mice employing the MBP promoter to 
drive reporter gene expression have encountered mosaic expression of the reporter gene 
product (Foran and Peterson, 1992). 
A number of transgenic lines expressing reporter genes under the influence of the MBP 
promoter regions have been produced and described fully. They have been used to 
elucidate the exact pattern of expression of the MBP gene both temporally and spatially 
in the central nervous system. The specificity of the promoter has also been proved by 
its use to regulate the rescue of mutant mouse phenotypes. However there remains a 
208 
Appendix B: MBP-EGFP Transgenic Mouse 
number of arguments as to why our particular animal model is worth continued 
investigation. 
Recent work investigating the potential of gene delivery and expression systems in the 
central nervous system have taken advantage of the specific expression regulated by the 
MBP promoter and the ease of detection of the GFP gene (Chen et al., 1998; Huang et 
al., 1999). In a search for therapeutic systems of gene delivery to target cells an adeno-
associated virus has been produced that contains the MBP promoter and the GFP gene. 
Chen et al. (1998) have shown that in this manner both in vitro and in vivo GFP can be 
successfully expressed in the target oligodendrocyte. This gives cause to believe that not 
only should the promoter sequence used be sufficient to describe specific expression, but 
also that the GFP itself is a suitable reporter gene that is capable of expression within the 
cell without toxicity. 
To have created a mouse in which oligodendrocytes may express EGFP may prove to be 
a valuable tool in which to follow the dynamic interactions of glia and neurons. As 
EGFP can be readily visualised in live cells with no manipulation, it would provide a 
novel opportunity to study the development of neuron-glia relationships in the CNS. 
The cerebellum contains a relatively small number of cell types organised in a 
stereotypic pattern. Much of the development of the interactions between these cells 
occurs postnatally making them accessible for study. Within the cerebellum 
oligodendrocytes can be identified and the full arbor of an individual cell may be seen. 
In organotypic and cerebellar thin slice cultures (Notterpek et al., 1993) the structure and 
relationships between cell types are maintained. It has been shown that oligodendrocytes 
within this culture system retain the ability to myelinate (Raval-Fernades and Rome, 
1998). This system of in vitro study, in conjunction with the MBP-EGFP mouse would 
provide a good model to study the associations of oligodendrocytes with neurons in the 
cerebellum. 
Laser scanning confocal microscopy techniques could be deployed to study the process 
of myelination, three dimensional reconstructions of Z-axis series combined with time 
lapse microscopy could visualise the whole process. Questions could be addressed such 
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as in what way does the oligodendrocyte select neurons with which to interact? 
Oligodendrocytes myelinate many fibres, does this occur simultaneously or in a 
sequential manner? 
The effect of factors that inhibit or stimulate myelination could be followed 
progressively over time, the observation of morphological changes and altered 
relationships with axons may suggest mechanisms of action. 
Tissue culture techniques exist in which populations of the transgenic oligodendrocytes 
could be expanded. The mice in this way could provide a source of fluorescent green 
cells for transplantation experiments. In multiple sclerosis, and the animal model 
experimental allergic encephalomyelitis (EAE, Martenson, 1984), demyelinated plaques 
appear in the CNS and are thought to be the result of immunologic attack against the 
myelin producing cells. Around the periphery of these plaques healthy oligodendrocytes 
exist (Raine, 1983) that can spontaneously and often transiently repair the lesion. 
Transplantation of transgenic oligodendrocytes into the site of lesion in the EAE animal 
would allow a straight forward method of identifying donor cells and assessing their 
success at remyelination and the pattern of migration and division that has occurred 
following their insertion. 
The focus of attention in the study of MBP rests on the central nervous system 
expression as it is this that is compromised following mutation of the gene. In the PNS 
compact myelin remains. Transgenic animals in which reporter genes are expressed with 
varying amounts of the MBP promoter fail to show expression in the peripheral nerve of 
these animals (Gow et al., 1992; Foran and Peterson, 1992; Wrabetz et al., 1998). 
Although weak expression has been reported when as much as 6.5kb of promoter region 
was utilised (Freidrich et al., 1990). Some aspect of the promoter structure is thought to 
be absent within the studied region that regulates Schwann cell specific expression of the 
gene. 
It has been shown here that 1.3 kb of the MBP promoter can direct expression of the 
reporter gene in primary Schwann cells in vitro. Other studies that have used this region 
of the promoter have studied its expression in neuronal/glial cell lines (Miura et al., 
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expression in primary Schwann cells of the reporter gene is found. Whilst previous 
studies indicate that this regulatory region is insufficient to drive Schwann cell 
expression, our transfection studies indicate that it would be interesting to observe PNS 
myelin in the search for expression. 
It should be noted however, that regulatory components of the in vivo environment may 
be absent within the tissue culture system, allowing tight restrictions on expression to be 
relaxed. However, this construct may prove a useful tool for the in vitro study of MBP 
expression and regulation in Schwann cells through either transient or stable transfection 
regimes. 
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